Overexpression of LEMD2, LEMD3, or CHMP7 as a therapeutic modality for tauopathies
By administering LEMD2, CHMP7, or LEMD3, or their encoding nucleic acids, the hyperphosphorylation and aggregation of tau protein in tauopathies are inhibited, effectively treating and preventing the progression of these diseases.
Patent Information
- Application Number
- JP2024525049
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-27
- Filing Date
- 2022-10-26
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-10-26
Smart Images

Figure 2024542982000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application No. 63 / 271,839, filed October 26, 2021, and U.S. Patent Application No. 63 / 369,557, filed July 27, 2022, each of which is incorporated by reference in its entirety herein. Submitted as a text file via EFS Web
[0002] Reference to sequence listing The sequence listing in file 057766-586530.xml is 452 kilobytes, was created on October 26, 2022, and is incorporated herein by reference. [Background technology]
[0003] Tau is a member of a large group of microtubule-associated proteins that are enriched in the brain. Tau is found primarily in neurons of the central nervous system and is restricted to axons, where it functions to enhance microtubule stability. There are six major isoforms of tau, ranging from 352 to 441 amino acids in length, produced by alternative splicing of transcripts from the MAPT gene, located on chromosome 17 in humans. Similar to other microtubule-associated proteins such as MAP2, each tau isoform contains a series of three or four tandem repeat units (3RD and 4RD) that are involved in microtubule binding. Most interest in tau has focused on its role in cytoskeletal microtubule dynamics, but recent evidence points to a nuclear function in RNA metabolism and pre-mRNA splicing. Despite decades of investigation, many questions remain regarding the normal function of tau in neurons and how its dysfunction promotes neurodegenerative diseases. Summary of the Invention
[0004] Provided herein are compositions and methods for inhibiting tau aggregates in a cell or subject, methods for reducing phosphorylation in a cell or subject, compositions and methods for treating or preventing a tauopathy in a subject, nucleic acids encoding LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), and expression constructs encoding LEMD2, CHMP7, or LEMD3. Also provided herein are compositions and methods for reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL) in a subject.
[0005] In one aspect, methods of inhibiting or reducing tau aggregates, inhibiting or reducing phosphorylation, or inhibiting or reducing accumulation of insoluble tau in a cell or subject are provided. Similarly, methods of reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL) in a subject are provided. Some such methods are for inhibiting or reducing tau aggregates in a cell or subject. Some such methods are for inhibiting tau aggregates in a cell or subject. Some such methods are for inhibiting tau aggregates in a cell or subject. Some such methods are for inhibiting or reducing phosphorylation in a cell or subject. Some such methods are for inhibiting phosphorylation in a cell or subject. Some such methods are for reducing phosphorylation in a cell or subject. In some such methods, the phosphorylation inhibited or reduced is phosphorylation of tau on serine 356. In some such methods, the level of phosphorylated tau (e.g., phosphorylated-tau-Ser356) is decreased in the cell body, in the perinuclear region, and / or in the nucleoplasm. In some such methods, the level of phosphorylated tau (e.g., phosphorylated-tau-Ser356) is decreased in the cell body. In some such methods, the level of phosphorylated tau (e.g., phosphorylated-tau-Ser356) is decreased in the perinuclear region. In some such methods, the level of phosphorylated tau (e.g., phosphorylated-tau-Ser356) is decreased in the nucleoplasm. Some such methods are for inhibiting or reducing accumulation of insoluble tau in a cell or subject. Some such methods are for inhibiting accumulation of insoluble tau in a cell or subject. Some such methods are for reducing accumulation of insoluble tau in a cell or subject.Some such methods include administering to a cell or subject LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding LEMD2, CHMP7, or LEMD3.
[0006] In one aspect, methods of inhibiting tau aggregates or reducing phosphorylation in a cell or subject are provided. Some such methods are for inhibiting tau aggregates in a cell or subject. Some such methods are for reducing phosphorylation in a cell or subject. Some such methods include administering to a cell or subject LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding LEMD2, CHMP7, or LEMD3.
[0007] Some such methods include administering LEMD2 or a nucleic acid encoding LEMD2 to a cell or subject. In some such methods, LEMD2 is human LEMD2. Optionally, LEMD2 comprises SEQ ID NO:1 or SEQ ID NO:5. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:7. In some such methods, LEMD2 is mouse LEMD2. Optionally, LEMD2 comprises SEQ ID NO:10. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:255.
[0008] Some such methods include administering CHMP7 or a nucleic acid encoding CHMP7 to a cell or subject. In some such methods, the CHMP7 is human CHMP7. Optionally, the CHMP7 comprises SEQ ID NO: 15. Optionally, the nucleic acid encoding CHMP7 comprises SEQ ID NO: 16 or SEQ ID NO: 17. In some such methods, the CHMP7 is mouse CHMP7. Optionally, the CHMP7 comprises SEQ ID NO: 19. Optionally, the nucleic acid encoding CHMP7 comprises SEQ ID NO: 20 or SEQ ID NO: 21.
[0009] Some such methods include administering LEMD3 or a nucleic acid encoding LEMD3 to a cell or subject. In some such methods, the LEMD3 is human LEMD3. Optionally, the LEMD3 comprises SEQ ID NO:23. Optionally, the nucleic acid encoding LEMD3 comprises SEQ ID NO:24 or SEQ ID NO:25. In some such methods, the LEMD3 is mouse LEMD3. Optionally, the LEMD3 comprises SEQ ID NO:27 or SEQ ID NO:29. Optionally, the nucleic acid encoding LEMD3 comprises SEQ ID NO:29 or SEQ ID NO:30.
[0010] In some such methods, a nucleic acid encoding LEMD2, CHMP7, or LEMD3 is administered to a cell or subject. Optionally, the nucleic acid is codon optimized for expression in a human or mouse cell. In some such methods, the nucleic acid comprises complementary DNA encoding LEMD2, CHMP7, or LEMD3. In some such methods, the nucleic acid comprises messenger RNA encoding LEMD2, CHMP7, or LEMD3.
[0011] In some such methods, the method comprises administering an expression construct comprising a nucleic acid encoding LEMD2, CHMP7, or LEMD3 operably linked to a promoter (enhancing factor). In some such methods, the promoter is a heterologous promoter. In some such methods, the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter. In some such methods, the promoter is a neuronal cell-specific promoter. Optionally, the promoter is a synapsin-1 promoter. Optionally, the promoter is a human synapsin-1 promoter.
[0012] In some such methods, the nucleic acid is present in a vector. In some such methods, the vector is a viral vector. In some such methods, the viral vector is a lentiviral vector or an Adeno-Associated Virus (AAV) vector. In some such methods, the vector is an AAV vector. Optionally, the AAV vector is an AAV-PHP.eB vector.
[0013] In some such methods, the cell is a mammalian cell or the subject is a mammal. In some such methods, the mammalian cell is a human cell, a rodent cell, a mouse cell, or a rat cell, or the subject is a human, a rodent, a mouse, or a rat. In some such methods, the cell is a human cell or the subject is a human.
[0014] In some such methods, the cell is a neuronal cell. In some such methods, the cell is in vivo in a subject. In some such methods, the cell is a neuronal cell in the brain of the subject. In some such methods, the LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, is administered to the subject by intraventricular, intracranial, or intrathecal injection. In some such methods, the LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, is administered to the subject by intraperitoneal injection.
[0015] Some such methods further include assessing one or more signs or symptoms of tauopathy or tau aggregates in the cell or subject.Some such methods further include assessing phosphorylated-tau levels in the cell or subject.Some such methods further include assessing serum neurofilament light chain (sNfL) levels in the subject.
[0016] Some such methods reduce the amount of new tau aggregate formation in a cell or subject.Some such methods reduce the amount of existing tau aggregate formation in a cell or subject.
[0017] In another aspect, methods of treating or preventing a tauopathy in a subject are provided. Some such methods are for treating a tauopathy in a subject. Some such methods are for preventing a tauopathy in a subject. Some such methods include administering to the subject LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, where LEMD2, CHMP7, or LEMD3 inhibits tau aggregates in cells of the subject.
[0018] Some such methods include administering LEMD2, or a nucleic acid encoding LEMD2, to a subject. In some such methods, LEMD2 is human LEMD2. Optionally, LEMD2 comprises SEQ ID NO:1 or SEQ ID NO:5. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:7. In some such methods, LEMD2 is mouse LEMD2. Optionally, LEMD2 comprises SEQ ID NO:10. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13. Optionally, the nucleic acid encoding LEMD2 comprises SEQ ID NO:255.
[0019] Some such methods include administering CHMP7, or a nucleic acid encoding CHMP7, to a subject. In some such methods, the CHMP7 is human CHMP7. Optionally, the CHMP7 comprises SEQ ID NO: 15. Optionally, the nucleic acid encoding CHMP7 comprises SEQ ID NO: 16 or SEQ ID NO: 17. In some such methods, the CHMP7 is mouse CHMP7. Optionally, the CHMP7 comprises SEQ ID NO: 19. Optionally, the nucleic acid encoding CHMP7 comprises SEQ ID NO: 20 or SEQ ID NO: 21.
[0020] Some such methods include administering LEMD3, or a nucleic acid encoding LEMD3, to a subject. In some such methods, the LEMD3 is human LEMD3. Optionally, the LEMD3 comprises SEQ ID NO:23. Optionally, the nucleic acid encoding LEMD3 comprises SEQ ID NO:24 or SEQ ID NO:25. In some such methods, the LEMD3 is mouse LEMD3. Optionally, the LEMD3 comprises SEQ ID NO:27 or SEQ ID NO:29. Optionally, the nucleic acid encoding LEMD3 comprises SEQ ID NO:29 or SEQ ID NO:30.
[0021] In some such methods, a nucleic acid encoding LEMD2, CHMP7, or LEMD3 is administered to the subject. Optionally, the nucleic acid is codon optimized for expression in a human or mouse cell. In some such methods, the nucleic acid comprises complementary DNA encoding LEMD2, CHMP7, or LEMD3. In some such methods, the nucleic acid comprises messenger RNA encoding LEMD2, CHMP7, or LEMD3.
[0022] In some such methods, the method comprises administering an expression construct comprising a nucleic acid encoding LEMD2, CHMP7, or LEMD3 operably linked to a promoter. In some such methods, the promoter is a heterologous promoter. In some such methods, the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter. In some such methods, the promoter is a neuronal cell-specific promoter. Optionally, the promoter is a synapsin-1 promoter. Optionally, the promoter is a human synapsin-1 promoter.
[0023] In some such methods, the nucleic acid is present in a vector. In some such methods, the vector is a viral vector. In some such methods, the viral vector is a lentiviral vector or an adeno-associated viral (AAV) vector. In some such methods, the vector is an AAV vector. Optionally, the AAV vector is an AAV-PHP.eB vector.
[0024] In some such methods, the subject is a mammal. In some such methods, the subject is a human, a rodent, a mouse, or a rat. In some such methods, the subject is a human.
[0025] In some such methods, the cell is a neuronal cell. In some such methods, the neuronal cell is in the brain of the subject. In some such methods, the LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, is administered to the subject by intraventricular, intracranial, or intrathecal injection. In some such methods, the LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, is administered to the subject by intraperitoneal injection.
[0026] Some such methods further include assessing one or more signs or symptoms of tauopathy or tau aggregates in the cell or subject.Some such methods further include assessing phosphorylated-tau levels in the cell or subject.Some such methods further include assessing serum neurofilament light chain (sNfL) levels in the subject.
[0027] Some such methods reduce the amount of new tau aggregate formation in a cell or subject.Some such methods reduce the amount of existing tau aggregate formation in a cell or subject.
[0028] In another aspect, an expression construct is provided that comprises a nucleic acid encoding LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), operably linked to a heterologous promoter.
[0029] Some such expression constructs include a nucleic acid encoding LEMD2. In some such expression constructs, LEMD2 is human LEMD2. Optionally, LEMD2 includes SEQ ID NO:1 or SEQ ID NO:5. Optionally, the nucleic acid encoding LEMD2 includes SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:7. In some such expression constructs, LEMD2 is mouse LEMD2. Optionally, LEMD2 includes SEQ ID NO:10. Optionally, the nucleic acid encoding LEMD2 includes SEQ ID NO:11, SEQ ID NO:12, or SEQ ID NO:13. Optionally, the nucleic acid encoding LEMD2 includes SEQ ID NO:255.
[0030] Some such expression constructs include a nucleic acid encoding CHMP7. In some such expression constructs, CHMP7 is human CHMP7. Optionally, CHMP7 includes SEQ ID NO: 15. Optionally, the nucleic acid encoding CHMP7 includes SEQ ID NO: 16 or SEQ ID NO: 17. In some such expression constructs, CHMP7 is mouse CHMP7. Optionally, CHMP7 includes SEQ ID NO: 19. Optionally, the nucleic acid encoding CHMP7 includes SEQ ID NO: 20 or SEQ ID NO: 21.
[0031] Some such expression constructs include a nucleic acid encoding LEMD3. In some such expression constructs, LEMD3 is human LEMD3. Optionally, LEMD3 includes SEQ ID NO:23. Optionally, the nucleic acid encoding LEMD3 includes SEQ ID NO:24 or SEQ ID NO:25. In some such expression constructs, LEMD3 is mouse LEMD3. Optionally, LEMD3 includes SEQ ID NO:27 or SEQ ID NO:29. Optionally, the nucleic acid encoding LEMD3 includes SEQ ID NO:29 or SEQ ID NO:30.
[0032] In some such expression constructs, the nucleic acid encoding LEMD2, CHMP7, or LEMD3 is codon optimized for expression in a human or mouse cell. In some such expression constructs, the nucleic acid comprises a complementary DNA encoding LEMD2, CHMP7, or LEMD3.
[0033] In some such expression constructs, the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter. In some such expression constructs, the promoter is a neuronal cell-specific promoter. Optionally, the promoter is a synapsin-1 promoter. Optionally, the promoter is a human synapsin-1 promoter.
[0034] In some such expression constructs, the nucleic acid is present in a vector. In some such expression constructs, the vector is a viral vector. In some such expression constructs, the viral vector is a lentiviral vector or an adeno-associated viral (AAV) vector. In some such expression constructs, the vector is an AAV vector. Optionally, the AAV vector is an AAV-PHP.eB vector. [Brief description of the drawings]
[0035] [Figure 1A] 1A-1D show screening for mutations that enhance tau aggregation. FIG. 1A shows a schematic illustrating the detection of tau aggregates by induction of FRET. Tau biosensor cells treated with conditioned medium from cells lacking tau aggregates, Tau-YFP Agg- (top left IF image), produce no FRET signal after 3 days in culture (top right flow cytometry plot). Biosensor cells treated with conditioned medium from cells containing tau aggregates, Tau-YFP Agg+ (bottom left IF image), induce detectable FRET signal in 0.1% of cells (bottom right flow cytometry plot). [Figure 1B] 1A-1D show the screen for mutations that enhance tau aggregation. FIG. 1B shows a schematic of the CRISPR screening timeline. Lentiviral packaged CRISPR gRNA library was transduced into Cas9-expressing biosensor cells on day 0. Different colored nuclei indicate that each cell received a different gRNA-expressing transgene. Cells were sampled on days 3 and 6, and FACS was performed on day 10 to sort and collect FRET+ cells. gRNA expression was determined by PCR amplification and sequencing of amplicons. [Figure 1C] Figures 1A-1D show a screen for mutations that enhance tau aggregation. Figure 1C shows a plot of gene center enrichment versus p-value in FRET+ cells at day 10 for gRNAs targeting the same genes. BANF1 is shown as a circle labeled with an "X" and PPP2CA is shown as an open circle. [Figure 1D] Figures 1A-1D show the screen for mutations that enhance tau aggregation. Figure 1D shows the secondary screen of 14 primary screen candidate genes for enhancement of tau aggregation in biosensor cells seeded with tau-YFP Agg+ conditioned media, measured as FRET induction (calculated as integrated FRET density) after inactivation with individual lentiviral gRNA expression vectors (four gRNAs for BANF1 and two gRNAs for each of the 13 other genes). Bar heights represent the mean ± SEM of all gRNAs analyzed. Genes targeted by the gRNAs are shown on the x-axis. The large enhancement of FRET induction for gRNAs targeting BANF1 or PPP2CA confirms these genes as hits in the screen for enhanced tau aggregation. Controls (first two bars) were mock transduction without virus and transduction with lentiviral vector expressing a non-targeting control gRNA. See also Figures 5A-5E and 6A-6G.
[0036] [Figure 2A] Figures 2A-E show that targeted modulation of genes encoding proteins in the nuclear membrane-associated BANF1 interaction network can promote or inhibit tau aggregation. Figure 2A shows that a string database query for BANF1 returns a functional interaction network of proteins involved in maintaining nuclear membrane integrity. [Figure 2B] Figures 2A-E show that targeted modulation of genes encoding proteins in the nuclear membrane-associated BANF1 interaction network can promote or inhibit tau aggregation. Figure 2B shows that members of the BANF1 interaction network reveal ANKLE2 as a gene whose gRNA-targeted inactivation enhances tau aggregation, measured as FRET induction (integrated FRET density, calculated as mean ± standard deviation) in biosensor cells with tau-YFP Agg+ conditioned medium. Cas9-expressing biosensor cells were transduced with a lentiviral vector expressing the targeting gRNA, LV-gRNA. Controls (first two bars) were mock-transduced without virus and transduced with a lentiviral vector expressing a control gRNA. Inactivation of ANKLE2, but not other BANF1-interacting proteins, enhances FRET induction. [Figure 2C] Figures 2A-E show that targeted modulation of genes encoding proteins in the nuclear membrane-associated BANF1 interaction network can promote or inhibit tau aggregation. Figure 2C shows confirmation that inactivation of BANF1, PPP2CA or ANKLE2, but not LEMD2 or LEMD3, by individual LV-gRNAs enhances tau aggregation measured as FRET induction by three different sources of tau seeding activity (sonicated whole cell lysates from tau-YFP Agg+ cells, purified recombinant tau fibrils, and spinal cord lysates from 9-month-old tau P301S transgenic mice). Cas9-expressing biosensor cells were transduced with individual LV-gRNAs. Controls were transduced with control gRNAs (first three bars) as well as gRNAs targeting LEMD2 and LEMD3 (last six bars), two genes not identified in the screen of network members. [Figure 2D] Figures 2A-E show that targeted modulation of genes encoding proteins in the nuclear membrane-associated BANF1 interaction network can promote or inhibit tau aggregation. Figure 2D shows a diagram of the nuclear membrane with the associated LEM domain-containing proteins ANKLE2, LEMD2, the short isoform LEMD2iso2, and LEMD3. The repair factor CHMP7 is also shown. ER, endoplasmic reticulum; NPC, nuclear pore complex; INM, inner nuclear membrane; ONM; outer nuclear membrane. [Figure 2E] Figures 2A-E show that targeted modulation of genes encoding proteins in the nuclear membrane-associated BANF1 interaction network can promote or inhibit tau aggregation. Figure 2E shows that expression in biosensor cells of cDNAs encoding LEMD2, LEMD2i2, LEMD3, and CHMP7 proteins reduces FRET induced by a strong seeding agent (tau-YFP Agg+whole cell lysate with LIPOFECTAMINE™) compared to control cells expressing firefly luciferase. Biosensor cells were transduced with lentiviral vectors expressing cDNA, LV-cDNA. Bars represent the mean integrated FRET density ± standard deviation for four replicate samples. Significance was determined using an unpaired two-tailed t-test (*p<0.01, **p<0.0001).
[0037] [Figure 3A]Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figures 3A and 3B show rescue of FRET-induced phenotypes by overexpression of LEMD2, LEMD2i2, LEMD3 and CHMP7 nuclear envelope components. dCas9-KRAB expressing biosensor cells were transduced with LV-gRNA targeting BANF1 (pink) or ANKLE2 (blue), or control gRNA (grey), which transcriptionally silence their gene targets, and LV-cDNAs encoding LEMD2, LEMD2i2, LEMD3 and CHMP7 proteins. FRET was induced by plating spinal cord lysates (Figure 3A) or tau-YFP Agg+ whole cell lysates (Figure 3B) from 9-month-old tau P301S transgenic mice. Bars represent the average integrated FRET density for three replicate samples. Graphs show the mean ± SEM. [Figure 3B] Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figures 3A and 3B show rescue of FRET-induced phenotypes by overexpression of LEMD2, LEMD2i2, LEMD3 and CHMP7 nuclear envelope components. dCas9-KRAB expressing biosensor cells were transduced with LV-gRNA targeting BANF1 (pink) or ANKLE2 (blue), or control gRNA (grey), which transcriptionally silence their gene targets, and LV-cDNAs encoding LEMD2, LEMD2i2, LEMD3 and CHMP7 proteins. FRET was induced by plating spinal cord lysates (Figure 3A) or tau-YFP Agg+ whole cell lysates (Figure 3B) from 9-month-old tau P301S transgenic mice. Bars represent the average integrated FRET density for three replicate samples. Graphs show the mean ± SEM. [Figure 3C]Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figures 3C and 3D show Western blots detecting total tau protein or tau phosphorylated on serine 356. dCas9-KRAB expressing tau biosensor cells transduced with gRNA targeting BANF1 or ANKLE2 were treated with whole cell lysates from tau-YFP Agg- cells (left) or tau-YFP Agg+ cells (right) and co-transduced with LV-cDNA for luciferase (Figure 3C) or LEMD2 (Figure 3D). Only cells treated with tau-YFP Agg+ whole cell lysates show an increase in total tau and P-tau-Ser356 in the insoluble fraction (Figure 3C, red box). This increase is prevented by transduction of LEMD2 cDNA (Figure 3D, red box). These Western blots were performed on denaturing gels and therefore cannot distinguish between monomeric and multimeric species of tau. [Figure 3D] Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figures 3C and 3D show Western blots detecting total tau protein or tau phosphorylated on serine 356. dCas9-KRAB expressing tau biosensor cells transduced with gRNA targeting BANF1 or ANKLE2 were treated with whole cell lysates from tau-YFP Agg- cells (left) or tau-YFP Agg+ cells (right) and co-transduced with LV-cDNA for luciferase (Figure 3C) or LEMD2 (Figure 3D). Only cells treated with tau-YFP Agg+ whole cell lysates show an increase in total tau and P-tau-Ser356 in the insoluble fraction (Figure 3C, red box). This increase is prevented by transduction of LEMD2 cDNA (Figure 3D, red box). These Western blots were performed on denaturing gels and therefore cannot distinguish between monomeric and multimeric species of tau. [Figure 3E]Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figure 3E shows representative confocal microscopy images of immunofluorescence detection of SRRM2 (yellow) and tau phosphorylated on serine 356 (magenta). Biosensor cells were treated with tau-YFP Agg+ whole cell lysates. In cells with tau aggregates, SRRM2 mislocalizes from the nucleus (indicated by blue DAPI staining) and colocalizes with cytoplasmic tau aggregates positive for P-tau-Ser356. [Figure 3F] Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figure 3F shows representative confocal microscopy images of immunofluorescence detection of SRRM2 (yellow) in dCas9-KRAB expressing biosensor cells transduced with control gRNA or gRNA targeting BANF1 or ANKLE2 and treated with tau-YFP Agg+ whole cell lysate. In cells depleted for BANF1 and ANKLE2, some SRRM2 is detected as cytoplasmic foci close to the nucleus. DAPI staining (blue) identifies the nucleus. Scale bar = 20 μm. [Figure 3G] Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates, and Figure 3G shows histogram plots showing the percentage of cells with only nuclear SRRM2 (solid color) and cells with nuclear as well as mislocalized cytoplasmic SRRM2 (hatched lines). [Figure 3H] Figures 3A-H show the identification of genes whose overexpression rescues tau aggregates. Figure 3H shows the quantification of the percentage of total SRRM2 immunofluorescence intensity in the nucleus of each cell. Quantification for biosensor cells depleted of BANF1 is shown in pink, for ANKLE2 in blue, and for control cells in grey. Fluorescence images of individual cells were quantified by Harmony software (Perkin-Elmer). Bar heights represent the mean ± SEM of all cells analyzed (n=113). Significance was determined using an unpaired two-tailed t-test (**p<0.0001).
[0038] [Figure 4A] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4A shows representative confocal microscopy images of immunofluorescence staining for P-tau-Ser356 (yellow) and microtubule-associated protein 2 (MAP2, red) in wild-type primary mouse cortical neurons 14 days after transduction with lentiviral vectors co-expressing Cas9 with either control gRNA or gRNA-targeting Banf1. DAPI staining (blue) identifies nuclei. Scale bar = 50 μm. [Figure 4B] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4B shows quantification of DAPI+ cells per culture well. [Figure 4C] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4C shows quantification of P-tau-Ser356 in cell bodies. [Figure 4D] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4D shows quantification of P-tau-Ser356 in the nucleoplasm. [Figure 4E] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4E shows quantification of P-tau-Ser356 in the perinuclear domain of control and Ankle2, Banf1, and Ppp2ca mutant cells. Primary mouse cortical neurons transduced with LV-Cas9-gRNA were immunostained with antibodies against MAP2 or P-tau-Ser356. [Figure 4F]Figure 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4F shows representative microscopy images of live primary mouse cortical neurons expressing EF1a-nls:mCherry treated for 8 days with gymnotically delivered ASOs. Brightfield and mCherry views (left, red) and merged images of mCherry alone (right, white) are shown. Scale bar = 10 µm. [Figure 4G] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances the production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figures 4G and 4H show Banf1 and Ankle2 relative expression, respectively, assessed by TaqMan qRT-PCR and normalized to control treatment. Each value represents the mean ± STDEV of two replicates. Gapdh expression was used as a reference gene. [Figure 4H] Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances the production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figures 4G and 4H show Banf1 and Ankle2 relative expression, respectively, assessed by TaqMan qRT-PCR and normalized to control treatment. Each value represents the mean ± STDEV of two replicates. Gapdh expression was used as a reference gene. [Figure 4I]Figures 4A-I show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons enhances the production of tau phosphorylated on serine 356 and impairs nuclear membrane integrity. Figure 4I shows quantification of mCherry fluorescence intensity. Three equivalent areas were measured in somas per cell. Graphs show mean ± SEM (n = 12 for Figures 4B-E and n = 7 for Figure 4I), analyzed by Mann-Whitney U test, two-tailed exact significance, *p<0.01, **p<0.007, ***p<0.0001, ns=not significant). See also Figures 8A-K and 9A-G.
[0039] [Figure 5A] Figure 5A-H show the development of a tau biosensor cell-based screening platform. Figure 5A shows negatively stained Transmission Electron Microscopy (TEM) micrographs of recombinant tau Q244-E372;P301L,V337M (tau 244-372LM tau) fibrils. [Figure 5B] Figures 5A-H show the development of a tau biosensor cell-based screening platform. Figure 5B shows static Thioflavin T (ThT) fluorescence of tau 244-372LM monomers and fibrils, demonstrating that fibrils, but not monomers, bind the amyloid-specific dye ThT. [Figure 5C]Figures 5A-H show the development of a tau biosensor cell-based screening platform. Figures 5C and 5D show the fibril formation kinetics of tau 244-372 LM (Figure 5C) with heparin or (Figure 5D) without heparin monitored by ThT fluorescence. Tau 244-372 LM was incubated at 37 °C with dual orbital shaking at 700 rpm, with a tau-to-heparin ratio of 4:1, and with or without heparin. With heparin, all three concentrations tested (50, 25, and 10 μM) show a rapid increase in ThT intensity corresponding to T1 / 2-0.5 h. Tau 244-372LM incubated without heparin showed a concentration-dependent increase in ThT intensity, with 50 μM Tau 244-372LM showing a T1 / 2~14 hours and 25 μM Tau 244-372LM showing a T1 / 2~31 hours, whereas 10 μM Tau 244-372LM did not show any increase in ThT intensity within the 120 hours measured. [Figure 5D] Figures 5A-H show the development of a tau biosensor cell-based screening platform. Figures 5C and 5D show the fibril formation kinetics of tau 244-372 LM (Figure 5C) with heparin or (Figure 5D) without heparin monitored by ThT fluorescence. Tau 244-372 LM was incubated at 37 °C with dual orbital shaking at 700 rpm, with a tau-to-heparin ratio of 4:1, and with or without heparin. With heparin, all three concentrations tested (50, 25, and 10 μM) show a rapid increase in ThT intensity corresponding to T1 / 2-0.5 h. Tau 244-372LM incubated without heparin showed a concentration-dependent increase in ThT intensity, with 50 μM Tau 244-372LM showing a T1 / 2~14 hours and 25 μM Tau 244-372LM showing a T1 / 2~31 hours, whereas 10 μM Tau 244-372LM did not show any increase in ThT intensity within the 120 hours measured. [Figure 5E]Figure 5A-5H show the development of a tau biosensor cell-based screening platform. Figure 5E shows that tau biosensor cells are HEK293T cells containing the P301S pathogenic mutation and carrying two transgenes expressing the 4-repeat domain (4RD) of human protein tau fused to a CFP or YFP fluorescent reporter. Upon treatment with a source of tau seeding activity, the biosensor cells form visible tau aggregates that are phosphorylated on Ser356. The biosensor cells generate a FRET signal upon tau aggregation. [Figure 5F] Figures 5A-H show the development of a tau biosensor cell-based screening platform. Figure 5F shows a representative confocal microscopy image of biosensor cells seeded with whole cell lysate from tau-YFP Agg+ cells, showing immunofluorescence detection of P-tau-Ser356 (magenta) and aggregated tau protein (tau-YFP, visualized in yellow). DAPI staining (blue) indicates nuclei. Scale bar = 20 µm. [Figure 5G] Figure 5A-5H show the development of the tau biosensor cell-based screening platform. Figure 5G shows the evaluation of the tau biosensor Cas9 clones. Cas9 transgene expression was evaluated by TaqMan qRT-PCR and cleavage efficiency was evaluated by digital PCR (dPCR) 3 and 7 days after transduction of gRNA targeting PERK. [Figure 5H] Figure 5A-H show the development of a tau biosensor cell-based screening platform. Figure 5H shows a plot of gRNA enrichment versus p-value in FRET+ cells at day 10 compared to cells at day 6. The gRNA targeting BANF1 is indicated by a circle labeled with an "X."
[0040] [Figure 6A]Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and associated phenotypes. Figure 6A shows that treatment with Tau-YFP Agg+ conditioned medium is necessary to generate a FRET signal and to detect the enhancement of the FRET signal resulting from disruption of tau modifier genes. Treatment with fresh medium did not result in a FRET signal, even after disruption of BANF1 or PPP2CA. [Figure 6B] Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and associated phenotypes. Figure 6B shows Western blots demonstrating specific reduction of protein levels in Cas9-expressing biosensor cells after transduction with LV-gRNA targeting BANF1 or PPP2CA. [Figure 6C] Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and associated phenotypes. Figure 6C shows that single-cell knockdown clones were isolated using Cas9-expressing biosensor cells transduced with LV-gRNA targeting BANF1 or PPP2CA. These clones show increased FRET induction only after treatment with Tau-YFP Agg+ conditioned medium, which correlates with the percentage of gene editing at the targeted locus as assessed by NGS (Next Generation Sequencing). In Figure 6C, FRET induction is calculated as integrated FRET density, and each value represents the mean ± STDEV of at least two replicates. [Figure 6D] Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and related phenotypes. Figure 6D shows co-transduction of multiple LV-gRNAs into biosensor cells at high MOI (Multiplicity Of Infection). Co-transduction of LV-gRNAs targeting BANF1, ANKLE2 and PPP2CA in different combinations does not result in increased FRET induction compared to targeting ANKLE2 alone. [Figure 6E]Figure 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and associated phenotypes. Figure 6E shows validation of the CRISPRa SAM activation system in biosensor cells. Tau biosensor cells expressing dCas9-SAM were transduced with LV-gRNAs targeting one of the 11 genes, respectively. TaqMan expression analysis revealed that SAM-mediated transcriptional activation (as RPKM, normalization unit for transcript expression) was inversely correlated with basal transcript levels. [Figure 6F] Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and related phenotypes. Figures 6F and 6G show cDNA expression analysis of potential tau modifier genes. Biosensor cells were transduced with individual lentiviral packaging cDNAs, LV-cDNAs, which induce high expression of the encoded proteins. Transduced cells were selected and collected for expression analysis using TaqMan assays designed to specifically amplify these codon-optimized cDNAs (Figure 6F) and MAPT-4RD cDNA (Figure 6G). ΔCt values are shown for each specific cDNA transduced sample. Each value represents the mean ± STDEV of four replicates (individually shown as symbols). [Figure 6G] Figures 6A-G show that modulation of nuclear membrane-associated genes affects tau aggregates and related phenotypes. Figures 6F and 6G show cDNA expression analysis of potential tau modifier genes. Biosensor cells were transduced with individual lentiviral packaging cDNAs, LV-cDNAs, which induce high expression of the encoded proteins. Transduced cells were selected and collected for expression analysis using TaqMan assays designed to specifically amplify these codon-optimized cDNAs (Figure 6F) and MAPT-4RD cDNA (Figure 6G). ΔCt values are shown for each specific cDNA transduced sample. Each value represents the mean ± STDEV of four replicates (individually shown as symbols).
[0041] [Figure 7A]Figures 7A-F show genetic interactions of nuclear envelope components that modify tau aggregates. Figure 7A shows an illustration of the recently undiscovered role of BANF1 and LEMD2 to promote sealing of the nuclear envelope after injury. Mechanical stress imposed on the nucleus can result in disruption of the nuclear envelope, which is repaired by recruitment of the Endosomal Sorting Complex Required for Transport-III (ESCRT-III complex). At the site of disruption, cytoplasmic BANF1 coats exposed chromatin and recruits the membrane via interaction with LEMD2. The locally increased concentration of LEMD2 allows recruitment of CHMP7 to the inner granule membrane promoting ESCRT-III nucleation. Finally, ESCRT-III complexes with the ATPase VPS4 constrict the rupture and promote sealing of the nuclear envelope, as discussed by Zhen et al., (2021) EMBO J. 40:e106922, which is incorporated by reference in its entirety in this application. [Figure 7B] Figures 7A-7F show the genetic interactions of nuclear membrane components that modify tau aggregates. Figure 7B shows the relative expression of BANF1. [Figure 7C] Figures 7A-7F show the genetic interactions of nuclear membrane components that modify tau aggregates, and Figure 7C shows the relative expression of ANKLE2. [Figure 7D] Figures 7A-7F show the genetic interactions of nuclear membrane components that modify tau aggregates. Figure 7D shows the relative expression of MAPT-4RD in dCas9-KRAB and cDNA expressing biosensor cells. Relative expression was assessed by TaqMan qRT-PCR and normalized to control treatment. Each value represents the mean ± STDEV of at least two replicates. GAPDH expression was used as a reference gene. [Figure 7E]Figures 7A-7F show genetic interactions of nuclear membrane components that modify tau aggregates. Figure 7E shows rescue of the FRET-induced phenotype by overexpression of nuclear membrane components. Overexpression of BANF1 cDNA specifically abolishes the increase in FRET induction by tau-YFP Agg+ cell lysates resulting from BANF1 knockdown, but not from ANKLE2 knockdown, in dCas9-KRAB-expressing biosensor cells. [Figure 7F] Figures 7A-7F show genetic interactions of nuclear membrane components that modify tau aggregates. Figure 7F shows western blots detecting BANF1 protein in dCas9-KRAB expressing biosensor cells transduced with LV-gRNA targeting BANF1 or ANKLE2, seeded with whole cell lysates from Tau-YFP Agg- cells (left) or Tau-YFP Agg+ cells (right), and co-transduced with cDNA expressing luciferase (top) or BANF1 (bottom). Disruption of ANKLE2 causes mislocalization of BANF1 protein from the chromatin-bound fraction to the cytoplasmic fraction, which is not rescued by overexpression of BANF1 cDNA.
[0042] [Figure 8A] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization but has no significant effect on total tau protein. Figure 8A shows confocal images of primary mouse cortical neurons highlighting compartments of interest segmented by Harmony software: nucleoplasm (left), perinuclear domain (center), and cell body (right). [Figure 8B] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization but has no significant effect on total tau protein. Figure 8B shows the percent gene editing at the targeted cleavage site as assessed by NGS. [Figure 8C]Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but has no strong effect on total tau protein. Figure 8C shows the relative gene expression of primary mouse cortical neurons transduced with LV-Cas9-gRNA, as assessed by TaqMan qRT-PCR assay. Data are normalized to control cells. Each value represents the mean ± STDEV of four replicates. Gapdh expression was used as a reference gene. [Figure 8D] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein. Figure 8D shows representative confocal microscopy images of immunofluorescence staining for P-tau-Ser356 (yellow) and microtubule-associated protein 2 (MAP2, red) in primary cortical neurons 14 days after transduction with LV-Cas9-gRNA. DAPI staining (blue) identifies nuclei. Scale bar = 50 μm. [Figure 8E] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein, and Figure 8E shows quantification of MAP2 protein in the cell body revealing a significant reduction in signal associated with disruption of Ankle2, Banf1, and Ppp2ca, the latter being the most severe. [Figure 8F] Figures 8A-8K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein. Figure 8F shows representative confocal images of primary mouse cortical neurons immunostained for MAP2 (red) and total tau protein (yellow) after disruption of Ankle2, Banf1, or Ppp2ca. [Figure 8G]Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein, and Figure 8G shows quantification of DAPI+ cells per culture well, demonstrating clear toxicity associated with loss of Ppp2ca. [Figure 8H] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein, and Figure 8H shows quantification of MAP2 protein in the soma of primary mouse cortical neurons. [Figure 8I] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein. Figures 8I-K show quantification of total tau in the soma, perinuclear domain, and nucleocytoplasm of primary mouse cortical neurons transduced with LV-Cas9-gRNA and immunostained with antibodies against map2 or total tau. Graphs show mean ± SEM (n=12), analyzed by Mann-Whitney U test, two-tailed exact significance, *p<0.01, ns=not significant. [Figure 8J] Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein. Figures 8I-K show quantification of total tau in the soma, perinuclear domain, and nucleocytoplasm of primary mouse cortical neurons transduced with LV-Cas9-gRNA and immunostained with antibodies against map2 or total tau. Graphs show mean ± SEM (n=12), analyzed by Mann-Whitney U test, two-tailed exact significance, *p<0.01, ns=not significant. [Figure 8K]Figures 8A-K show that disruption of Ankle2, Banf1, or Ppp2ca in primary mouse cortical neurons affects phosphorylation and subcellular localization, but not total tau protein. Figures 8I-K show quantification of total tau in the soma, perinuclear domain, and nucleocytoplasm of primary mouse cortical neurons transduced with LV-Cas9-gRNA and immunostained with antibodies against map2 or total tau. Graphs show mean ± SEM (n=12), analyzed by Mann-Whitney U test, two-tailed exact significance, *p<0.01, ns=not significant.
[0043] [Figure 9A] Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9B]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9C]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9D]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9E]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9F]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. [Figure 9G]Figures 9A-G show that Lemd2, Lemd3 and Chmp7 cDNAs can rescue increased phosphorylated tau-Ser356 in Banf1 or Ankle2 targeted knockdown in primary mouse cortical neurons. Neurons were treated with individual ASOs via gymnotic delivery for 10 days. ASOs were replenished at each medium change. LV-hSyn1-cDNA was transduced 4 days after the first ASO treatment. Quantification of DAPI+ cells per replicate well, MAP2 protein in neuronal soma, P-tau-Ser356 in soma, perinuclear domain and nucleocytoplasmic domain is shown in Figures 9A-D. Neurons were transduced with LV-hSyn1-cDNA encoding luciferase (Figure 9A), Lemd2 (Figure 9B), Lemd3 (Figure 9C), and Chmp7 (Figure 9D). On day 14, the relative expression of ASO-treated neurons for Banf1 (Figure 9E) or Ankle2 (Figure 9F) was assessed by target-specific TaqMan qRT-PCR assays as well as codon-optimized cDNA-specific TaqMan assays (Figure 9G). Graphs show mean ± SEM (n=12), two-tailed exact significance analyzed by Mann-Whitney U test, *p<0.05, **p<0.005, ***p<0.0001, ns=not significant. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0044] definition The terms "protein," "polypeptide," and "peptide," used interchangeably herein, include polymeric forms of amino acids of any length, including coded and non-coded amino acids and amino acids that have been chemically or biochemically modified or derivatized. These terms also include modified polymers, such as polypeptides having modified peptide backbones. The term "domain" refers to any portion of a protein or polypeptide having a specific function or structure.
[0045] The terms "nucleic acid" and "polynucleotide," used interchangeably herein, include polymeric forms of nucleotides of any length, including ribonucleotides, deoxyribonucleotides, or analogs or modified versions thereof. These include single-, double-, and multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, and polymers that contain purine bases, pyrimidine bases, or other natural, chemically modified, biochemically modified, non-natural, or derivatized nucleotide bases.
[0046] The term "expression vector" or "expression construct" or "expression cassette" refers to a recombinant nucleic acid comprising a desired coding sequence operably linked to appropriate nucleic acid sequences necessary for expression of the operably linked coding sequence in a particular host cell or organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), a ribosome binding site, and other sequences. Eukaryotic cells are generally well known to utilize promoters, enhancers, termination and polyadenylation signals, and some elements may be deleted and others added without sacrificing the required expression.
[0047] The term "viral vector" refers to a recombinant nucleic acid that contains at least one element of viral origin and contains elements sufficient for or permitting packaging into a viral vector particle. The vectors and / or particles can be used to transfer DNA, RNA, or other nucleic acids into cells, either ex vivo or in vivo. Many forms of viral vectors are well known.
[0048] The term "isolated" with respect to proteins, nucleic acids, and cells includes proteins, nucleic acids, and cells that are relatively purified, usually with respect to other cellular or biological components that may be present in situ, up to and including substantially pure preparations of proteins, nucleic acids, or cells. The term "isolated" may also include proteins and nucleic acids that have no naturally occurring counterpart, or proteins or nucleic acids that are chemically synthesized and thus are substantially uncontaminated by other proteins or nucleic acids. The term "isolated" may also include proteins, nucleic acids, or cells that have been separated or purified from most other cellular or biological components with which they are naturally associated (e.g., other cellular proteins, nucleic acids, or cellular or extracellular components).
[0049] The term "wild type" includes entities that have a structure and / or activity as found in a normal state or context (as opposed to mutant, diseased, altered, etc.). Wild-type genes and polypeptides often exist in multiple alternative forms (e.g., alleles).
[0050] The term "endogenous sequence" refers to a nucleic acid sequence that is naturally occurring in a cell or animal. For example, an endogenous LEMD2 sequence of an animal refers to the native LEMD2 sequence that is naturally occurring at the LEMD2 locus of the animal.
[0051] "Exogenous" molecules or sequences include molecules or sequences that are not normally present in a cell in that form or that are introduced into a cell from an external source. Normal presence includes presence in relation to a particular developmental stage and environmental conditions of the cell. Exogenous molecules or sequences can include, for example, mutated versions of a corresponding endogenous sequence in a cell, such as a humanized version of an endogenous sequence, or can include a sequence that corresponds to an endogenous sequence within a cell but in a different form (i.e., not within a chromosome). In contrast, endogenous molecules or sequences include molecules or sequences that are normally present in that form, in a particular cell, at a particular developmental stage, and under particular environmental conditions.
[0052] The term "heterologous" when used in the context of a nucleic acid or a protein indicates that the nucleic acid or protein comprises at least two segments that do not naturally occur together in the same molecule. For example, the term "heterologous" when used in reference to a segment of a nucleic acid or a segment of a protein indicates that the nucleic acid or protein comprises two or more subsequences that are not found in the same relationship (e.g., linked together) to each other in nature. As an example, a "heterologous" region of a nucleic acid vector is a segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with that other molecule in nature. For example, a heterologous region of a nucleic acid vector can include a coding sequence adjacent to a heterologous promoter that is not found in association with the coding sequence in nature. Similarly, a "heterologous" region of a protein is a segment of amino acids within or attached to another peptide molecule that is not found in association with other peptide molecules in nature (e.g., a fusion protein, or a tagged protein). Similarly, a nucleic acid or protein can include a heterologous label or a heterologous secretion or localization sequence.
[0053] "Codon optimization" refers to the process of modifying a nucleic acid sequence for enhanced expression in a particular host cell by taking advantage of the degeneracy of codons, as indicated by the diversity of combinations of three base pair codons that specify amino acids, generally by replacing at least one codon of the native sequence with a codon that is more frequently or most frequently used in the host cell's genes while maintaining the native amino acid sequence. For example, a nucleic acid encoding a Cas9 protein can be modified to an alternative codon that is more frequently used in a given prokaryotic or eukaryotic cell, including bacterial cells, yeast cells, human cells, non-human cells, mammalian cells, rodent cells, mouse cells, rat cells, hamster cells, or any other host cell, compared to the naturally occurring nucleic acid sequence. Codon usage tables are readily available, for example in the "Codon Usage Database." These tables can be applied in a variety of ways. See Nakamura et al. (2000), Nucleic Acids Research 28:292, which is incorporated herein by reference in its entirety in this application. Computer algorithms are also available (see, eg, Gene Forge) for codon optimization of a particular sequence for expression in a particular host.
[0054] A "promoter" is a regulatory region of DNA, usually including a TATA box, that can direct RNA polymerase II to begin RNA synthesis at the appropriate transcription initiation site for a particular polynucleotide sequence. A promoter may further include other regions that affect the rate of transcription initiation. The promoter sequences disclosed herein regulate the transcription of an operably linked polynucleotide. The promoter may be active in one or more cell types disclosed herein (e.g., eukaryotic cells, non-human mammalian cells, human cells, rodent cells, pluripotent cells, one-cell stage embryos, differentiated cells, or combinations thereof). The promoter may be, for example, a constitutively active promoter, a conditional promoter, an inducible promoter, a temporally restricted promoter (e.g., a developmentally regulated promoter), or a spatially restricted promoter (e.g., a cell-specific promoter or a tissue-specific promoter). Examples of promoters can be found, for example, in PCT International Publication WO2013 / 176772, which is incorporated by reference in its entirety.
[0055] A constitutive promoter is one that is active in all tissues or in a particular tissue at all developmental stages. Examples of constitutive promoters include human cytomegalovirus immediate early (hCMV), mouse cytomegalovirus immediate early (mCMV), human elongation factor 1 alpha (hEF1α), mouse elongation factor 1 alpha (mEF1α), mouse phosphoglycerate kinase (PGK), chicken beta actin hybrid (CAG or CBh), SV40 early, and beta2 tubulin promoters.
[0056] Examples of inducible promoters include, for example, chemically regulated promoters and physically regulated promoters. Examples of chemically regulated promoters include, for example, alcohol regulated promoters (e.g., alcohol dehydrogenase (alcA) gene promoter), tetracycline regulated promoters (e.g., tetracycline responsive promoter, tetracycline operator sequence (tetO), tet-On promoter, or tet-Off promoter), steroid regulated promoters (e.g., rat glucocorticoid receptor, estrogen receptor promoter, or ecdysone receptor promoter), or metal regulated promoters (e.g., metalloprotein promoters). Examples of physically regulated promoters include, for example, temperature regulated promoters (e.g., heat shock promoters), and light regulated promoters (e.g., light inducible promoters or light repressible promoters).
[0057] The tissue-specific promoter can be, for example, a neuronal cell-specific promoter.
[0058] Developmentally-regulated promoters include, for example, promoters that are active only during the embryonic stages of development or only in adult cells.
[0059] "Operable linkage" or "operably linked" includes the juxtaposition of two or more components (e.g., a promoter and another sequence element) that allows for both components to function normally and for at least one of the components to mediate a function on at least one of the other components. For example, a promoter may be operably linked to a coding sequence if the promoter controls the level of transcription of the coding sequence depending on the presence or absence of one or more transcriptional regulatory factors. Operable linkage may include that such sequences are in close proximity to each other, or that they act in trans (e.g., regulatory sequences may act at a distance to control transcription of the coding sequence).
[0060] The term "in vitro" includes an artificial environment and processes or reactions that occur within an artificial environment (e.g., a test tube or an isolated cell or cell line). The term "in vivo" includes a natural environment (e.g., a cell or organism or body) and processes or reactions that occur within a natural environment. The term "ex vivo" includes cells that have been removed from an individual's body and processes or reactions that occur within such cells.
[0061] A composition or method that "comprising" or "including" one or more recited elements may include other elements not specifically recited. For example, a composition that "comprises" or "includes" a protein may include the protein alone or in combination with other components. The transitional phrase "consisting essentially of" means that the claims are to be interpreted to include the specific elements recited in the claims, as well as elements that do not materially affect the basic and novel characteristics of the claimed invention. Thus, the term "consisting essentially of" when used in the claims of the present invention is not intended to be interpreted as equivalent to "comprising."
[0062] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes examples when the event or circumstance occurs and examples when it does not occur.
[0063] The specification of a range of values includes every integer within or defining that range, and every subrange defined by integers within that range.
[0064] Unless otherwise clear from the context, the term "about" encompasses values that are ±5% of the stated value.
[0065] The term "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items, including the lack of combinations when interpreted in the alternative ("or").
[0066] The term "or" refers to any one member of a particular list, and also includes any combination of members of that list.
[0067] The singular articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "protein" or "at least one protein" can include a plurality of proteins, including mixtures thereof.
[0068] Statistically significant means p≦0.05. (Mode for carrying out the invention)
[0069] I. Overview The microtubule-associated protein tau is an abundant component of neurons in the central nervous system, where it functions to maintain microtubule stability and promote axonal growth. In Alzheimer's disease and other neurodegenerative tauopathies, tau is found to be hyperphosphorylated and aggregated in neurofibrillary tangles. To gain a better understanding of the cellular perturbations that initiate tau pathogenesis, we performed a CRISPR-Cas9 genetic screen for mutations that enhance tau aggregation. This screen yielded three genes, BANF1, ANKLE2, and PPP2CA, whose inactivation promoted the accumulation of tau in phosphorylated and insoluble forms. In a complementary screen, we identified three additional genes, LEMD2, LEMD3, and CHMP7, that provide protection against tau aggregates when overexpressed. The proteins encoded by the identified genes are involved in the maintenance and repair of the nuclear membrane. These results implicate disruption of nuclear envelope integrity as a possible initiating event in tauopathies and reveal new targets for therapeutic intervention.
[0070] Provided herein are methods of inhibiting tau aggregates in a cell or subject, comprising administering to the cell or subject LEM domain containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Also provided herein are methods of reducing phosphorylation (e.g., phosphorylation on serine 356) in a cell or subject, comprising administering to the cell or subject LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Also provided herein are methods of reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL) in a subject, comprising administering to the subject LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Also provided herein is a method of treating a tauopathy in a subject, comprising administering to the subject LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, where LEMD2, CHMP7, or LEMD3 inhibits tau aggregates in cells of the subject. Also provided are nucleic acids encoding LEMD2, CHMP7, or LEMD3 (e.g., in an expression construct and operably linked to a heterologous promoter), constructs comprising the nucleic acid, vectors comprising the nucleic acid or construct, lipid nanoparticles comprising the nucleic acid, construct, or vector, and cells or subjects (e.g., animals) comprising the nucleic acid, construct, vector, or lipid nanoparticle.
[0071] II. Methods of Inhibiting Tau Aggregations and Treating or Preventing Tauopathies Provided herein are methods of inhibiting tau aggregates in a cell or subject. Such methods may include administering to a cell LEM domain containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3) (i.e., exogenous LEMD2, CHMP7, or LEMD3), or such methods may include administering to a cell or to a subject a nucleic acid encoding LEMD2, CHMP7, or LEMD3 (i.e., an exogenous nucleic acid encoding LEMD2, CHMP7, or LEMD3), such that LEMD2, CHMP7, or LEMD3 is expressed. Also provided herein is a method of reducing phosphorylation (e.g., phosphorylation on serine 356) in a cell or subject, comprising administering LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 (i.e., an exogenous nucleic acid encoding LEMD2, CHMP7, or LEMD3) to the cell or subject. Phosphorylated-tau can be, for example, phosphorylated-tau (S356) or phosphorylated-tau AT8 (S202, T205). Also provided is a method of reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL) in a subject. Such a method can comprise administering LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 to the subject. Also provided is a method of treating a tauopathy in a subject. Such methods may include administering LEMD2, CHMP7, or LEMD3 (i.e., exogenous LEMD2, CHMP7, or LEMD3) to the subject, or such methods may include administering a nucleic acid encoding LEMD2, CHMP7, or LEMD3 (i.e., an exogenous nucleic acid encoding LEMD2, CHMP7, or LEMD3) to the subject such that LEMD2, CHMP7, or LEMD3 is expressed. The LEMD2, CHMP7, or LEMD3 then inhibits tau aggregation in the subject (e.g., in cells of the subject or in one or more cells of the subject).Methods of preventing tauopathy in a subject are also provided. Such methods may include administering LEMD2, CHMP7, or LEMD3 (i.e., exogenous LEMD2, CHMP7, or LEMD3) to the subject, or such methods may include administering a nucleic acid encoding LEMD2, CHMP7, or LEMD3 (i.e., an exogenous nucleic acid encoding LEMD2, CHMP7, or LEMD3) to the subject such that LEMD2, CHMP7, or LEMD3 is expressed. The LEMD2, CHMP7, or LEMD3 then inhibits tau aggregates in the subject (e.g., in cells of the subject or in one or more cells of the subject).
[0072] The microtubule-associated protein tau (also called neurofibrillary tangle protein, paired helical filament-tau (PHF-tau), or tau) is a protein that promotes the assembly and stability of microtubules and is primarily expressed in neurons and preferentially localized to the axonal compartment. Tau is encoded by the MAPT gene (also called MAPTL, MTBT1, TAU, or MTAPT). Tau plays a role in stabilizing neuronal microtubules and thus promoting axonal outgrowth. In humans, it appears as a set of six isoforms that are differentially spliced from the transcript of a single gene located on chromosome 17. Each tau isoform contains a series of 3 / 4 tandem repeat units (depending on the isoform) that bind to and stabilize microtubules. The microtubule-binding repeat region of tau is adjacent to a serine / threonine-rich region that can be phosphorylated by a variety of kinases and is associated with hyperphosphorylation of tau in a family of related neurodegenerative diseases called tauopathies.
[0073] Tau protein is the product of alternative splicing from a single gene, called MAPT (microtubule-associated protein tau) in humans. The tau repeat domain carries sequence motifs involved in aggregation (i.e., it is the aggregation-prone domain from tau). Depending on the splicing, the repeat domain of tau protein has either three or four repeat regions that constitute the aggregation-prone core of the protein, often referred to as the repeat domain (RD). Specifically, the repeat domain of tau represents the core of the microtubule-binding region and harbors the R2 and R3 hexapeptide motifs involved in tau aggregates. In the human brain, there are six tau isoforms ranging from 352 to 441 amino acids in length. These isoforms vary at the carboxyl terminus according to the presence or absence of either three or four repeat domains (R1-R4), in addition to the presence or absence of one or two insert domains at the amino terminus. A repeat domain located in the carboxyl-terminal half of tau is thought to be important for microtubule binding and for the pathological aggregation of tau into paired helical filaments (PHFs), the core components of the neurofibrillary tangles seen in tauopathies.
[0074] In some of the above methods for inhibiting tau aggregates, reducing phosphorylation, treating tauopathy, or preventing tauopathy, the method comprises administering LEMD2 or a nucleic acid encoding LEMD2 to a cell or subject. In some of the above methods for reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL), the method comprises administering LEMD2 or a nucleic acid encoding LEMD2 to a subject. For example, the LEMD2 can be wild-type LEMD2. LEMD2 is involved in the organization of nuclear structure and is necessary for maintaining the integrity of the nuclear membrane.
[0075] In one example, the LEMD2 is human LEMD2. Human LEMD2 (also called LEM domain containing protein 2, hLEM2, or LEM domain nuclear membrane protein 2) is assigned the UniProt reference number Q8NC56. The human gene encoding LEMD2 (LEMD2, or LEM domain nuclear membrane protein 2) is assigned the NCBI GeneID 221496 and is found on chromosome 6 at location 6p21.31 (construct: GRCh38.p13 (GCF_000001405.39); location: NC_000006.12 (33771213.33794274, complement)). At least two isoforms of human LEMD2 are known. The first isoform is 503 amino acids and is assigned the UniProt reference number Q8NC56-1 and the NCBI reference number NP_851853.1 (SEQ ID NO: 1). An exemplary coding sequence has been assigned the reference number CCDS4785.1 (SEQ ID NO:2), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_181336.4 (SEQ ID NO:4). A codon-optimized coding sequence to distinguish it from the natural CDS is set forth in SEQ ID NO:3. The second isoform is 201 amino acids and has been assigned the UniProt reference number Q8NC56-2 and the NCBI reference numbers NP_001137416.1 and NP_001335638.1 (SEQ ID NO:5). An exemplary coding sequence has been assigned the reference number CCDS47411.1 (SEQ ID NO:6), and exemplary mRNA (cDNA) sequences have been assigned the reference numbers NM_001143944.1 and NM_001348709.2 (SEQ ID NO:8 and SEQ ID NO:9, respectively). A codon-optimized coding sequence to distinguish it from the natural CDS is set forth in SEQ ID NO:7.
[0076] In another example, the LEMD2 is mouse LEMD2. Mouse LEMD2 has been assigned the UniProt reference number Q6DVA0. The mouse gene encoding LEMD2 (LEMD2) has been assigned the NCBI GeneID 224640 and is found on chromosome 17 at position 17;17 A3.3 (construct: GRCm39 (GCF_000001635.27); position: NC_000083.7 (27408574.27426228, complement)). An exemplary mouse LEMD2 is 511 amino acids and has been assigned the UniProt reference number Q6DVA0-1 and the NCBI reference number NP_666187.2 (SEQ ID NO: 10). An exemplary coding sequence has been assigned the reference number CCDS50043.1 (SEQ ID NO: 11), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_146075.2 (SEQ ID NO: 14). Codon-optimized coding sequences to distinguish from the native CDS are set forth in SEQ ID NO: 12 and SEQ ID NO: 13. Another codon-optimized coding sequence to distinguish from the native CDS is set forth in SEQ ID NO: 255.
[0077] In some of the above methods for inhibiting tau aggregates, reducing phosphorylation, treating tauopathy, or preventing tauopathy, the method comprises administering CHMP7 or a nucleic acid encoding CHMP7 to a cell or a subject. In some of the above methods for reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL), the method comprises administering CHMP7 or a nucleic acid encoding CHMP7 to a subject. For example, CHMP7 can be wild-type CHMP7. CHMP7 is an ESCRT-III-like protein that is required for recruiting ESCRT-III complex to the nuclear membrane during late anaphase. Together with SPAST, ESCRT-III complex promotes nuclear membrane sealing and mitotic spindle disassembly during late anaphase. CHMP7 also plays a role in the endosomal sorting pathway.
[0078] In one example, the CHMP7 is human CHMP7. Human CHMP7 (also called charged multivesicular body protein 7 or chromatin modifying protein 7) has been assigned the UniProt reference number Q8WUX9. The human gene encoding CHMP7 (CHMP7) has been assigned the NCBI GeneID 91782 and is found on chromosome 8 at position 8p21.3 (construct: GRCh38.p13 (GCF_000001405.39); position: NC_000008:11 (23243637..23262000)). An exemplary CHMP7 protein is 453 amino acids and has been assigned the UniProt reference number Q8WUX9-1 and the NCBI reference number NP_689485.1 (SEQ ID NO: 15). An exemplary coding sequence has been assigned the reference number CCDS6040.1 (SEQ ID NO: 16), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_152272.5 (SEQ ID NO: 18). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 17.
[0079] In another example, CHMP7 is mouse CHMP7. Mouse CHMP7 is assigned the UniProt reference number Q8R1T1. The mouse gene encoding CHMP7 (CHMP7) is assigned the NCBI GeneID 105513 and is found on chromosome 14 at position 14;14 D2 (construct: GRCm39 (GCF_000001635.27); position: NC_000080.7 (69954428.69970019, complement)). An exemplary mouse CHMP7 is 451 amino acids and is assigned the UniProt reference number Q8R1T1-1 and the NCBI reference number NP_598839.2 (SEQ ID NO: 19). An exemplary coding sequence has been assigned the reference number CCDS27242.1 (SEQ ID NO: 20), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_134078.4 (SEQ ID NO: 22). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 21.
[0080] In some of the above methods for inhibiting tau aggregates, reducing phosphorylation, treating tauopathy, or preventing tauopathy, the method comprises administering LEMD3 or a nucleic acid encoding LEMD3 to a cell or subject. In some of the above methods for reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL), the method comprises administering LEMD3 or a nucleic acid encoding LEMD3 to a subject. For example, the LEMD3 can be wild-type LEMD3.
[0081] In one example, the LEMD3 is human LEMD3. Human LEMD3 (also called inner nuclear membrane protein Man1 or LEM domain containing protein 3) has been assigned the UniProt reference number Q9Y2U8. The human gene encoding LEMD3 (LEMD3, MAN1, or LEM domain containing 3) has been assigned the NCBI GeneID 23592 and is found on chromosome 12 at location 12q14.3 (construct: GRCh38.p13 (GCF_000001405.39); location: NC_000012.12 (65169583..65248355)). An exemplary LEMD3 protein is 911 amino acids and has been assigned the UniProt reference number Q9Y2U8-1 and the NCBI reference number NP-055134.2 (SEQ ID NO: 23). An exemplary coding sequence has been assigned the reference number CCDS8972.1 (SEQ ID NO: 24), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_014319.5 (SEQ ID NO: 26). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 25.
[0082] In another example, the LEMD3 is mouse LEMD3. Mouse LEMD3 has been assigned the UniProt reference number Q9WU40. The mouse gene encoding LEMD3 (Lemd3) has been assigned the NCBI GeneID 380664 and is found on chromosome 10 at position 10;10 D2 (construct: GRCm39 (GCF_000001635.27); position: NC_000076.7 (120759316..120815491, complement)). An exemplary mouse LEMD3 is 921 amino acids and has been assigned the UniProt reference number Q9WU40-1 (SEQ ID NO: 27). The codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 28. Another exemplary mouse LEMD3 is 918 amino acids in length and has been assigned NCBI reference number NP_001074662.2 (SEQ ID NO: 29). An exemplary coding sequence has been assigned reference number CCDS48703.1 (SEQ ID NO: 30), and one exemplary mRNA (cDNA) sequence has been assigned reference number NM_001081193.2 (SEQ ID NO: 31).
[0083] Some such methods include administering to a cell or subject a nucleic acid encoding LEMD2, a nucleic acid encoding CHMP7, or a nucleic acid encoding LEMD3. The nucleic acid may be a nucleic acid construct, as described in more detail elsewhere herein. In some cases, the nucleic acid encoding LEMD2, CHMP7, or LEMD3 may be a native coding sequence. In other cases, it may be codon optimized (e.g., codon optimized for expression in humans or expression in mice). For example, the nucleic acid may be modified to alternative codons that are more frequently used in human cells, non-human cells, mammalian cells, rodent cells, mouse cells, rat cells, or any other host cell of interest.
[0084] The nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be DNA or RNA. The nucleic acid can optionally be messenger RNA (mRNA) encoding LEMD2, CHMP7, or LEMD3. The nucleic acid can optionally be complementary DNA (cDNA) encoding LEMD2, CHMP7, or LEMD3. For example, such a nucleic acid can include only the coding sequence without any intervening introns. In other cases, the nucleic acid can include one or more introns that separate exons in the LEMD2, CHMP7, or LEMD3 coding sequence. For example, the nucleic acid can include a LEMD2, CHMP7, or LEMD3 genomic sequence that includes both exons and introns.
[0085] In some methods, the nucleic acid is present in an expression construct that includes a nucleic acid encoding LEMD2, CHMP7, or LEMD3 operably linked to a promoter. The promoter can be any suitable promoter for in vivo expression in an animal or in vitro expression in an isolated cell. The promoter can be a constitutively active promoter (e.g., a CAG promoter or a U6 promoter), a conditional promoter, an inducible promoter, a temporally restricted promoter (e.g., a developmentally regulated promoter), or a spatially restricted promoter (e.g., a cell-specific promoter or a tissue-specific promoter). Such promoters are well known and are discussed elsewhere herein. In certain examples, the promoter is active in neuronal cells. In some cases, the promoter is a heterologous promoter (i.e., a promoter to which the LEMD2, CHMP7, or LEMD3 nucleic acid is not naturally operably linked). In other cases, the promoter can be an endogenous promoter (i.e., a LEMD2 nucleic acid operably linked to a LEMD2 promoter, a CHMP7 nucleic acid operably linked to a CHMP7 promoter, or a LEMD3 nucleic acid operably linked to a LEMD3 promoter). The heterologous promoter can be any type of promoter disclosed elsewhere herein. For example, the promoter can be a constitutive promoter, such as an EF1α promoter. Alternatively, the promoter can be a tissue-specific promoter or an inducible promoter. For example, as another example, the promoter can be a neuron-specific promoter. One example of a suitable neuron-specific promoter that is highly specific with low levels of expression is the synapsin-1 promoter (e.g., the human synapsin-1 promoter, such as the promoter set forth in SEQ ID NO: 44). In some embodiments, the synapsin-1 promoter can be used with the Hemoglobin Subunit Beta (HBB) intron 2 (e.g., downstream of the synapsin-1 promoter), such as that set forth in SEQ ID NO: 254. Inclusion of this element can enhance gene expression.
[0086] The nucleic acids and expression constructs disclosed herein can also include post-transcriptional regulatory elements, such as the post-transcriptional regulatory elements of the Woodchuck Hepatitis Virus.
[0087] The nucleic acids and expression constructs may further comprise one or more polyadenylation signal sequences. For example, the nucleic acid constructs may comprise a polyadenylation signal sequence located 3' of the LEMD2, CHMP7, or LEMD3 coding sequence. Any suitable polyadenylation signal sequence may be used. The term polyadenylation signal sequence refers to any sequence that directs the termination of transcription and the addition of a polyA tail to the mRNA transcript. In eukaryotes, transcription terminators are recognized by protein factors, and termination is followed by polyadenylation, the process of adding a poly(A) tail to the mRNA transcript in the presence of poly(A) polymerase. Mammalian poly(A) signals typically consist of a core sequence about 45 nucleotides long, which may be flanked by a variety of auxiliary sequences that serve to increase the efficiency of cleavage and polyadenylation. The core sequence, termed the polyA recognition motif or sequence, consists of a highly conserved upstream element (AATAAA or AAUAAA) in the mRNA that is recognized by the Cleavage and Polyadenylation-Specificity Factor (CPSF) and a downstream region (rich in U or G and U) that is poorly defined and bound by the cleavage stimulation factor (CstF). Examples of transcription terminators that can be used include, for example, Human Growth Hormone (HGH) polyadenylation signal, Simian Virus 40 (SV40) late polyadenylation signal, rabbit beta globin polyadenylation signal, Bovine Growth Hormone (BGH) polyadenylation signal, phosphoglycerate kinase (PGK) polyadenylation signal, AOX1 transcription termination sequence, CYC1 transcription termination sequence, or any transcription termination sequence known to be suitable for regulating gene expression in eukaryotic cells.Examples of suitable polyadenylation signals include, for example, those listed in SEQ ID NO: 252 and SEQ ID NO: 253.
[0088] The nucleic acid and expression constructs may also optionally include a polyadenylation signal sequence upstream of the LEMD2, CHMP7, or LEMD3 coding sequence. The polyadenylation signal sequence upstream of the LEMD2, CHMP7, or LEMD3 coding sequence may be adjacent to a recombinase recognition site that is recognized by a site-specific recombinase. In some constructs, the recombinase recognition site also flanks a selection cassette that includes, for example, a coding sequence for a drug resistance protein. In some constructs, the recombinase recognition site does not flank the selection cassette. The polyadenylation signal sequence prevents transcription and expression of the protein or RNA encoded by the coding sequence. However, upon exposure to a site-specific recombinase, the polyadenylation signal sequence may be excised, allowing the protein or RNA to be expressed.
[0089] Such a configuration may allow for tissue- or developmental stage-specific expression if the polyadenylation signal sequence is excised in a tissue- or developmental stage-specific manner. Excision of the polyadenylation signal sequence in a tissue- or developmental stage-specific manner may be achieved if the animal containing the nucleic acid or expression construct further comprises a coding sequence for a site-specific recombinase operably linked to a tissue- or developmental stage-specific promoter. The polyadenylation signal sequence is then excised only in those tissues or those developmental stages, allowing for tissue- or developmental stage-specific expression. In one example, the LEMD2, CHMP7, or LEMD3 encoded by the nucleic acid or expression construct may be expressed in a neuronal cell-specific manner.
[0090] Site-specific recombinases include enzymes that can promote recombination between recombinase recognition sites, where the two recombination sites are physically separated within a single nucleic acid or on separate nucleic acids. Examples of recombinases include Cre, Flp, and Dre recombinase. One example of a Cre recombinase gene is Crei, where the two exons encoding Cre recombinase are separated by an intron, preventing expression in prokaryotic cells. Such recombinases may further include a nuclear localization signal to promote localization to the nucleus (e.g., NLS-Crei). Recombinase recognition sites include nucleotide sequences that can be recognized by site-specific recombinases and serve as substrates for recombination events. Examples of recombinase recognition sites include FRT, FRT11, FRT71, attp, att, rox, and lox sites, such as loxP, lox511, lox2272, lox66, lox71, loxM2, and lox5171.
[0091] The nucleic acids disclosed herein may comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), which may be single-stranded or double-stranded, and which may be in linear or circular form. The nucleic acid constructs may be naked nucleic acids, as described elsewhere herein, or may be delivered by vectors, such as AAV vectors. When in linear form, the ends of the nucleic acid may be protected (e.g., from exonuclease degradation) by well-known methods. For example, one or more dideoxynucleotide residues may be added to the 3' end of the linear molecule, and / or self-complementary oligonucleotides may be attached to one or both ends. See, for example, Chang et al. (1987) Proc. Natl. Acad. Sci. USA 84:4959-4963, and Nehls et al. (1996) Science 272:886-889, each of which is incorporated herein by reference in its entirety. Additional methods for protecting exogenous polynucleotides from degradation include, but are not limited to, the addition of terminal amino groups and the use of modified internucleotide linkages, such as, for example, phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues. The nucleic acid or expression construct may optionally include one or more of the following terminal structures: hairpins, loops, inverted terminal repeats (ITRs), or toroids. For example, the nucleic acid or expression construct may include ITRs.
[0092] The nucleic acid or expression construct may include modifications or sequences that provide additional desirable features (e.g., modified or regulated stability, tracking or detection by fluorescent labels, binding sites for proteins or protein complexes, etc.). The nucleic acid construct may include one or more fluorescent labels, purification tags, epitope tags, or combinations thereof. For example, the nucleic acid construct may include one or more fluorescent labels (e.g., fluorescent proteins or other fluorophores or dyes), such as at least one, at least two, at least three, at least four, or at least five fluorescent labels. Exemplary fluorescent labels include fluorophores such as fluorescein (e.g., 6-carboxyfluorescein (6-FAM)), Texas Red, HEX, Cy3, Cy5, Cy5.5, Pacific Blue, 5-(and-6)-carboxytetramethylrhodamine (TAMRA), and Cy7. A wide range of fluorescent dyes for labeling oligonucleotides are commercially available (e.g., from Integrated DNA Technologies). The label or tag can be at the 5' end, the 3' end, or internally of the nucleic acid construct. For example, the nucleic acid construct can be conjugated to the 5' end with an IR700 fluorophore (5'IRDYE® 700) from Integrated DNA Technologies.
[0093] The nucleic acids and expression constructs may also include conditional alleles. The conditional alleles may be multifunctional alleles, as described in US 2011 / 0104799, the entire contents of which are incorporated herein by reference in this application. For example, the conditional allele may include (a) an operating sequence in a sense orientation relative to the transcription of a target gene, (b) a drug selection cassette (DSC) in a sense or antisense orientation, (c) a nucleotide sequence of interest (Nucleotide Sequence of Interest (NSI)) in an antisense orientation, and (d) a conditional by inversion module (COIN, utilizing an exon split intron and an invertible gene trap-like module) in an inverted orientation. See, for example, US 2011 / 0104799. The conditional allele may further comprise recombinable units that recombine upon exposure to a first recombinase to form a conditional allele that (i) lacks an operating sequence and a DSC, and (ii) comprises an NSI in a sense orientation and a COIN in an antisense orientation. See, e.g., US 2011 / 0104799.
[0094] The nucleic acid and expression construct may also include a polynucleotide encoding a selection marker. Alternatively, the nucleic acid and expression construct may lack a polynucleotide encoding a selection marker. The selection marker may be included in a selection cassette. Optionally, the selection cassette may be a self-deleting cassette. See, for example, U.S. Pat. Nos. 8,697,851 and 2013 / 0312129, each of which is incorporated herein by reference in its entirety in this application. By way of example, the self-deleting cassette may include a Crei gene (comprising two exons, encoding Cre recombinase, separated by an intron) operably linked to a mouse Prm1 promoter and a neomycin resistance gene operably linked to a human ubiquitin promoter. The Prm1 promoter may be used to specifically delete the self-deleting cassette in the male germ cells of the F0 animal. Exemplary selection markers include neomycin phosphotransferase (neomycin phosphotransferase) and the human ubiquitin promoter. r ), hygromycin B phosphotransferase (hyg r ), puromycin N-acetyltransferase (puro r ), Blasticidin S deaminase (bsr r ), xanthine / guanine phosphoribosyltransferase (gpt), or herpes simplex virus thymidine kinase (HSV-k), or a combination thereof. The polynucleotide encoding the selection marker may be operably linked to a promoter active in the targeted cells. Examples of promoters are described elsewhere herein.
[0095] The nucleic acid or expression construct may also include a reporter gene. Exemplary reporter genes include those encoding luciferase, β-galactosidase, Green Fluorescent Protein (GFP), enhanced Green Fluorescent Protein (eGFP), Cyan Fluorescent Protein (CFP), Yellow Fluorescent Protein (YFP), enhanced Yellow Fluorescent Protein (eYFP), Blue Fluorescent Protein (BFP), enhanced Blue Fluorescent Protein (eBFP), DsRed, ZsGreen, MmGFP, mPlum, mCherry, tdTomato, mStrawberry, J-Red, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, Cerulean, T-Sapphire, and alkaline phosphatase. Such a reporter gene may be operably linked to a promoter that is active in the targeted cells, examples of which are described elsewhere herein.
[0096] The nucleic acid or expression construct can be in a vector, such as a viral vector. The vector can include additional sequences, such as, for example, an origin of replication, a promoter, and genes encoding antibiotic resistance.
[0097] Some vectors may be circular. Alternatively, vectors may be linear. Vectors may be packaged for delivery via lipid nanoparticles, liposomes, non-lipid nanoparticles, or viral capsids. Non-limiting exemplary vectors include plasmids, phagemids, cosmids, artificial chromosomes, mini-chromosomes, transposons, viral vectors, and expression vectors.
[0098] The nucleic acid or expression construct can be in a vector, such as a viral vector. The viral vector can be, for example, an adeno-associated viral (AAV) vector or a lentiviral (LV) vector (i.e., a recombinant AAV vector or a recombinant LV vector). Other exemplary viruses / viral vectors include retroviruses, adenoviruses, vaccinia viruses, poxviruses, and herpes simplex viruses. The virus can infect dividing cells, non-dividing cells, or both dividing and non-dividing cells. The virus can integrate into the host genome, or alternatively, does not integrate into the host genome. Such viruses can also be engineered to reduce immunity. The virus can be replication competent or replication deficient (e.g., defective in one or more genes required for additional rounds of virion replication and / or packaging). The virus can cause transient expression, long-term expression (e.g., at least 1 week, 2 weeks, 1 month, 2 months, or 3 months), or permanent expression. Exemplary viral titers (e.g., AAV titers) include titers of about 10 12 , about 10 13 , about 10 14 , about 10 15 , and about 10 16 Other exemplary viral titers (e.g., AAV titers) include about 10 12 , about 10 13 , about 10 14 , about 10 15 , and about 10 16 Vector genomes (vg) / kg body weight are included.
[0099] In one example, the nucleic acid or expression construct is present in an AAV vector. AAV can be of any suitable serotype and can be single-stranded AAV (ssAAV) or self-complementary AAV (scAAV). The ssDNA AAV genome is composed of two open reading frames, Rep and Cap, flanked by two inverted terminal sequences that allow the synthesis of complementary DNA strands. When constructing an AAV transfer plasmid, the transgene is placed between the two ITRs, and Rep and Cap can be supplied in trans. In addition to Rep and Cap, AAV may require a helper plasmid that contains genes from adenovirus. These genes (E4, E2a, and VA) mediate AAV replication. For example, the transfer plasmid, Rep / Cap, and helper plasmid can be transfected into HEK293 cells that contain adenovirus genes E1+ to generate infectious AAV particles. Alternatively, the Rep, Cap and adenovirus helper genes may be combined into a single plasmid. Similar packaging cells and methods can be used for other viruses, such as retroviruses.
[0100] Several serotypes of AAV have been identified. These serotypes differ in the type of cells they infect (i.e., their tropism), allowing preferential transduction of certain cell types. Serotypes for CNS tissues include AAV1, AAV2, AAV4, AAV5, AAV8, and AAV9. The selectivity of AAV serotypes for gene delivery in neural cells is described, for example, in Hammond et al. (2017) PLoS One 12(12):e0188830, which is incorporated herein by reference in its entirety in this application. In a specific embodiment, the AAV-PHP.eB vector is used. The AAV-PHP.eB vector shows a high ability to cross the blood-brain barrier, increasing its CNS transduction efficiency. In a specific embodiment, the AAV9 vector is used.
[0101] Tropism can be further refined by pseudotyping, which is a mixture of capsids and genomes from different viral serotypes. For example, AAV2 / 5 refers to a virus that contains a serotype 2 genome packaged in a serotype 5 capsid. The use of pseudotyped viruses can not only improve transduction efficiency but also alter tropism. Hybrid capsids from different serotypes can also be used to modify the tropism of the virus. For example, AAV-DJ contains hybrid capsids from eight serotypes and shows high infectivity across a wide range of cell types in vivo. AAV-DJ8 is another example that shows the properties of AAV-DJ but with enhanced brain uptake. AAV serotypes can also be modified by mutation. Examples of mutational modifications of AAV2 include Y444F, Y500F, Y730F, and S662V. Examples of mutational modifications of AAV3 include Y705F, Y731F, and T492V. Examples of mutational modifications of AAV6 include S663V and T492V. Other pseudotype / modified AAV variants include AAV2 / 1, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2.5, AAV8.2, and AAV / SASTG.
[0102] To accelerate transgene expression, self-complementary AAV (scAAV) mutants can be used. Because AAV relies on the cell's DNA replication machinery to synthesize the complementary strand of the AAV's single-stranded DNA genome, transgene expression may be delayed. To address this delay, scAAV can be used, which contains complementary sequences that can spontaneously anneal upon infection, eliminating the need for host cell DNA synthesis. However, single-stranded AAV (ssAAV) vectors can also be used.
[0103] To increase packaging capacity, a longer transgene may be split into two AAV transfer plasmids, one being the 3' splice donor and the second being the 5' splice acceptor. Upon co-infection of cells, these viruses may form concatemers and be spliced together to express the full-length transgene. This allows for expression of longer transgenes, but at a reduced efficiency of expression. A similar method to increase capacity utilizes homologous recombination. For example, a transgene may be split into two transfer plasmids, but with substantial sequence overlap, such that co-expression induces homologous recombination and expression of the full-length transgene.
[0104] In some methods, LEMD2, CHMP7, or LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3, is associated with a lipid nanoparticle. The lipid formulation can protect biomolecules from degradation while improving cellular uptake. Lipid nanoparticles are particles that contain multiple lipid molecules physically bound to each other by intermolecular forces. These include microspheres (including unilamellar and multilamellar vesicles, e.g., liposomes), the dispersed phase in an emulsion, micelles, or the internal phase in a suspension. Such lipid nanoparticles can be used to encapsulate one or more nucleic acids or proteins for delivery. Formulations that include cationic lipids are useful for delivering polyanions such as nucleic acids. Other lipids that can be included are neutral lipids (i.e., uncharged lipids or zwitterionic lipids), anionic lipids, helper lipids that enhance transfection, and stealth lipids that increase the time that nanoparticles can exist in vivo. Examples of suitable cationic lipids, neutral lipids, anionic lipids, helper lipids, and stealth lipids can be found in PCT International Publication WO2016 / 010840A1, the entire contents of which are incorporated herein by reference in this application. Exemplary lipid nanoparticles can include cationic lipids and one or more other components. In one example, the other components can include a helper lipid such as cholesterol. In another example, the other components can include a helper lipid such as cholesterol and a neutral lipid such as DSPC. In another example, the other components can include a helper lipid such as cholesterol, any neutral lipid such as DSPC, and a stealth lipid such as S010, S024, S027, S031, or S033.
[0105] LNPs may contain one or more or all of the following: (i) lipids for encapsulation and endosomal escape, (ii) neutral lipids for stabilization, (iii) helper lipids for stabilization, and (iv) stealth lipids. See, e.g., Farnleitner et al., (2018) Cell Rep. 22(9):2227-2235, and PCT International Publication WO2017 / 173054A1, each of which is incorporated herein by reference in its entirety. A specific example of using LNPs for delivery to the brain is disclosed in Nabhan et al., (2016) Sci.Rep. 6:20019, which is incorporated herein by reference in its entirety.
[0106] LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be administered to a cell or subject by any suitable means. Various methods and compositions are provided herein to allow for the introduction of a molecule (e.g., a nucleic acid or a protein) into a cell or subject.
[0107] The methods provided herein do not depend on a particular method for introducing a nucleic acid or protein into a cell, but only on the ability of the nucleic acid or protein to access the interior of the cell. Methods for introducing nucleic acids and proteins into various cell types are well known in the art and include, for example, stable transfection methods, transient transfection methods, and viral-mediated methods.
[0108] Transfection protocols and protocols for introducing molecules (e.g., nucleic acids or proteins) into cells can vary. Non-limiting transfection methods include chemical transfection methods using liposomes; nanoparticles; calcium phosphate (Graham et al., (1973) Virology 52(2):456-67; Bacchetti et al., (1977) Proc. Natl. Acad. Sci. USA 74(4):1590-4; and Kriegler, M (1991). Transcription and Expression: A Laboratory Manual. New York: WH Freeman and Company. pp9697, each of which is incorporated herein by reference in its entirety in this application), dendrimers, or cationic polymers such as DEAE-dextran or polyethyleneimine. Non-chemical methods include electroporation, sonoporation, and phototransfection. Particle-based transfection includes the use of a gene gun or magnet-assisted transfection (Bertram (2006) Current Pharmaceutical Biotechnology 7, 277-28, which is incorporated herein by reference in its entirety). Viral methods can also be used for transfection.
[0109] The introduction of molecules (e.g., nucleic acids or proteins) into cells can also be mediated by electroporation, intracytoplasmic injection, viral infection, adenovirus, adeno-associated virus, lentivirus, retrovirus, transfection, lipid-mediated transfection, or nucleofection. Nucleofection is an improved electroporation technique that allows delivery of nucleic acid substrates not only to the cytoplasm but also to the nucleus through the nuclear membrane. It should be noted that the use of nucleofection in the methods disclosed herein typically requires much fewer cells than conventional electroporation (e.g., only about 2 million cells compared to 7 million cells for conventional electroporation). In one example, nucleofection is performed using the LONZA® NUCLEOFECTOR™ system.
[0110] Introduction of molecules (e.g., nucleic acids or proteins) into cells can also be achieved by microinjection. Microinjection of mRNA is preferably into the cytoplasm (e.g., to deliver the mRNA directly to the translation machinery), while microinjection of proteins or DNA encoding proteins is preferably into the nucleus. Alternatively, microinjection can be performed by injection into both the nucleus and the cytoplasm, but the needle can first be introduced into the nucleus and the first amount injected, and the second amount injected into the cytoplasm while removing the needle from the cell. Methods for performing microinjection are well known. See, e.g., Nagy et al. (Nagy A, Gertsenstein M, Vintersten K, Behringer R., 2003, "Manipulating the Mouse Embryo." Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press), Meyer et al. (2010) Proc. Natl. Acad. Sci. USA 107:15022-15026, and Meyer et al. (2012) Proc. Natl. Acad. Sci. USA 109:9354-9359, the entireties of which are incorporated herein by reference.
[0111] Other methods for introducing molecules (e.g., nucleic acids or proteins) into cells may include, for example, vector delivery, particle-mediated delivery, exosome-mediated delivery, lipid nanoparticle-mediated delivery, cell-penetrating peptide-mediated delivery, or implantable device-mediated delivery. Methods for administering nucleic acids or proteins to a subject to modify cells in vivo are disclosed elsewhere herein. As specific examples, molecules (e.g., nucleic acids or proteins) may be introduced into cells or non-human animals in carriers such as poly(lactic acid) (PLA) microspheres, poly(D,L-lactic-coglycolic-acid) (PLGA) microspheres, liposomes, micelles, reverse micelles, lipid cochleates, or lipid microtubules. Some specific examples of delivery to non-human animals include hydrodynamic delivery, viral mediated delivery (e.g., lentivirus-mediated delivery, or adeno-associated virus (AAV)-mediated delivery), and lipid nanoparticle-mediated delivery.
[0112] In one example, LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be administered via viral transduction, such as lentiviral transduction or adeno-associated viral transduction. In another example, LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be administered via lipid nanoparticle (LNP) mediated delivery.
[0113] Administration in vivo can be by any suitable route such that LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 reaches the intended target cell(s) (e.g., neuronal cells in the brain of a subject) or target tissue (e.g., the brain). Examples of routes of administration include parenteral, intravenous, oral, subcutaneous, intraarterial, intracranial, intrathecal, intraperitoneal, topical, intranasal, or intramuscular. Systemic modes of administration include, for example, oral and parenteral routes. Examples of parenteral routes include intravenous, intraarterial, intraosseous, intramuscular, intradermal, subcutaneous, intranasal, and intraperitoneal routes. A particular example is intravenous infusion. Intranasal infusion and intravitreal injection are other particular examples. Local modes of administration include, for example, intrathecal, intracerebroventricular, intraparenchymal (e.g., localized intraparenchymal delivery to the striatum (e.g., to the caudate nucleus or putamen), cerebral cortex, precentral gyrus, hippocampus (e.g., dentate gyrus or CA3 region), temporal cortex, amygdala, frontal cortex, thalamus, cerebellum, medulla, thalamus, optic tectum, putamen, or parenchyma of the nigra), intraocular, intraorbital, subconjunctival, intravitreal, subretinal, and transscleral routes. Significantly smaller amounts of components (compared to systemic approaches) may exert an effect when administered locally (e.g., intraparenchymal or intravitreal) compared to when administered systemically (e.g., intravenously). Local modes of administration may also reduce or eliminate the incidence of potentially toxic side effects that may occur when therapeutically effective amounts of components are administered systemically. For example, LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be administered directly to the brain of a subject or to neurons in the brain of a subject. In particular examples, administration to the subject is by intrathecal injection or intracranial injection (e.g., stereotactic surgery for injection into the hippocampus and other brain regions, or intraventricular injection). In particular examples, administration to the subject is by intraventricular injection. In another embodiment, administration to the subject is by intracranial injection. In another embodiment, administration to the subject is by intrathecal injection.
[0114] The frequency and number of doses may depend on the half-life of the administered composition and the route of administration, among other factors. The introduction of the nucleic acid or protein into the cell or non-human animal may be performed one or more times over a period of time. For example, the introduction may be performed at least 2 times over a period of time, at least 3 times over a period of time, at least 4 times over a period of time, at least 5 times over a period of time, at least 6 times over a period of time, at least 7 times over a period of time, at least 8 times over a period of time, at least 9 times over a period of time, at least 10 times over a period of time, at least 11 times over a period of time, at least 12 times over a period of time, at least 13 times over a period of time, at least 14 times over a period of time, at least 15 times over a period of time, at least 16 times over a period of time, at least 17 times over a period of time, at least 18 times over a period of time, at least 19 times over a period of time, or at least 20 times over a period of time.
[0115] The cell or subject in the method can be, for example, a mammal, a non-human mammal, and a human. The mammal can be, for example, a non-human mammal, a human, a rodent, a rat, a mouse, or a hamster. Other non-human mammals include, for example, non-human primates, monkeys, apes, cats, dogs, rabbits, horses, bulls, deer, bison, livestock (e.g., bovine species such as cows and steers, ovine species such as sheep and goats, and porcine species such as pigs and wild boars). The term "non-human" excludes humans. In a specific example, the cell or subject is a human.
[0116] The cell can be an isolated cell (e.g., in vitro) or can be in vivo within a subject (e.g., an animal or mammal). The cell can also be in any type of undifferentiated or differentiated state. In one example, the cell is a neuronal cell.
[0117] The cells provided herein can be normal, healthy cells, or can be diseased cells that contain tau aggregates. The cells can, for example, be prone to tau aggregates or they can have pre-existing tau aggregates.
[0118] In one example, the cell is a human cell, a rodent cell, a mouse cell, or a rat cell, such as a human neuron, a rodent neuron, a mouse neuron, or a rat cell. In a specific example, the cell is a human neuron. In a particular example, the cell is in vivo in a subject (e.g., a neuron in the brain of the subject). For example, such a method can be a method of inhibiting tau aggregates or a method of reducing phosphorylation in a cell of a subject (e.g., a neuron in the brain of the subject).
[0119] Such methods may further include screening the cell or subject to confirm the presence of LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Screening the cell or subject for LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3 may be performed by any known means. Such methods may further include screening the cell or subject to confirm expression of a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Screening the cell or subject for expression of a nucleic acid encoding LEMD2, CHMP7, or LEMD3 may be performed by any known means. For example, methods for measuring protein expression and methods for measuring expression of mRNA encoded by a coding sequence are well known.
[0120] One example of an assay that can be used is the BASESCOPE™ RNA In Situ Hybridization (ISH) assay, a method that can quantify cell-specific edited transcripts, including single nucleotide changes, in the context of intact fixed tissue. The BASESCOPE™ RNA ISH assay can complement NGS and qPCR in the characterization of gene editing. NGS / qPCR can provide quantitative averages of wild-type and edited sequences, but provide no information on the heterogeneity or percentage of edited cells within a tissue. The BASESCOPE™ ISH assay can provide a landscape view of the entire tissue and quantification of wild-type vs. edited transcripts at single-cell resolution that can quantify the actual number of cells in a target tissue that contain edited mRNA transcripts. The BASESCOPE™ assay uses paired oligo ("ZZ") probes to amplify the signal and achieve single molecule RNA detection without non-specific background. However, the BASESCOPE™ probe design and signal amplification system allows for the detection of single molecule RNA using 1ZZ probes, which can differentially detect single nucleotide edits and mutations in intact, fixed tissues.
[0121] As another example, a reporter gene may be used for screening. For example, a nucleic acid encoding LEMD2, CHMP7, or LEMD3 may encode LEMD2, CHMP7, or LEMD3 fused to a reporter gene, such as a fluorescent protein. Exemplary reporter genes include those encoding luciferase, β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP), blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), DsRed, ZsGreen, MmGFP, mPlum, mCherry, tdTomato, mStrawberry, J-Red, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, Cerulean, T-Sapphire, and alkaline phosphatase.
[0122] As another example, a selectable marker can be used to screen for cells that have LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. Exemplary selectable markers include neomycin phosphotransferase (neomycin phosphotransferase). r ), hygromycin B phosphotransferase (hyg r ), puromycin N-acetyltransferase (puro r ), blasticidin S deaminase (bsr r ), xanthine / guanine phosphoribosyltransferase (gpt), or herpes simplex virus thymidine kinase (HSV-k).
[0123] The method may further comprise assessing one or more signs or symptoms of tauopathy or tau aggregation by any suitable means. Examples of such signs and symptoms are discussed in more detail elsewhere herein, and include, for example, tau hyperphosphorylation or tau aggregation. Other signs and symptoms may include, for example, increased tau and / or phosphorylated-tau in the insoluble fraction after cellular fractionation, increased phosphorylated-tau, increased phosphorylated-tau in the somatodendritic compartment of neurons, increased phosphorylated-tau in the perinuclear region of neurons, decreased nuclear to cytoplasmic ratio of nuclear pore complex protein Nup98-Nup96 (Nup98) in neurons, decreased nuclear to cytoplasmic ratio of GTP-binding nuclear protein Ran (Ran) in neurons, or decreased nuclear to cytoplasmic ratio of Ran GTPase activating protein 1 (RanGAP1) in neurons. The phosphorylated-tau can be, for example, phosphorylated-tau (S356) or phosphorylated-tau AT8 (S202, T205). Other signs and symptoms can include, for example, serum neurofilament light chain (sNfL). This can be done, for example, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, or more after introduction of LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3. For example, the evaluation can be done about 2 weeks to about 6 weeks, or about 3 weeks to about 5 weeks after introduction of LEMD2, CHMP7, LEMD3, or a nucleic acid encoding LEMD2, CHMP7, or LEMD3.
[0124] The methods described herein may, for example, reduce the amount of new tau aggregate formation (new tau aggregates) in a cell or subject, and / or may reduce the amount of existing tau aggregate formation (existing tau aggregates) in a cell or subject. For example, the methods described herein may prevent new tau aggregate formation and / or reverse existing tau aggregate formation. The methods described herein may also, for example, reduce levels of phosphorylated tau (e.g., phosphorylated tau (S356) or phosphorylated tau AT8 (S202, T205)) in a cell or subject.
[0125] The methods described herein may, for example, reduce the amount of new serum neurofilament light chain (sNfL) accumulation in a subject and / or reduce the amount of existing serum neurofilament light chain (sNfL) levels in a subject. For example, the methods described herein may prevent new tau serum neurofilament light chain (sNfL) accumulation and / or reverse existing serum neurofilament light chain (sNfL) accumulation.
[0126] In some of the methods described herein, the method is for treating or preventing tauopathy in a subject. In some methods (e.g., methods for treating), the subject has one or more signs or symptoms of tauopathy. For example, the subject may have pre-existing tau aggregate formation in one or more cells. Tauopathies are a class of diseases caused by misfolding of tau protein. They are a group of progressive neurodegenerative disorders pathologically defined by the presence of tau protein aggregates in the brain. Tauopathies are a group of heterogeneous neurodegenerative conditions characterized by abnormal tau deposition in the brain. These include, for example, Alzheimer's disease, Down's syndrome, Pick's disease, Progressive Supranuclear Palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome (FTDP-17). In AD and other tauopathies, tau protein is abnormally hyperphosphorylated and aggregates into bundles of filaments (paired helical filaments) that appear as neurofibrillary tangles.
[0127] In some methods described herein, the method is for treating or preventing primary tauopathy. Primary tauopathy is a group of neurodegenerative diseases in which tau is believed to be the main contributor to the neurodegenerative process. In primary tauopathy, there is a dissociation between tau, a microtubule-associated protein, and microtubules as a result of tau hyperphosphorylation. This dissociation between tau and microtubules leads to tau fibrillation and inclusion formation, and microtubule dysfunction. All diseases considered to be primary tauopathies have in common the abnormal deposition of aggregated tau in the brain. There are other diseases in which tau deposition can be observed, but for some reason tau coexists with another protein or tau is not considered the main neurodegenerative process. Diseases in this latter category include: β-amyloid is also present in Alzheimer's disease, α-synuclein is also present in Lewy body disease, myotonic dystrophy, subacute sclerosing panencephalitis, Down's syndrome, and Niemann-Pick disease type C.
[0128] There are six isoforms of tau expressed in the adult brain. These six isoforms are derived from alternative splicing of three N-terminal exons in the tau gene: exon 2, exon 3, and exon 10. Three of the six isoforms are due to splicing in of exon 10, while the other three are the result of splicing out of exon 10. Splicing in of exon 10 results in an isoform with four repeated microtubule-binding domains, whereas splicing out of exon 10 results in an isoform with three repeated microtubule-binding domains. This is important because while healthy human brains consist of equal amounts of tau with three and four repeat binding domains, some primary tauopathies are characterized by a predominance of isoforms with four repeat binding domains (4R tauopathies), some by a predominance of isoforms with three repeat binding domains (3R tauopathies), and some by a near equal mixture of isoforms with three and four repeat binding domains (3R+4R tauopathies). See Table 1.
[0129] [Table 1]
[0130] There are several tau pathogenic mutations, such as pro-aggregation mutations, that are associated with (e.g., segregate with) or cause tauopathy. Pathogenic tau mutations, which can be either exonic or intronic, generally alter the relative production of tau isoforms, which may result in changes in microtubule assembly and / or the propensity of tau to aggregate. As an example, the mutation may be an aggregation-sensitizing mutation that sensitizes tau to seeding but does not result in tau easily aggregating by itself. For example, the mutation may be a disease-associated P301S mutation. By P301S mutation, we mean the human tau P301S mutation, or the corresponding mutation of another tau protein when optimally aligned with the human tau protein. Other pathogenic tau mutations include, for example, A152T, G272V, K280del, P301L, S320F, V337M, R406W, P301L / V337M, K280del / I227P / I308P, G272V / P301L / R406W, and A152T / P301L / S320F. See alzforum.org / mutations / mapt, Brandt et al. (2005) Biochim. Biophys. Acta 1739:331-354, and Wolfe (2009) J. Biol. Chem. 284(10):6021-6025, all of which are incorporated by reference in their entireties in this application.
[0131] The methods described herein may alleviate one or more signs and symptoms of tauopathy in a cell or subject. Some examples of signs and symptoms of tauopathy at the cellular level include hyperphosphorylation of tau (e.g., in the somatodendritic compartment of a neuron, because tau is generally considered to be an axonal protein, but is found in the dendritic compartment of degenerated neurons, and this redistribution is believed to trigger the neurodegeneration of Alzheimer's disease), tau aggregation, abnormal shape of nuclear lamina, and impaired nucleocytoplasmic transport. Other signs and symptoms at the organismal level may include neurofibrillary tangles (e.g., in the neocortex, amygdala, hippocampus, brainstem, or spinal cord), neuronal cell loss (e.g., in the hippocampus, amygdala, or neocortex), microgliosis, synapse loss, cognitive impairment, or motor impairment. Other signs and symptoms may include, for example, increased tau and / or phosphorylated-tau in the insoluble fraction after cellular fractionation, increased phosphorylated-tau in the somatodendritic compartment of neurons, increased phosphorylated-tau in the perinuclear region of neurons, decreased nuclear to cytoplasmic ratio of nuclear pore complex protein Nup98-Nup96 (Nup98) in neurons, decreased nuclear to cytoplasmic ratio of GTP-binding nuclear protein Ran (Ran) in neurons, or decreased nuclear to cytoplasmic ratio of Ran GTPase activating protein 1 (RanGAP1) in neurons. Phosphorylated-tau may be, for example, phosphorylated-tau (S356) or phosphorylated-tau AT8 (S202, T205). Other signs and symptoms may include, for example, serum neurofilament light chain (sNfL), a biomarker of neuronal damage that is a strong indicator of neurodegenerative processes. Neurofilament light chain (NF1) is a cytoskeletal protein component whose release into the blood indicates neuronal cell damage and is a well-known biomarker for many neurodegenerative diseases. See, e.g., Rubsamen et al., (2021), BMC Medicine, 19:38, and Loeffler et al., (2020), Front. Neurosci., 14:295-579, the entire contents of which are incorporated herein by reference in this application.Neurofilament light (NF-L) is a 68 kDa cytoskeletal intermediate filament protein expressed in neurons. It associates with 125 kDa neurofilament medium (NF-M) and 200 kDa neurofilament heavy (NF-H) to form neurofilaments. They are major components of the neuronal cytoskeleton and are thought to function primarily to provide structural support for axons and regulate axon diameter. Neurofilaments can be released in significant amounts following axonal injury or neuronal degeneration. NF-L has been shown to be associated with traumatic brain injury, multiple sclerosis, frontotemporal dementia, and other neurodegenerative diseases.
[0132] III. Nucleic Acids Encoding LEMD2, CHMP7, or LEMD3 Provided herein is a nucleic acid or nucleic acid construct encoding LEMD2, CHMP7, or LEMD3 (i.e., an exogenous nucleic acid encoding LEMD2, CHMP7, or LEMD3). The nucleic acid or nucleic acid construct can be an isolated nucleic acid construct.
[0133] Some nucleic acids or nucleic acid constructs described herein include a nucleic acid encoding LEMD2. For example, LEMD2 can be wild-type LEMD2. In one example, LEMD2 is human LEMD2. Human LEMD2 (also called LEM domain containing protein 2, hLEM2, or LEM domain nuclear membrane protein 2) is assigned the UniProt reference number Q8NC56. The human gene encoding LEMD2 (LEMD2, or LEM domain nuclear membrane protein 2) is assigned NCBI GeneID 221496 and is found on chromosome 6 at location 6p21.31 (construct: GRCh38.p13 (GCF_000001405.39); location: NC_000006.12 (33771213.33794274, complement)). At least two isoforms of human LEMD2 are known. The first isoform is 503 amino acids and has been assigned the UniProt reference number Q8NC56-1 and the NCBI reference number NP_851853.1 (SEQ ID NO: 1). An exemplary coding sequence has been assigned the reference number CCDS4785.1 (SEQ ID NO: 2), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_181336.4 (SEQ ID NO: 4). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 3. The second isoform is 201 amino acids and has been assigned the UniProt reference number Q8NC56-2 and the NCBI reference numbers NP_001137416.1 and NP_001335638.1 (SEQ ID NO: 5). An exemplary coding sequence has been assigned the reference number CCDS47411.1 (SEQ ID NO:6), and exemplary mRNA (cDNA) sequences have been assigned the reference numbers NM_001143944.1 and NM_001348709.2 (SEQ ID NO:8 and SEQ ID NO:9, respectively). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO:7.
[0134] In another example, the LEMD2 is mouse LEMD2. Mouse LEMD2 has been assigned the UniProt reference number Q6DVA0. The mouse gene encoding LEMD2 (LEMD2) has been assigned the NCBI GeneID 224640 and is found on chromosome 17 at position 17;17 A3.3 (construct: GRCm39 (GCF_000001635.27); position: NC_000083.7 (27408574.27426228, complement)). An exemplary mouse LEMD2 is 511 amino acids and has been assigned the UniProt reference number Q6DVA0-1 and the NCBI reference number NP_666187.2 (SEQ ID NO: 10). An exemplary coding sequence has been assigned the reference number CCDS50043.1 (SEQ ID NO: 11), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_146075.2 (SEQ ID NO: 14). Codon-optimized coding sequences to distinguish from the native CDS are set forth in SEQ ID NO: 12 and SEQ ID NO: 13. Another codon-optimized coding sequence to distinguish from the native CDS is set forth in SEQ ID NO: 255.
[0135] Some nucleic acids or nucleic acid constructs described herein include a nucleic acid encoding CHMP7. For example, the CHMP7 can be wild-type CHMP7. In one example, the CHMP7 is human CHMP7. Human CHMP7 (also called charged multivesicular body protein 7 or chromatin modifying protein 7) has been assigned the UniProt reference number Q8WUX9. The human gene encoding CHMP7 (CHMP7) has been assigned the NCBI GeneID 91782 and is found on chromosome 8 at position 8p21.3 (construct: GRCh38.p13 (GCF_000001405.39); position: NC_000008:11 (23243637..23262000)). An exemplary CHMP7 protein is 453 amino acids and has been assigned the UniProt reference number Q8WUX9-1 and the NCBI reference number NP_689485.1 (SEQ ID NO: 15). An exemplary coding sequence has been assigned the reference number CCDS6040.1 (SEQ ID NO: 16), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_152272.5 (SEQ ID NO: 18). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 17.
[0136] In another example, CHMP7 is mouse CHMP7. Mouse CHMP7 is assigned the UniProt reference number Q8R1T1. The mouse gene encoding CHMP7 (CHMP7) is assigned the NCBI GeneID 105513 and is found on chromosome 14 at position 14;14 D2 (construct: GRCm39 (GCF_000001635.27); position: NC_000080.7 (69954428.69970019, complement)). An exemplary mouse CHMP7 is 451 amino acids and is assigned the UniProt reference number Q8R1T1-1 and the NCBI reference number NP_598839.2 (SEQ ID NO: 19). An exemplary coding sequence has been assigned the reference number CCDS27242.1 (SEQ ID NO: 20), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_134078.4 (SEQ ID NO: 22). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 21.
[0137] Some nucleic acids or nucleic acid constructs described herein include a nucleic acid encoding LEMD3. For example, the LEMD3 can be wild-type LEMD3. In one example, the LEMD3 is human LEMD3. Human LEMD3 (also called inner nuclear membrane protein Man1 or LEM domain containing protein 3) has been assigned the UniProt reference number Q9Y2U8. The human gene encoding LEMD3 (LEMD3, MAN1, or LEM domain containing 3) has been assigned the NCBI GeneID 23592 and is found on chromosome 12 at location 12q14.3 (construct: GRCh38.p13 (GCF_000001405.39); location: NC_000012.12 (65169583..65248355)). An exemplary LEMD3 protein is 911 amino acids and has been assigned the UniProt reference number Q9Y2U8-1 and the NCBI reference number NP-055134.2 (SEQ ID NO: 23). An exemplary coding sequence has been assigned the reference number CCDS8972.1 (SEQ ID NO: 24), and one exemplary mRNA (cDNA) sequence has been assigned the reference number NM_014319.5 (SEQ ID NO: 26). A codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 25.
[0138] In another example, the LEMD3 is mouse LEMD3. Mouse LEMD3 has been assigned the UniProt reference number Q9WU40. The mouse gene encoding LEMD3 (Lemd3) has been assigned the NCBI GeneID 380664 and is found on chromosome 10 at position 10;10 D2 (construct: GRCm39 (GCF_000001635.27); position: NC_000076.7 (120759316..120815491, complement)). An exemplary mouse LEMD3 is 921 amino acids and has been assigned the UniProt reference number Q9WU40-1 (SEQ ID NO: 27). The codon-optimized coding sequence to distinguish it from the native CDS is set forth in SEQ ID NO: 28. Another exemplary mouse LEMD3 is 918 amino acids in length and has been assigned NCBI reference number NP_001074662.2 (SEQ ID NO: 29). An exemplary coding sequence has been assigned reference number CCDS48703.1 (SEQ ID NO: 30), and one exemplary mRNA (cDNA) sequence has been assigned reference number NM_001081193.2 (SEQ ID NO: 31).
[0139] In some cases, the nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be a native coding sequence. In other cases, it can be codon optimized (e.g., codon optimized for expression in humans or for expression in mice). For example, the nucleic acid can be modified to alternative codons that are more frequently used in human cells, non-human cells, mammalian cells, rodent cells, mouse cells, rat cells, or any other host cell of interest.
[0140] The nucleic acid encoding LEMD2, CHMP7, or LEMD3 can be DNA or RNA. The nucleic acid can optionally be messenger RNA (mRNA) encoding LEMD2, CHMP7, or LEMD3. The nucleic acid can optionally be complementary DNA (cDNA) encoding LEMD2, CHMP7, or LEMD3. For example, such a nucleic acid can include only the coding sequence without any intervening introns. In other cases, the nucleic acid can include one or more introns that separate exons in the LEMD2, CHMP7, or LEMD3 coding sequence. For example, the nucleic acid can include a genomic sequence that includes both exons and introns.
[0141] In some cases, the nucleic acid is present in an expression construct that includes a nucleic acid encoding LEMD2, CHMP7, or LEMD3 operably linked to a promoter. The promoter can be any suitable promoter for in vivo expression in an animal or in vitro expression in an isolated cell. The promoter can be a constitutively active promoter (e.g., a CAG promoter or a U6 promoter), a conditional promoter, an inducible promoter, a temporally restricted promoter (e.g., a developmentally regulated promoter), or a spatially restricted promoter (e.g., a cell-specific promoter or a tissue-specific promoter). Such promoters are well known and are discussed elsewhere herein. In certain examples, the promoter is active in neuronal cells. In some cases, the promoter is a heterologous promoter (i.e., a promoter to which the LEMD2, CHMP7, or LEMD3 nucleic acid is not naturally operably linked). In other cases, the promoter can be an endogenous promoter (i.e., a LEMD2 nucleic acid operably linked to a LEMD2 promoter, a CHMP7 nucleic acid operably linked to a CHMP7 promoter, or a LEMD3 nucleic acid operably linked to a LEMD3 promoter). The heterologous promoter can be any type of promoter disclosed elsewhere herein. For example, the promoter can be a constitutive promoter, such as an EF1α promoter. Alternatively, the promoter can be a tissue-specific promoter or an inducible promoter. For example, as another example, the promoter can be a neuronal cell-specific promoter. One example of a suitable neuronal cell-specific promoter is the synapsin-1 promoter (e.g., a human synapsin-1 promoter, such as the promoter set forth in SEQ ID NO: 44). In some embodiments, the synapsin-1 promoter can be used with the hemoglobin subunit beta (HBB) intron 2 (e.g., downstream of the synapsin-1 promoter), such as that set forth in SEQ ID NO: 254. Inclusion of this element can enhance gene expression.
[0142] The nucleic acids and expression constructs disclosed herein can also include post-transcriptional regulatory elements, such as the post-transcriptional regulatory elements of the Woodchuck Hepatitis Virus.
[0143] The nucleic acids and expression constructs may further comprise one or more polyadenylation signal sequences. For example, the nucleic acid constructs may comprise a polyadenylation signal sequence located 3' of the LEMD2, CHMP7, or LEMD3 coding sequence. Any suitable polyadenylation signal sequence may be used. The term polyadenylation signal sequence refers to any sequence that directs the termination of transcription and the addition of a polyA tail to the mRNA transcript. In eukaryotes, transcription terminators are recognized by protein factors, and termination is followed by polyadenylation, the process of adding a poly(A) tail to the mRNA transcript in the presence of poly(A) polymerase. Mammalian poly(A) signals typically consist of a core sequence about 45 nucleotides long, which may be flanked by a variety of auxiliary sequences that serve to increase the efficiency of cleavage and polyadenylation. The core sequence is called polyA recognition motif or polyA recognition sequence and is composed of a highly conserved upstream element (AATAAA or AAUAAA) in mRNA that is recognized by cleavage and polyadenylation specificity factor (CPSF) and a downstream region (rich in U or G and U) that is poorly defined and bound by cleavage stimulatory factor (CstF). Examples of transcription terminators that can be used include, for example, human growth hormone (HGH) polyadenylation signal, simian virus 40 (SV40) late polyadenylation signal, rabbit beta globin polyadenylation signal, bovine growth hormone (BGH) polyadenylation signal, phosphoglycerate kinase (PGK) polyadenylation signal, AOX1 transcription termination sequence, CYC1 transcription termination sequence, or any transcription termination sequence known to be suitable for regulating gene expression in eukaryotic cells. Examples of suitable polyadenylation signals include, for example, those set forth in SEQ ID NO: 252 and SEQ ID NO: 253.
[0144] The nucleic acid and expression construct may also include a polyadenylation signal sequence upstream of the LEMD2, CHMP7, or LEMD3 coding sequence. The polyadenylation signal sequence upstream of the LEMD2, CHMP7, or LEMD3 coding sequence may be adjacent to a recombinase recognition site that is recognized by a site-specific recombinase. In some constructs, the recombinase recognition site also flanks a selection cassette that includes, for example, a coding sequence for a drug resistance protein. In some constructs, the recombinase recognition site does not flank the selection cassette. The polyadenylation signal sequence prevents transcription and expression of the protein or RNA encoded by the coding sequence. However, upon exposure to a site-specific recombinase, the polyadenylation signal sequence may be excised, allowing the protein or RNA to be expressed.
[0145] Such a configuration may allow for tissue- or developmental stage-specific expression if the polyadenylation signal sequence is excised in a tissue- or developmental stage-specific manner. Excision of the polyadenylation signal sequence in a tissue- or developmental stage-specific manner may be achieved if the animal containing the nucleic acid or expression construct further comprises a coding sequence for a site-specific recombinase operably linked to a tissue- or developmental stage-specific promoter. The polyadenylation signal sequence is then excised only in those tissues or those developmental stages, allowing for tissue- or developmental stage-specific expression. In one example, the LEMD2, CHMP7, or LEMD3 encoded by the nucleic acid or expression construct may be expressed in a neuronal cell-specific manner.
[0146] Site-specific recombinases include enzymes that can promote recombination between recombinase recognition sites, where the two recombination sites are physically separated within a single nucleic acid or on separate nucleic acids. Examples of recombinases include Cre, Flp, and Dre recombinase. One example of a Cre recombinase gene is Crei, where the two exons encoding Cre recombinase are separated by an intron, preventing expression in prokaryotic cells. Such recombinases may further include a nuclear localization signal to promote localization to the nucleus (e.g., NLS-Crei). Recombinase recognition sites include nucleotide sequences that can be recognized by site-specific recombinases and serve as substrates for recombination events. Examples of recombinase recognition sites include FRT, FRT11, FRT71, attp, att, rox, and lox sites, such as loxP, lox511, lox2272, lox66, lox71, loxM2, and lox5171.
[0147] The nucleic acids disclosed herein may comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), which may be single-stranded or double-stranded, and which may be in linear or circular form. The nucleic acid constructs may be naked nucleic acids, as described elsewhere herein, or may be delivered by vectors, such as AAV vectors. When in linear form, the ends of the nucleic acid may be protected (e.g., from exonuclease degradation) by well-known methods. For example, one or more dideoxynucleotide residues may be added to the 3' end of the linear molecule, and / or self-complementary oligonucleotides may be attached to one or both ends. See, for example, Chang et al. (1987) Proc. Natl. Acad. Sci. USA 84:4959-4963, and Nehls et al. (1996) Science 272:886-889, each of which is incorporated herein by reference in its entirety. Additional methods for protecting exogenous polynucleotides from degradation include, but are not limited to, the addition of terminal amino groups and the use of modified internucleotide linkages, such as phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues. The nucleic acid or expression construct may optionally include one or more of the following terminal structures: hairpins, loops, inverted terminal repeats (ITRs), or toroids. For example, the nucleic acid or expression construct may include an ITR.
[0148] The nucleic acid or expression construct may include modifications or sequences that provide additional desirable features (e.g., modified or regulated stability, tracking or detection by fluorescent labels, binding sites for proteins or protein complexes, etc.). The nucleic acid construct may include one or more fluorescent labels, purification tags, epitope tags, or combinations thereof. For example, the nucleic acid construct may include one or more fluorescent labels (e.g., fluorescent proteins or other fluorophores or dyes), such as at least one, at least two, at least three, at least four, or at least five fluorescent labels. Exemplary fluorescent labels include fluorophores such as fluorescein (e.g., 6-carboxyfluorescein (6-FAM)), Texas Red, HEX, Cy3, Cy5, Cy5.5, Pacific Blue, 5-(and-6)-carboxytetramethylrhodamine (TAMRA), and Cy7. A wide range of fluorescent dyes for labeling oligonucleotides are commercially available (e.g., from Integrated DNA Technologies). The label or tag can be at the 5' end, the 3' end, or internally of the nucleic acid construct. For example, the nucleic acid construct can be conjugated to the 5' end with an IR700 fluorophore (5'IRDYE® 700) from Integrated DNA Technologies.
[0149] The nucleic acid and expression construct may also include a conditional allele. The conditional allele may be a multifunctional allele, as described in US 2011 / 0104799, the entirety of which is incorporated herein by reference in this application. For example, the conditional allele may include (a) an operating sequence in a sense orientation relative to the transcription of a target gene, (b) a drug selection cassette (DSC) in a sense or antisense orientation, (c) a nucleotide sequence of interest (NSI) in an antisense orientation, and (d) a conditional inversion module (COIN, utilizing an exon split intron and an invertible gene trap-like module) in an inverted orientation. See, for example, US 2011 / 0104799. The conditional allele may further include a recombinable unit that recombines upon exposure to a first recombinase to form a conditional allele that (i) lacks the operating sequence and DSC, and (ii) includes a NSI in a sense orientation and a COIN in an antisense orientation. See, for example, U.S. Patent No. 2011 / 0104799.
[0150] The nucleic acid and expression construct may also include a polynucleotide encoding a selection marker. Alternatively, the nucleic acid and expression construct may lack a polynucleotide encoding a selection marker. The selection marker may be included in a selection cassette. Optionally, the selection cassette may be a self-deleting cassette. See, for example, U.S. Pat. Nos. 8,697,851 and 2013 / 0312129, each of which is incorporated herein by reference in its entirety in this application. By way of example, the self-deleting cassette may include a Crei gene (comprising two exons, encoding Cre recombinase, separated by an intron) operably linked to a mouse Prm1 promoter and a neomycin resistance gene operably linked to a human ubiquitin promoter. The Prm1 promoter may be used to specifically delete the self-deleting cassette in the male germ cells of the F0 animal. Exemplary selection markers include neomycin phosphotransferase (neomycin phosphotransferase) and the human ubiquitin promoter. r ), hygromycin B phosphotransferase (hyg r), puromycin N-acetyltransferase (puro r ), Blasticidin S deaminase (bsr r ), xanthine / guanine phosphoribosyltransferase (gpt), or herpes simplex virus thymidine kinase (HSV-k), or a combination thereof. The polynucleotide encoding the selection marker may be operably linked to a promoter active in the targeted cells. Examples of promoters are described elsewhere herein.
[0151] The nucleic acid or expression construct may also include a reporter gene. Exemplary reporter genes include those encoding luciferase, β-galactosidase, green fluorescent protein (GFP), enhanced green fluorescent protein (eGFP), cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), enhanced yellow fluorescent protein (eYFP), blue fluorescent protein (BFP), enhanced blue fluorescent protein (eBFP), DsRed, ZsGreen, MmGFP, mPlum, mCherry, tdTomato, mStrawberry, J-Red, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, Cerulean, T-Sapphire, and alkaline phosphatase. Such reporter genes may be operably linked to a promoter active in the targeted cells. Examples of promoters are described elsewhere herein.
[0152] IV. Vectors Also provided herein are vectors comprising a nucleic acid, nucleic acid construct, or expression construct encoding LEMD2, CHMP7, or LEMD3. Vectors can include additional sequences, such as, for example, origins of replication, promoters, and genes encoding antibiotic resistance.
[0153] Some vectors may be circular. Alternatively, vectors may be linear. Vectors may be packaged for delivery via lipid nanoparticles, liposomes, non-lipid nanoparticles, or viral capsids. Non-limiting exemplary vectors include plasmids, phagemids, cosmids, artificial chromosomes, mini-chromosomes, transposons, viral vectors, and expression vectors.
[0154] The nucleic acid or expression construct may be in a vector, such as a viral vector. The viral vector may be, for example, an adeno-associated viral (AAV) vector or a lentiviral (LV) vector (i.e., a recombinant AAV vector or a recombinant LV vector). Other exemplary viruses / viral vectors include retroviruses, adenoviruses, vaccinia viruses, poxviruses, and herpes simplex viruses. The viruses may infect dividing cells, non-dividing cells, or both dividing and non-dividing cells. The viruses may integrate into the host genome, or alternatively, do not integrate into the host genome. Such viruses may also be engineered to reduce immunity. The viruses may be replication competent or replication deficient (e.g., defective in one or more genes required for additional rounds of virion replication and / or packaging). The viruses may cause transient expression, long-term expression (e.g., at least 1 week, 2 weeks, 1 month, 2 months, or 3 months), or permanent expression. The viral vectors may be genetically modified from their wild-type counterparts. For example, a viral vector may include one or more nucleotide insertions, deletions, or substitutions to facilitate cloning or to alter one or more properties of the vector. Such properties may include packaging ability, transduction efficiency, immunogenicity, genomic integration, replication, transcription, and translation. In some examples, a portion of the viral genome may be deleted so that the virus can package exogenous sequences with a larger size. In some examples, the viral vector may have enhanced transduction efficiency. In some examples, the immune response induced by the virus in the host may be reduced. In some examples, a viral gene (such as integrase) that facilitates integration of viral sequences into the host genome may be mutated so that the virus becomes non-integrating. In some examples, the viral vector may be replication-deficient. In some examples, the viral vector may include exogenous transcriptional or translational control sequences to drive expression of coding sequences on the vector. In some examples, the virus may be helper-dependent.For example, a virus may require one or more helper viruses to provide viral components (such as viral proteins) necessary for amplifying and packaging a vector into a viral particle. In such cases, one or more helper components, including one or more vectors encoding viral components, may be introduced into a host cell or a population of host cells along with the vector system described herein. In other examples, the virus may not include a helper. For example, the virus may be capable of amplifying and packaging a vector without a helper virus. In some examples, the vector system described herein may also encode viral components necessary for viral amplification and packaging. An exemplary viral titer (e.g., AAV titer) is about 10. 12 , about 10 13 , about 10 14 , about 10 15 , and about 10 16 Other exemplary viral titers (e.g., AAV titers) include about 10 12 , about 10 13 , about 10 14 , about 10 15 , and about 10 16 In one example, the viral titer is about 10 13 ~about 10 14 vg / mL or vg / kg.
[0155] In one example, the nucleic acid or expression construct is present in an AAV vector. AAV can be of any suitable serotype and can be single-stranded AAV (ssAAV) or self-complementary AAV (scAAV). The ssDNA AAV genome is composed of two open reading frames, Rep and Cap, flanked by two inverted terminal sequences that allow for the synthesis of complementary DNA strands. When constructing an AAV transfer plasmid, the transgene is placed between the two ITRs, and Rep and Cap can be supplied in trans. In addition to Rep and Cap, AAV may require a helper plasmid that contains genes from adenovirus. These genes (E4, E2a, and VA) mediate AAV replication. For example, the transfer plasmid, Rep / Cap, and helper plasmid can be transfected into HEK293 cells that contain adenovirus genes E1+ to generate infectious AAV particles. Alternatively, Rep, Cap, and adenovirus helper genes can be combined into a single plasmid. Similar packaging cells and methods can be used for other viruses, such as retroviruses.
[0156] Adeno-associated viruses (AAV) are endemic to multiple species, including humans and non-human primates (NHPs). To date, at least 12 naturally occurring serotypes and hundreds of naturally occurring variants have been discovered and characterized. See, for example, Li et al. (2020), Nat. Rev. Genet., 21:255-272, which is incorporated by reference in its entirety in this application. AAV particles are naturally composed of a non-membrane icosahedral protein capsid containing a single-stranded DNA (ssDNA) genome. The DNA genome is flanked by two inverted terminal repeats (ITRs), which act as viral origins of replication and packaging signals. The rep gene encodes four proteins required for viral replication and packaging, while the cap gene encodes the three structural capsid subunits that define the AAV serotypes, as well as an assembly-activating protein (AAP) that promotes virion assembly in some serotypes.
[0157] Recombinant AAV (rAAV) is currently one of the most commonly used viral vectors used in gene therapy to treat human diseases by delivering therapeutic transgenes to target cells in vivo. In fact, rAAV vectors are composed of icosahedral capsids similar to natural AAV, but rAAV virions do not encapsidate AAV protein coding sequences or AAV replication sequences. These viral vectors are non-replicative. The only viral sequences required in rAAV vectors are the two ITRs, which are required to induce genome replication and packaging during the manufacture of rAAV vectors. The rAAV genome lacks AAV rep and cap genes and does not replicate in vivo. rAAV vectors are generated by expressing the rep and cap genes in trans, together with additional viral helper proteins, in combination with a transgene cassette of interest flanked by AAV ITRs.
[0158] In therapeutic rAAV genomes, gene expression cassettes are placed between ITR sequences. Typically, rAAV genome cassettes contain a promoter to drive expression of therapeutic transgenes, followed by a polyadenylation sequence. The ITRs flanking the rAAV expression cassettes are usually derived from AAV2, the first serotype to be isolated and converted into recombinant viral vectors. Since then, most rAAV production methods rely on the AAV2Rep-based packaging system. See, for example, Colella et al., (2017), Mol. Ther. Methods Clin. Dev. 8:87-104, which is incorporated herein by reference in its entirety in this application.
[0159] Some non-limiting examples of ITRs that may be used include an ITR that comprises, consists essentially of, or consists of SEQ ID NO:245, SEQ ID NO:246, or SEQ ID NO:247, or SEQ ID NO:248. Other examples of ITRs contain one or more mutations compared to SEQ ID NO:245, SEQ ID NO:246, or SEQ ID NO:247, or SEQ ID NO:248, and may be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO:245, SEQ ID NO:246, or SEQ ID NO:247, or SEQ ID NO:248. In some rAAV genomes disclosed herein, the nucleic acid encoding the nuclease agent (or a component thereof) is flanked on both sides by the same ITR (i.e., the ITR on the 5' end and the reverse complement of the ITR on the 3' end). In one example, the ITR on each end may comprise, consist essentially of, or consist of SEQ ID NO:245. In another example, the ITR on each end may comprise, consist essentially of, or consist of SEQ ID NO:246. In one example, the ITR on at least one end may comprise, consist essentially of, or consist of SEQ ID NO:247 or SEQ ID NO:248. In one example, the ITR on the 5' end may comprise, consist essentially of, or consist of SEQ ID NO:247 or SEQ ID NO:248. In one example, the ITR on the 3' end may comprise, consist essentially of, or consist of SEQ ID NO:247 or SEQ ID NO:248. In one example, the ITR on at least one end may comprise, consist essentially of, or consist of SEQ ID NO:245. In one example, the ITR on the 5' end may comprise, consist essentially of, or consist of SEQ ID NO:245. In one example, the ITR on the 3' end comprises, consists essentially of, or consists of SEQ ID NO: 245. In one example, the ITR at each end can comprise, consist essentially of, or consist of SEQ ID NO: 245. In other rAAV genomes disclosed herein, the nucleic acid encoding the nuclease agent (or a component thereof) is flanked by different ITRs at each end.In one example, the ITR at one end comprises, consists essentially of, or consists of SEQ ID NO: 245 and the ITR at the other end comprises, consists essentially of, or consists of SEQ ID NO: 246. In another example, the ITR at one end comprises, consists essentially of, or consists of SEQ ID NO: 245 and the ITR at the other end comprises, consists essentially of, or consists of SEQ ID NO: 247 or SEQ ID NO: 248. In one example, the ITR at one end comprises, consists essentially of, or consists of SEQ ID NO: 246 and the ITR at the other end comprises, consists essentially of, or consists of SEQ ID NO: 247 or SEQ ID NO: 248.
[0160] The particular serotype of a recombinant AAV vector influences its in vivo tropism for a particular tissue. AAV capsid proteins mediate attachment and entry into target cells, followed by endosomal escape and transport to the nucleus. Thus, the choice of serotype when developing a rAAV vector influences which cell types and tissues the vector is most likely to bind and transduce when injected in vivo.
[0161] Once in the nucleus, the ssDNA genome is released from the virion and the complementary DNA strand is synthesized to generate a double-stranded DNA (dsDNA) molecule. The double-stranded AAV genome naturally circularizes through their ITRs and becomes an episome that persists extrachromosomally in the nucleus. Thus, for episomal gene therapy programs, the rAAV-delivered rAAV episome provides long-term promoter-driven gene expression in non-dividing cells. However, this rAAV-delivered episomal DNA is diluted as cells divide. In contrast, the gene therapy described herein is based on gene insertion that allows long-term gene expression.
[0162] Several serotypes of AAV have been identified. These serotypes differ in the type of cells they infect (i.e., their tropism), allowing preferential transduction of certain cell types. Serotypes for CNS tissues include AAV1, AAV2, AAV4, AAV5, AAV8, and AAV9. The selectivity of AAV serotypes for gene delivery in neural cells is discussed, for example, in Hammond et al. (2017) PLoS One 12(12):e0188830, which is incorporated herein by reference in its entirety in this application. In a specific embodiment, the AAV-PHP.eB vector is used. The AAV-PHP.eB vector shows a high ability to cross the blood-brain barrier, increasing its CNS transduction efficiency. In a specific embodiment, the AAV9 vector is used.
[0163] Tropism can be further refined by pseudotyping, which is a mixture of capsids and genomes from different viral serotypes. For example, AAV2 / 5 refers to a virus that contains a serotype 2 genome packaged in a serotype 5 capsid. The use of pseudotyped viruses can not only improve transduction efficiency but also alter tropism. Hybrid capsids from different serotypes can also be used to modify the tropism of the virus. For example, AAV-DJ contains hybrid capsids from eight serotypes and shows high infectivity across a wide range of cell types in vivo. AAV-DJ8 is another example that shows the properties of AAV-DJ but with enhanced brain uptake. AAV serotypes can also be modified by mutation. Examples of mutational modifications of AAV2 include Y444F, Y500F, Y730F, and S662V. Examples of mutational modifications of AAV3 include Y705F, Y731F, and T492V. Examples of mutational modifications of AAV6 include S663V and T492V. Other pseudotype / modified AAV variants include AAV2 / 1, AAV2 / 6, AAV2 / 7, AAV2 / 8, AAV2 / 9, AAV2.5, AAV8.2, and AAV / SASTG.
[0164] To accelerate transgene expression, self-complementary AAV (scAAV) mutants can be used. Because AAV relies on the cell's DNA replication machinery to synthesize the complementary strand of the AAV's single-stranded DNA genome, transgene expression may be delayed. To address this delay, scAAV can be used, which contains complementary sequences that can spontaneously anneal upon infection, eliminating the need for host cell DNA synthesis. However, single-stranded AAV (ssAAV) vectors can also be used.
[0165] To increase packaging capacity, a longer transgene may be split into two AAV transfer plasmids, one being the 3' splice donor and the second being the 5' splice acceptor. Upon co-infection of cells, these viruses may form concatemers and be spliced together to express the full-length transgene. This allows for expression of longer transgenes, but at a reduced efficiency of expression. A similar method to increase capacity utilizes homologous recombination. For example, a transgene may be split into two transfer plasmids, but with substantial sequence overlap, such that co-expression induces homologous recombination and expression of the full-length transgene.
[0166] IV. Lipid Nanoparticles Also provided herein are lipid nanoparticles comprising LEMD2, CHMP7, or LEMD3, or a nucleic acid, nucleic acid construct, expression construct, or vector encoding LEMD2, CHMP7, or LEMD3.
[0167] Lipid formulations can protect biomolecules from degradation while improving cellular uptake. Lipid nanoparticles are particles that contain multiple lipid molecules physically bound to each other by intermolecular forces. These include microspheres (including unilamellar and multilamellar vesicles, e.g., liposomes), dispersed phases in emulsions, micelles, or internal phases in suspensions. Such lipid nanoparticles can be used to encapsulate one or more nucleic acids or proteins for delivery. Formulations that contain cationic lipids are useful for delivering polyanions such as nucleic acids. Other lipids that can be included are neutral lipids (i.e., uncharged lipids or zwitterionic lipids), anionic lipids, helper lipids that enhance transfection, and stealth lipids that increase the time that nanoparticles can exist in vivo. Examples of suitable cationic lipids, neutral lipids, anionic lipids, helper lipids, and stealth lipids can be found in PCT International Publication WO2016 / 010840A1, which is incorporated herein by reference in its entirety. Exemplary lipid nanoparticles may include cationic lipids and one or more other components. In one example, the other components may include a helper lipid such as cholesterol. In another example, the other components may include a helper lipid such as cholesterol and a neutral lipid such as DSPC. In another example, the other components may include a helper lipid such as cholesterol, any neutral lipid such as DSPC, and a stealth lipid such as S010, S024, S027, S031, or S033.
[0168] LNPs may contain one or more or all of the following: (i) lipids for encapsulation and endosomal escape, (ii) neutral lipids for stabilization, (iii) helper lipids for stabilization, and (iv) stealth lipids. See, e.g., Farnleitner et al., (2018) Cell Rep. 22(9):2227-2235, and PCT International Publication WO2017 / 173054A1, each of which is incorporated herein by reference in its entirety. A specific example of using LNPs for delivery to the brain is disclosed in Nabhan et al., (2016) Sci.Rep. 6:20019, which is incorporated herein by reference in its entirety.
[0169] V. Composition Also provided herein are compositions comprising LEMD2, CHMP7, or LEMD3, or a nucleic acid, nucleic acid construct, expression construct, vector, or lipid nanoparticle disclosed herein. Such compositions can be, for example, for use in administering LEMD2, CHMP7, or LEMD3 to a cell or subject, or for use in expressing LEMD2, CHMP7, or LEMD3 in a cell or subject. Such compositions can be, for example, for use in inhibiting tau aggregates in a cell or subject. Such compositions can be, for example, for use in reducing phosphorylation in a cell or subject. Such compositions can be, for example, for use in reducing serum neurofilament light chain (sNfL) or preventing accumulation of serum neurofilament light chain (sNfL) in a subject. Such compositions can be, for example, for use in treating a tauopathy in a subject. Such compositions can be, for example, for use in preventing a tauopathy in a subject.
[0170] VI. Cells or Animals Also provided is a cell or subject (e.g., an animal) comprising a LEMD2, CHMP7, or LEMD3, or a nucleic acid, nucleic acid construct, expression construct, vector, or lipid nanoparticle disclosed herein. The cell or subject may express LEMD2, CHMP7, or LEMD3.
[0171] The cells or subjects can be, for example, mammals, non-human mammals, and humans. Mammals can be, for example, non-human mammals, humans, rodents, rats, mice, or hamsters. Other non-human mammals include, for example, non-human primates, monkeys, apes, cats, dogs, rabbits, horses, bulls, deer, bison, livestock (e.g., bovine species such as cows and steers, ovine species such as sheep and goats, and porcine species such as pigs and wild boars). The term "non-human" excludes humans.
[0172] The cell can be an isolated cell (e.g., in vitro) or can be in vivo within a subject (e.g., an animal or mammal). The cell can also be in any type of undifferentiated or differentiated state. In one example, the cell is a neuronal cell.
[0173] The cells provided herein can be normal, healthy cells, or can be diseased cells that contain tau aggregates. The cells can, for example, be prone to tau aggregates or they can have pre-existing tau aggregates.
[0174] In one example, the cell is a human cell, a rodent cell, a mouse cell, or a rat cell, such as a human neuronal cell, a rodent neuronal cell, a mouse neuronal cell, or a rat cell. In a specific example, the cell is a human neuronal cell. In a particular example, the cell is in vivo in a subject (e.g., a neuronal cell in the brain of the subject).
[0175] All patent applications, websites, other publications, accession numbers, etc. cited above or below are incorporated herein by reference in their entirety in this application to the same extent as if each item was specifically and individually indicated to be incorporated by reference. Where different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the filing date of the actual application or the priority application prior to the accession number, if applicable. Similarly, where different versions of a publication, website, etc. are published at different times, the version published closest to the effective filing date of this application is meant, unless otherwise specified. Any feature, step, element, embodiment, or aspect of the invention may be used in combination with any other, unless otherwise indicated. The invention has been described in some detail through diagrams and examples for purposes of clarity and understanding, but it will be apparent that certain changes and modifications can be made within the scope of the appended claims.
[0176] A brief description of the sequence The nucleotide and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases and three-letter code for amino acids. The nucleotide sequences follow the standard convention of beginning at the 5' end of the sequence and proceeding in a forward direction (i.e., left to right on each line) to the 3' end. Only one strand of each nucleotide sequence is shown, but the complementary strand is understood to be included by any reference to the strand shown. Where a nucleotide sequence encoding an amino acid sequence is provided, it is understood that codon-degenerate variants thereof which encode the same amino acid sequence are also provided. The amino acid sequences follow the standard convention of beginning at the amino terminus of the sequence and proceeding in a forward direction (i.e., left to right on each line) to the carboxy terminus.
[0177] [Table 2-1] [Table 2-2]
[0178] Example 1. Loss of nuclear membrane integrity promotes aggregation of the microtubule-associated protein tau In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated and aggregates into bundles of paired helical filaments, manifesting as neurofibrillary tangles. Tau fibrillization into insoluble aggregates is not only a hallmark of the disease but has also been implicated as a causative factor in neurotoxicity. Neurodegenerative diseases with tau pathology are characterized by the propagation of tau aggregates through the central nervous system following a stereotypical pattern, a process that correlates with disease progression. This progressive pathology is proposed to proceed along neuroanatomical circuits and occurs by a prion-like mechanism of cell-to-cell transmission of misfolded tau. Mutations in the MAPT gene have been associated with frontotemporal dementia and other tauopathies, providing a mechanism for disease causation in these cases, but the pathogenesis of tau pathology in Alzheimer's disease and other tauopathies not associated with MAPT mutations is poorly understood. Although most interest in tau has focused on its role in cytoskeletal microtubule dynamics, recent evidence that nuclear components can associate with tau aggregates in the cytoplasm may provide insight into the mechanisms by which tau becomes misfolded and aggregated in disease.
[0179] To discover perturbations that may cause tau aggregation and to uncover normal processes that protect cells from tau pathology, we performed a series of genetic screens for mutations that promote or inhibit tau aggregation in a human embryonic kidney (HEK293T) biosensor cell line. See, for example, Holmes et al., (2014) Proc. Natl. Acad. Sci. USA, 111:E4376-4385, and Sanders et al., (2014) Neuron, 82 1271-1288, each of which is incorporated herein by reference in its entirety in this application. The biosensor cells stably express two transgenes, each encoding the 4RD complete microtubule-binding domain of tau, containing a pathogenic proline 301 to serine mutation, fused to either cyan fluorescent protein (tau-CFP) or yellow fluorescent protein (tau-YFP). Aggregates of tau fragments are detected when two tau fusion proteins are brought into close proximity and favorable orientation to induce Förster Resonance Energy Transfer (FRET) between CFP and YFP. Tau aggregates can be induced in biosensor cells by treatment with tau seeding agents such as extracts from cells and tissues with pathogenic tau aggregates or misfolded fibrils of wild-type or mutant tau. Tau aggregates in biosensor cells can be visualized by fluorescence microscopy, while FRET allows quantification of the number of cells with aggregates by flow cytometry and their purification by Fluorescence-Activated Cell Sorting (FACS). Tau aggregates can also be visualized by fluorescence microscopy.
[0180] To facilitate genetic screening, we expressed Cas9 in a tau biosensor cell line and then introduced a library of lentivirus-expressed CRISPR guide RNAs (gRNAs) that direct specific Cas9 cleavage in nearly every protein-coding gene in the genome to generate a large collection of cells, each of which carries an integrated gene-specific mutagen. Cells with the desired properties (e.g., gain or loss of FRET) can be isolated by FACS, and the integrated gRNAs they carry can be discovered by DNA sequencing, thereby identifying genes that, when mutated, produce the desired properties. As a complementary screening strategy, we modified the tau biosensor cell line with the Synergistic Activation Mediator (SAM) CRISPR platform for gRNA-targeted gene activation. From genetic screens using the two complementary approaches, we identified genes that promote or enhance tau aggregation when inactivated and prevent or inhibit tau aggregation when overexpressed. These genes shared a common biological function: maintenance of nuclear membrane integrity, a process that had not been implicated in tau pathology prior to our studies.
[0181] result Use of tau biosensor cell lines for CRISPR-Cas9 genetic screening. Tau biosensor cells express tau-CFP and tau-YFP reporter fusion proteins in a stable, soluble state without visible fluorescent aggregates or FRET signals. Treatment of biosensor cells with a strong seeding agent, such as purified recombinant tau fibrils complexed with a transfection reagent, induces visible fluorescent aggregates and FRET in the majority of cells (Figure 5A-F). Intracellular aggregates are detected by an antibody that recognizes tau phosphorylated on serine 356 (P-tau-Ser356, Figure 5F), a hallmark of pathological tau aggregates in the human brain that correlates with seeding activity that promotes cell-to-cell spread. To prepare a tau biosensor cell line for CRISPR-Cas9 genetic screening, we transduced it with a lentiviral vector expressing S. pyogenes Cas9 and selected clones that were evaluated for Cas9 mRNA expression and mutagenesis efficiency using gene-specific gRNAs. We selected the clone with the lowest Cas9 expression level sufficient to induce maximum gene disruption activity (>80% of alleles mutated) as the biosensor cell line for CRISPR-Cas9 gene inactivation screening (clone E, FIG. 5G).
[0182] Visible fluorescent tau aggregates can also be induced in HEK293T cells stably expressing only one of the biosensor fluorescent fusion proteins (FIG. 1A), but these cells do not produce a FRET signal. To establish aggregation-positive (Agg+) cell lines, we treated tau-YFP cells with recombinant tau fibrils complexed with LIPOFECTAMINE™ and isolated cell clones that stably grew and maintained tau-YFP aggregates through many cell divisions. Treatment of tau biosensor cells with cell-free conditioned medium from tau-YFP Agg+ cells induced low levels of tau aggregates, as indicated by a FRET signal, in approximately 0.1% of cells (FRET+ cells) analyzed by flow cytometry (FIG. 1A). In contrast, conditioned medium from the tau-YFP Agg- parent cell line did not induce FRET. The weak induction of tau aggregates by conditioned medium from Agg+ cells may represent a more natural seeding agent and a model for cell-to-cell spread in tauopathies than purified tau fibrils complexed with transfection reagents or tissue extracts. For these reasons, we decided to use conditioned medium as the seeding modality in our screen for mutations that promote tau aggregation.
[0183] Screening for mutations that enhance tau aggregation. Figure 1B shows the protocol for screening to discover mutations that enhance tau aggregation. We transduced a Cas9-expressing subclone of a tau biosensor cell line with a human genome-scale CRISPR-Cas9 knockout (GeCKO) library packaged in a lentiviral expression vector. The combined hGeCKO-A and B half library contains 111,985 unique single gRNAs (6 gRNAs per gene) targeting 19,050 genes in the human genome, and 1,000 non-targeting gRNAs as negative controls. We performed library transduction at a low multiplicity of infection (MOI) to ensure that most cells received at most one gRNA construct, with a coverage of 300 cells per gRNA, and selected for viral vector integration events in transduced cells by growth in the presence of puromycin. Six days after transduction of the GeCKO library, we introduced the tau aggregate seeding agent by transferring the cells to new medium consisting of a 3:1 mixture of Agg+ conditioned medium:fresh growth medium. We sampled the transduced cell cultures on day 3 post-transduction and on day 6 immediately prior to the addition of the conditioned medium seeding agent. After an additional 4 days of growth in the presence of the seeding agent, the cultures were harvested and FRET+ cells were purified by FACS. We performed five replicate pairwise screens with the GeCKO A and GeCKO B libraries separately, generating samples at day 3 and day 6, and FACS-purified cells at day 10.
[0184] As a control, we performed the same paired screening but without adding seeding agent. FACS analysis of these screenings did not detect FRET+ cells, identical to seeding with conditioned medium from Agg- cell lines (Figure 1A). These results showed that without seeding agent, CRISPR-Cas9 mutagenesis alone is unable to induce spontaneous tau aggregates measured by FRET. Either single gene mutations are insufficient to induce tau aggregates or such mutations are too rare to be detected with the number of cells analyzed. Even in experimental screening with Agg+conditioned medium seeding agent, final FACS analysis on day 10 revealed that CRISPR-Cas9 mutagenesis did not enhance the percentage of FRET+ cells beyond the level of about 0.1% produced in the absence of mutagenesis (Figure 1A). These results suggested that our CRISPR-Cas9 screening protocol failed to discover any mutations that could enhance seeding-induced tau aggregates, or that such mutations were too rare to result in a discernible increase in the small number of FRET+ cells produced by the weak seeding agent.
[0185] To search for evidence of mutations that may have promoted tau aggregation, we isolated DNA from 10 pools of FRET+ cells and performed quantitative ILLUMINA® sequencing on PCR amplicons derived from the gRNA expression cassettes. We used two strategies to identify potential gRNA-specific mutations. First, we used DESeq2 (Love et al., (2014), Genome Genetics, a methodology that is incorporated herein by reference in its entirety in this application. Biol., 15:550 was used to identify gRNAs whose sequence reads were enriched in FRET+day 10 samples compared to day 3 or day 6 samples, but not in day 6 samples compared to day 3. Using an enrichment factor of 1.5 or greater (≧) and a negative binomial Wald test p-value of less than 0.05 (<) as cutoff thresholds, we found that 104 gRNAs associated with 100 genes were significantly enriched in FRET+day 10 samples compared to both day 3 and day 6 samples. Of the 100 genes identified, only one, barrier pair autointegration factor 1 (BANF1), was represented by four significantly enriched gRNAs (circle labeled with an "X" in FIG. 5H). The remaining 99 genes were represented by a single significantly enriched gRNA. From the CRISPR screen Because the generated read count data may not follow the data distribution assumed by the Wald test used by DESeq2, we developed an alternative gene-centric enrichment analysis algorithm that does not require any assumptions of data distribution across samples. Similar to DESeq2, our alternative algorithm has two components: enrichment factor (referred to as fold change in DESeq2) and enrichment p-value. The enrichment factor is similar to that used in DESeq2, except that it is summarized at the gene level by averaging the enrichment of all gRNAs targeting the same gene. Unlike existing CRISPR data analysis methods, our method used a p-value calculation based on hypergeometric distribution that is applied only to the enrichment of different gRNAs targeting a gene in each of the FRET+10 day samples.The final enrichment p-value for a gene is the average of the p-values obtained from each of the 10 FRET+day 10 samples. Our alternative algorithm revealed BANF1 as the top hit (Figure 1C), confirming the DESeq2 results. From visual inspection of data quality among genes ranked by p-value and enrichment from DESeq2 and our gene-centric method, we selected BANF1 and 13 other genes with at least two active gRNAs that showed enrichment for experimental validation.
[0186] To validate candidate genes, we tested 30 individual GeCKO library lentiviral gRNA expression vectors, four for BANF1, and two each for 13 other genes, for their ability to enhance FRET induced by Agg+ conditioned medium. Transduction of tau biosensor cells with each of the four BANF1-targeting gRNAs (pink bars in Figure 1D), and both gRNAs targeting the PPP2CA gene (blue bars in Figure 1D, and blue dots in Figure 1C), increased induction of FRET signal by 15-20 fold compared to no gRNA or control gRNA (Figure 1D). None of the gRNAs against the other candidate genes promoted enhanced FRET. CRISPR-Cas9 disruption of BANF1 and PPP2CA did not induce FRET when fresh medium was used instead of conditioned medium (Figure 6A). Western blot assays confirmed that gRNA-targeted BANF1 and PPP2CA significantly reduced the proteins produced from the targeted genes (Figure 6B). Furthermore, individual isolated BANF1 and PPP2CA knockdown clones revealed a positive correlation between the degree of gene editing and the enhancement of FRET induced by Agg+ conditioned medium (Figure 6C). Combined inactivation of BANF1 and PPP2CA resulted in a clear additive effect on FRET induction (Figure 6D), suggesting that these two genes are involved in a common function.
[0187] The validated gene hits from the gene disruption screen encode proteins that are part of a functional network of components that maintain the nuclear membrane. To better understand the biology of the confirmed hits from the screen, we used the top hit BANF1 to search its protein-protein association network in String. See Szklarczyk et al., (2019), Nucleic Acids Res., 47:D607-D613, which is incorporated herein by reference in its entirety in this application. The network revealed that BANF1 directly interacts with the second confirmed hit, PPP2CA, in a catalytic relationship (Figure 2A). In multiple functional enrichment analysis of the network, the nuclear membrane stands out as the most important feature. To test whether mutations in other components of the BANF1 interaction network could promote enhanced tau aggregation, we tested gRNAs against ANKLE2, VRK1, PPP2R2A, EMD, LEMD2, LEMD3, and TMPO for their ability to induce enhanced FRET (Figure 2A). We also included CHMP7 because of its role in maintaining nuclear membrane integrity. Only gRNA targeting ANKLE2 was able to induce a large enhancement of FRET compared to the control (Figure 2B). We confirmed that disruption of BANF1, PPP2CA, and ANKLE2 resulted in enhanced tau aggregates as shown by FRET using three different seeding formats: sonicated whole cell lysates from tau-YFP Agg+ cells, purified misfolded recombinant tau fibrils (tau244-372LM, Figures 5A-5D), and spinal cord extracts from tauP301S transgenic mice (Figure 2C). See, for example, Yoshiyama et al., (2007), Neuron, 53:337-351, the entire contents of which are incorporated herein by reference in this application. Inactivation of ANKLE2 induced a stronger FRET signal than loss of either BANF1 or PPP2CA, and combining ANKLE2 inactivation with inactivation of BANF1 or PPP2CA did not result in an additive effect (Figure 6D).Results from our primary screen, secondary validation, and tertiary screen for biologically relevant genes point to an unexpected link between the microtubule-associated protein tau and biological processes that maintain the nuclear envelope (Figure 2D), suggesting that defects in nuclear envelope integrity may initiate pathology or promote its spread in tauopathies.
[0188] Screening for genes that inhibit or prevent tau aggregation when overexpressed. Because disruption of BANF1, PPP2CA, or ANKLE2 enhances tau aggregation, the normal function of these genes may act to protect cells from tau pathology. To discover additional protective genes whose expression can reverse or prevent tau aggregation, we reversed the logic of our CRISPR-Cas9 gene disruption screen by using the SAM system for gRNA-targeted gene activation to screen for genes whose activated or enhanced expression abolishes FRET induction in tau biosensor cells. Similar to the gene disruption screen, we first established tau biosensor subclones that stably express components of the SAM system and confirmed that gene expression could be induced or enhanced using specific SAM gRNAs (Figure 6E). Next, we performed five replicate screens by transduction of the SAM-ready biosensor cell line with the human SAM gRNA library, except that we replaced the weak conditioned medium seeding agent with a strong seeding agent, sonicated lysate of Tau-YFP Agg+ cells complexed with LipofectamineTM, as shown in FIG. 1B. This seeding method routinely produces approximately 60% FRET+ cells, compared to 0.1% for conditioned medium. For overexpression screening, cells were sampled on days 7 and 10 after seeding agent addition. On day 13, FRET+ and FRET- cells were collected by FACS. For gRNA sequence enrichment analysis, we used the DESeq2 algorithm to compare the FRET- population to both FRET+ cells and cells sampled on days 7 and 10. These analyses revealed two gRNAs for the gene LEMD2 that were significantly enriched in FRET cells. String analysis (Figure 2A) identified LEMD2 within the nuclear envelope functional network, where LEMD2 binds to BANF1 and, like ANKLE2, is an integral component of the inner nuclear membrane of the nuclear envelope (Figure 2D). For secondary confirmation of LEMD2, we used cDNA expression rather than dCas9-SAM transcriptional enhancement.We tested cDNAs expressing two isoforms of LEMD2 and the closely related LEMD3 protein, as well as a cDNA of CHMP7, because CHMP7 binds to LEMD2 and is involved in repairing nuclear envelope breaks to promote membrane sealing (Figure 7A). The sequences of the lentiviral cDNA constructs are listed in SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 37, and SEQ ID NO: 39. Expression of all four cDNAs in biosensor cells reduced FRET induction by potent seeding agents (Figures 2E and 6F) and did not affect expression of the MAPT-4RD transgene (Figure 6G). LEMD2 isoforms and CHMP7 showed stronger rescue than LEMD3.
[0189] To further explore the protective properties of LEMD2, LEMD3, and CHMP7, we tested the ability of cDNA overexpression of these proteins to rescue tau aggregates induced by loss of BANF1 and ANKLE2. To set up these screens, we first established tau biosensor subclones stably expressing a catalytically dead form of Cas9 fused to a Kruppel-associated box transcriptional repression domain (dCas9-KRAB). We then transduced promoter-targeted lentiviral gRNA expression vectors to establish stable knockdown of BANF1 and ANKLE2 gene expression. The seeding agents induced tau aggregates, as indicated by the strong FRET signals in BANF1 and ANKLE2 knockdown biosensor cells compared to control cells stably expressing the control gRNA, gNT303 (Figure 3A and Figure 3B). As a positive control, expression of BANF1 cDNA abolished seeding-induced FRET in BANF1 knockdown cell lines, but not in cells with ANKLE2 knockdown (Figure 7E). Expression of both isoforms of LEMD2, as well as LEMD3 and CHMP7 cDNAs, all abolished or significantly reduced FRET induction by two different seeding agents (Figures 3A and 3B). Expression of all four cDNAs did not reverse dCas9-KRAB transcriptional repression of BANF1 and ANKLE2 (Figures 7B and 7C). Although we did not evaluate Tau-4RD protein levels, expression of these cDNAs did not affect expression of the MAPT-4RD cDNA transgene assessed by TAQMAN qRT-PCR (Figure 7D), indicating that the rescue of FRET induction by these cDNAs was a direct effect. The sequences of the lentiviral cDNA constructs are set forth in SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:39.
[0190] To investigate how LEMD2 expression affects the biochemical behavior of tau, we analyzed the subcellular fractions of BANF1 and ANKLE2 knockdown cell lines with and without LEMD2 overexpression. In the absence of seeding agent, we found that the majority of tau protein was distributed between the cytoplasmic and soluble nuclear fractions in control dCas9-KRAB biosensor cells expressing a control gRNA (Figure 3C and Figure 3D, upper left quadrant). This pattern was not altered by knockdown of BANF1 or ANKLE2, whereas treatment with tau-YFP Agg+ cell lysates led to accumulation of tau in the insoluble fraction in BANF1 or ANKLE2 knockdown cells but not in control cells (Figure 3C, upper right quadrant). Insoluble tau was phosphorylated on serine 356 (Fig. 3C, lower right quadrant), a marker of tau aggregates in seeded tau biosensor cells, correlating with seeding activity in tau-YFP Agg+ cells (Fig. 5F). Consistent with its ability to prevent tau aggregation assessed by FRET (Fig. 2E, Fig. 3A, and Fig. 3B), expression of LEMD2 cDNA prevented the accumulation of tau in seeding-induced insoluble and phosphorylated biochemical isoforms (Fig. 3D).
[0191] Loss of BANF1 or ANKLE2 induces mislocalization of the nuclear speckle component SRRM2. Our results demonstrate that loss of the nuclear envelope components BANF1 and ANKLE2 enhances tau aggregates in tau biosensor cells and promotes accumulation of P-tau-Ser356 in the insoluble subcellular fraction (Figure 3A-D), but these changes in tau biochemical properties require induction by a seeding agent. Our biochemical fractionation shows that tau is an abundant component of the nucleus. Could reduction of BANF1 and ANKLE2 cause disruption of nuclear function that promotes susceptibility to tau seeding? Lester et al. showed that small nuclear and nucleolar RNAs as well as components of the nuclear speckle, sites of pre-mRNA splicing, are associated with tau aggregates induced by potent seeding agents in tau biosensor cells. Lester et al., (2021), Neuron, 109(10):1675-1691, is incorporated herein by reference in its entirety in this application. Notably, the nuclear speckle component SRRM2 colocalized with tau in large cytoplasmic aggregates. We reproduced this result using tau-YFP Agg+ whole cell lysate as tau seeding agent (Figure 3E). However, even without tau seeding, we found that biosensor cells with dCas9-KRAB-induced reduction of BANF1 or ANKLE2 showed mislocalization of SRRM2 from the nucleus to the cytoplasm (Figure 3F), yet these cells did not show any signs of tau aggregates or phosphorylation (see biochemical analysis of similar cells in Figure 3C). In normal tau biosensor cells, immunofluorescence detection of SRRM2 was almost entirely restricted to the nucleus, whereas in BANF1- and ANKLE2-deficient cells, some SRRM2 was clearly seen in perinuclear foci (Fig. 3F), indicating leakage of the protein in a form that appears to be locally concentrated.Visual counting of immunofluorescent cells revealed that approximately half of the BANF1-deficient cells lost the exclusive nuclear retention of SRRM2 and showed both nuclear and cytoplasmic localization patterns, whereas nearly 30% of the ANKLE 2-deficient cells showed both nuclear and cytoplasmic SRRM2 detection (Figure 3G). Using different types of quantitative analysis, we determined the percentage of SRRM2 immunofluorescence associated with the nucleus in each cell tested. The majority of control cells had approximately 90% of their SRRM2 signal in the nucleus. In BANF1-deficient and ANKLE2-deficient cells, we observed two populations: the first group was similar to the control, with 90% of SRRM2 retained in the nucleus; the second group showed an almost equal (40-60%) distribution of SRRM2 between the nucleus and cytoplasm (Figure 3H). We observed a similar effect for BANF1. Reduction of ANKLE2 expression leads to accumulation of BANF1 protein in the cytoplasm and its loss from the chromatin-bound fraction (Figure 7F). These results indicate that loss of nuclear membrane integrity in the absence of overt tau aggregates may be an initiating event that allows leakage of SRRM2, tau, and possibly other nuclear components into the cytoplasm, ultimately inducing their aggregation.
[0192] Decreased expression of Banf1, Ankle2, and Ppp2ca leads to increased phosphorylation of tau on serine 356 and impaired nuclear membrane integrity in mouse cortical neurons. Our genetic screen was performed in highly proliferative HEK293T cells, which undergo constant cycles of nuclear breakdown and reformation. To investigate the consequences of nuclear membrane perturbation in postmitotic cells, which are more relevant to tau pathology, we transduced wild-type primary mouse cortical neurons with lentiviruses co-expressing Cas9 with either control gRNA, or gRNAs targeting either Banf1, Ankle2, or Ppp2ca, or control gRNA. We confirmed gene disruption by NGS and TAQMAN qRT-PCR (Figures 8B-C). Disruption of Banf1, Ankle2, or Ppp2ca caused a significant increase in P-tau-Ser356 in the perinuclear domain and nucleocytoplasm (Fig. 4A, 4D, 4E, 8D). P-tau-Ser356 signal was enhanced in the cell body upon knockdown of Banf1 or Ankle2, but not Ppp2ca (Fig. 4C). Disruption of any of the three genes did not affect total tau in the cell body (Fig. 8F, 8I). Disruption of Banf1 caused a slight loss of tau detection in the perinuclear domain and nucleocytoplasm (Fig. 8J-K), while knockdown of Ppp2ca resulted in a slight increase in tau detection in the perinuclear domain (Fig. 8J). Disruption of Ppp2ca appeared to cause some toxicity (Fig. 4B, 8E, 8G, 8H).
[0193] Next, we sought to evaluate the effect of Banf1 and Ankle2 depletion on the nuclear membrane integrity of primary mouse cortical neurons. To this end, we used a fluorescent nuclear reporter (NLS: mCherry) and ASO targeting mouse Banf1, Ankle2, or a scrambled ASO sequence as a control. ASOs were introduced into mouse cortical neurons via gymnotic delivery, and qRT-PCR analysis confirmed the specific and significantly reduced expression of Banf1 and Ankle2 (Figure 4G and Figure 4H). Live cell imaging studies revealed increased detection of mCherry in the soma of mouse cortical neurons treated with Banf1 or Ankle2 ASO compared to the control ASO, as evident in Figure 4F. Quantification of mCherry fluorescence intensity revealed a significant increase in mCherry in the soma of Ankle2 or Banf1 depleted neurons, likely due to nuclear leakage.
[0194] To further confirm the specific nuclear membrane-associated effect of ASO-mediated depletion of Ankle2 and Banf1 in mouse cortical neurons, we reproduced the rescue experiments performed in biosensor cells (Figures 3A-D). We treated mouse cortical neurons with control ASOs or ASOs targeting Banf1 or Ankle2 together with LV-cDNAs encoding Lemd2, Lemd3, Chmp7, or luciferase as a control. Depletion of Ankle2 or Banf1 in mouse cortical neurons increases P-tau-Ser356 in the soma, perinuclear domain, and nucleocytoplasmic domain (Figure 9A). This effect is significantly reduced or eliminated by co-expression of cDNAs encoding Lemd2, Lemd3, or Chmp7 (Figures 9B-D). Knockdown expression of Banf1 or Ankle2 was confirmed by qRT-PCR and cDNA expression (Figure 9E-G). Taken together, these results provide strong evidence of an association between nuclear envelope leakage and increased phosphorylation of tau on serine 356 in both biosensor cells and primary cortical neurons. P-tau-Ser356 is a biomarker of tau aggregates, insolubility, and seeding activity (Figure 5D and Figure 3C), yet cortical neurons in these experiments were not treated with tau seeding agents. Unlike proliferating HEK293T biosensor cells, which require seeding events to induce phosphorylation of tau on serine 356 in response to loss of Banf1, Ankle2, or Ppp2ca in postmitotic cortical neurons, loss of nuclear envelope components is sufficient to cause biochemical changes in tau that may be precursors to pathogenesis.
[0195] Consideration Most of the research on tauopathies focuses on the damage to cells and tissues caused by the widespread misfolding and aggregation of tau. Cellular and mouse models of the disease often use strong overexpression of mutant tau protein or application of high doses of misfolded amyloid fibrils derived from mutant forms. See, for example, Allen et al. (2002), J. Neurosci., 22:9340-9351; Frank et al. (2008), Acta Neuropathol., 115:39-53; and Yoshiyama et al. (2007), 53:337-351, which are incorporated herein by reference in their entirety in this application. These types of studies may model the impairments associated with the later stages of tauopathic disease, but do not necessarily address the underlying causes. In this study, our point was different. We hoped to gain a better understanding of the early events that initiate tau pathology by asking what normal cellular processes, pathways, and functions, if disrupted, might promote tau misfolding and aggregation.
[0196] Our initial genetic screen used CRISPR-Cas9 mutagenesis to discover mutations that enhance tau aggregation in a tau biosensor cell line that is highly sensitive to tau seeding agents. See, for example, Holmes et al., (2014) Proc. Natl. Acad. Sci. USA, 111:E4376-4385, and Sanders et al., (2014) Neuron, 82 1271-1288, each of which is incorporated herein by reference in its entirety in this application. We found that diluted conditioned medium from cells with stable tau aggregates can induce FRET in a small percentage of cells without the aid of a transfection reagent. When biosensor cells were mutated in the absence of seeding agents, we did not find any FRET-positive cells. This result implied that mutations in single genes causing spontaneous aggregation are very rare or absent, even in systems primed for tau aggregates. However, when we challenged the mutagenized cells with conditioned medium weak seeding agent, we found two genes that promoted tau aggregation when disrupted, as shown by enhanced FRET. One gene, PPP2CA, is the major tau phosphatase and encodes the catalytic subunit of the 2A family of serine / threonine protein phosphatases that are associated with Alzheimer's disease. The other gene, BANF1, encodes barrier-to-autointegration factor, a small, abundant, and highly conserved DNA-binding protein that is associated with several important cellular processes. Furthermore, homozygous missense mutations in the BANF1 gene have been found in patients diagnosed with progeria syndromes whose cells showed morphological abnormalities of the nuclear envelope. PPP2CA and BANF1 are part of a functional network involved in nuclear envelope maintenance, cycling, and repair (Figures 2A-E, 3A-H, and 7A-F).Systematic examination of other members of this network identified a third gene, ANKLE2 (ankyrin repeat and LEM domain-containing protein 2), which, when disrupted, promoted enhanced FRET in biosensor cells.
[0197] BANF1 connects chromatin to the inner membrane of the nuclear envelope and interacts with the nuclear lamina (Figure 2D). It also binds to the LEM (LAP2 / Emerin / MAN1) domains of other protein components of the inner nuclear membrane. In dividing cells, phosphorylation of BANF1 by VRK1 kinase (Figure 2A), a member of BANF1's interaction network, disrupts its association with chromatin and LEM proteins, promoting nuclear envelope dissolution before entry into mitosis. After completion of mitosis, ANKLE2 has two functions during nuclear envelope reformation: ANKLE2 inhibits VRK1 kinase activity and enhances PPP2CA phosphatase activity to promote the dephosphorylation of BANF1 so that it can reconnect chromatin to the nuclear envelope via its association with LEM proteins. In addition to its documented functions, the association of PPP2CA with Alzheimer's disease may be due, in part, to its involvement in the maintenance and recycling of the nuclear envelope. During interphase, BANF1 promotes repair of nuclear envelope breaks and coats nuclear DNA at the break sites to prevent activation of the cyclic GMP-AMP synthase-interferon gene (cGAS-STING) innate immune pathway.
[0198] We confirmed the link between tau and the nuclear membrane by demonstrating that the seeding-induced enhancement of tau aggregates upon loss of BANF1 and ANKLE2 could be rescued by overexpression of LEMD2, its associated protein LEMD3, or CHMP7, a protein involved in repair of nuclear envelope breakdown. We demonstrated that overexpression of LEMD2 not only abolished enhanced tau aggregates as measured by FRET, but also prevented the biochemical accumulation of insoluble tau phosphorylated on serine 356. The lack of hits for LEMD2, LEMD3, and CHMP7 in loss-of-function screens for enhanced tau aggregates suggests that their roles in nuclear envelope maintenance may be redundant. Especially considering the role of CHMP7 in nuclear envelope repair, its discovery in the overexpression screen indicates a more prominent function of these three proteins in repairing nuclear envelope damage that would otherwise promote tau aggregation. Previous studies have shown a link between tau misfolding and defects in nuclear function. Pathogenic tau aggregates have been linked to disruption of nucleocytoplasmic transport through the nuclear pore complex, a regulating gatekeeper for transport in and out of the nucleus. In contrast, the genes identified by our CRISPR-Cas9 screen encode proteins that maintain the basic barrier function of the nuclear membrane. Our biochemical fractionation and immunofluorescence analysis show that tau is abundant in the nucleus (Figures 3A-3H and 8A-8K), suggesting a critical function in this cellular compartment. Lester et al. have also shown that tau is an abundant component of the nucleus, and when induced to aggregate, it associates with small RNAs in the nucleus and nucleoli, as well as components of nuclear speckles, one of which is the RNA-binding protein SRRM2, which has been found to be mislocalized in the cytoplasm. Lester et al., (2021), Neuron, 109(10):1675-1691, is incorporated herein by reference in its entirety in this application. We reproduced SRRM2 mislocalization by reducing expression of BANF1 or ANKLE2, but in our case we did not use a seeding agent and did not detect tau aggregates.Loss of nuclear envelope components alone initiated events related to tau pathogenesis in Alzheimer's disease. Similarly, in primary mouse cortical neurons, a cell type more relevant to tauopathy, we found that disruption of Banf1, Ankle2, or Ppp2ca caused enhanced production of P-tau-Ser356, especially in the perinuclear and nuclear domains. The induction of this biomarker of tau aggregation, insolubility, and seeding activity in mouse neurons that were not treated with seeding agents strongly suggested loss of nuclear envelope integrity as an initiating event for the promotion of tau aggregates and the initiation of tau pathogenesis. Abrogation of nuclear envelope function may alter the biochemical properties of tau and disrupt the retention of nuclear components whose appearance in the cytoplasm may nucleate tau aggregates. Postmitotic neurons that do not undergo continuous cycles of nuclear envelope breakdown and reassembly may be more susceptible to events that compromise nuclear envelope integrity.
[0199] Most of the interest in tau in neurodegenerative diseases has focused on its role in promoting axonal microtubule stability. What is the connection between axonal microtubules and the nuclear membrane? As axons lengthen during normal neuronal growth, this elongation may be transmitted to the nucleus via the cytoskeleton, causing deformation of the nuclear membrane. Structural modifications of the nuclear membrane may alter the binding of BANF1 to chromatin, promoting an adaptive response in gene expression. This same type of communication between axonal microtubules and the nucleus may also cause a transient breakdown of the nuclear membrane that releases some of the nuclear contents into the cytoplasm. One such component may be tau, which may bind to unoccupied sites on growing microtubules as it is released from its nuclear reservoir. Both the nucleic acid binding partners of tau in the nucleus and the microtubules in the cytoplasm are polyanions that can be bound by the positively charged microtubule-binding domain of tau, implying an exchange of binding partners from the nucleus to the cytoplasm. Alternatively, if tau is released from the nucleus as a result of compromised nuclear membrane integrity in the absence of axonal microtubule synthesis, it enters the cytoplasm without available binding partners. This may promote tau misfolding, insolubility, and aggregation. Subsequent axonal microtubule growth may stimulate the release of tau from the nucleus, which is filled by previously aggregated forms that may seed further tau aggregates and prevent their binding to newly created microtubules, thereby compromising their stability. Thus, an initial injury to the nuclear membrane may tip the balance between nuclear and cytoplasmic tau toward dead-end cytoplasmic aggregated forms, leading to loss of neuronal health and function. Such a scenario may also be imagined for the RNA-binding protein TDP-43, a predominantly nuclear component, found in cytoplasmic aggregates at the end stages of the disease in many cases of amyotrophic lateral sclerosis and frontotemporal dementia not associated with TDP-43 mutations. In these cases, like tau, TDP-43 may not have the appropriate cytoplasmic RNA binding partners to prevent its misfolding and aggregation.
[0200] Our results point to nuclear membrane integrity as a promising new area of research in efforts to understand the origins of tauopathy diseases and develop novel therapeutic modalities.
[0201] Materials and Methods Tau FRET biosensor cell culture. HEK293T tau-CFP / tau-YFP (tau) biosensor cells expressing a transgene encoding the 4RD microtubule-binding domain of tau fused to the fluorescent reporters CFP or YFP were grown in DMEM culture medium (GIBCO, Cat. No. 11971-025) containing 10% fetal bovine serum (GIBCO, Cat. No. 16000-036), and 1% penicillin / streptomycin (GIBCO, Cat. No. 15140-122) at 5% CO. 2 The incubation was continued at 37°C for 1 h.
[0202] Primary Mouse Cortical Neuron Cultures. Wild-type primary mouse cortical neurons (Mouse Cortical Neurons, MCNs) were purchased from ThermoFisher (GIBCO, Cat. No. A15586) and cells were cultured at a density of approximately 20,000 neurons in a volume of 100 μL per well in Poly-D-Lysine treated 96-well plates (Greiner Bio-One, Cat. No. 655946) in Neurobasal Plus Medium (GIBCO, Cat. No. A35829-01) + 1% B-27 Plus Supplement (GIBCO, Cat. No. A35828-01) + 1X GlutaMAX Supplement (GIBCO, Cat. No. 35050-061) according to the manufacturer's user guide, at 37°C, 5% CO 2Three days after seeding, neurons were transduced with (Cas9+gRNA) constructs as mouse targeting gRNA Banf1_gRNA3, Ankle2_gRNA3, Ppp2ca_gRNA2, or control gRNA non-targeting 303, gNT303, cloned into pLentiCRISPR-v2 Cas9 expression vector and packaged into lentivirus (GenScript). After 6 h, half of the Neurobasal medium volume was replaced and replenished every 3-4 days. For ASO treatment, MCNs were treated 3 days after seeding via gymnotic delivery with ASO targeting Banf1 or Ankle2 or scrambled control ASO (synthesized by IDT). MCNs were maintained in culture for 2 weeks before fixation for expression analysis and analysis by immunofluorescence.
[0203] Production of lentiviral particles. Lentiviral particles are produced following standard LIPOFECTAMINE™-mediated co-transfection of HEK293T cells with transfer plasmids (expression vectors, GenScript) encoding gRNA libraries or individual gRNAs or Cas9 components together with second generation packaging plasmids encoding the gag, pol and rev genes, and a third plasmid encoding the VSV-G envelope. 24 hours prior to transfection, HEK293T cells were transfected with 10×10 6The cells were plated in 150 mm cell culture dishes at a density of cells / plate in DMEM medium (GIBCO, Catalog No. 11971-025) containing 10% fetal bovine serum (GIBCO, Catalog No. 16000-036) and 1% penicillin / streptomycin (GIBCO, Catalog No. 15140-122). On the day of transfection, the DMEM medium was replaced by Opti-MEM medium (GIBCO, Catalog No. 31985-070) supplemented with 25 nM chloroquine (Sigma-Aldrich, Catalog No. C6628-25G). A DNA mixture was prepared by mixing 20 μg of transfer DNA with 20 μg of packaging DNA and 10 μg of membrane DNA in 1.5 mL of Opti-MEM with 60 μL of PLUS™ Reagent (GIBCO, Cat. No. 11514015). In parallel, 100 μL of LIPOFECTAMINE™ LTX (Life Technologies, Cat. No. 15338500) was diluted in 1.5 mL of OptiMEM medium. Both mixtures were mixed for 20 min before being added to the cells. The culture medium was changed 6 h after transfection. The cells were incubated at 4 °C for 2 h at 37 °C for 1 h at 37 ... 2 The culture was performed at 37°C in an incubator with atmosphere. After 48 hours, the culture medium containing the lentiviral particles was centrifuged to remove debris and filtered. The supernatant was treated with DNase to remove residual DNA. The lentiviral batch was concentrated by ultracentrifugation and resuspended overnight in phosphate-buffered saline solution (PBS, GIBCO, Cat. No. 14040-133). The viral particles were finally aliquoted and stored at -80°C. The lentiviral vector was titrated using NucleoSpin RNA Virus Kit (Takara, Cat. No. 740956.250) and Lenti-X qRT-PCR Titration Kit (Takara, Cat. No. 631235). The lentiviral gRNA library particle titer was determined by limiting dilution (adapted protocol from SIGMA Mission RNAi).
[0204] Expression and purification of recombinant human MAPT (Q244-E372; P301L, V337M) protein. Recombinant human tau (Q244-E372; P301L, V337M) protein (tau244-372LM) was expressed in BL21(DE3) competent E. coli. Lysis and purification of tau244-372LM protein were performed similarly to published reports. The supernatant from the cell lysate was passed through HiTrap SP-Sepharose HP resin to isolate tau244-372LM protein. The peak fractions from this step were then applied to a Superdex 75 26 / 600 column (Cytiva) and eluted in 50 mM HEPES, pH 7.0, 50 mM NaCl, 1 mM EDTA, 2.5% glycerol, 10 mM dithiothreitol. SDS-Page analysis showed that the protein was purified to >90% homogeneity. The concentration of this material was determined against a standard curve in a colorimetric BCA assay kit from Pierce.
[0205] Preparation of recombinant human MAPT (Q244-E372; P301L, V337M) fibrils. A stock concentration of low molecular weight heparin (United States Pharmacopeia, Catalog No. 1235820; average molecular weight 4370 Daltons) was prepared by dissolving enoxaparin sodium in Milli-Q water. A 73 μM concentration of recombinant tau 244-372LM protein was mixed with freshly prepared 1 mM dithiothreitol and 18 μM heparin and then transferred to a small polycarbonate vessel. A 10 mM magnetic Teflon stir bar was added to the vessel. The solution was incubated at 37° C. for 4 days with constant stirring at 750 rpm. Fibrils were collected by ultracentrifugation at 150,000 rcf for 30 minutes in a Beckman T-55 bio-contained rotor. Following the first spin, excess heparin and soluble proteins were removed from the fibril pellet by performing three washing steps. Briefly, the supernatant was discarded and the fibril pellet was resuspended in a few milliliters of 50 mM HEPES, 25 mM NaCl buffer and then centrifuged again. Prior to aliquoting, the fibril pellet was resuspended in the same buffer as above and then sonicated in a Qsonica cup horn at 50% amplitude for 30 seconds. This step helped to disperse the fibrils evenly in the solution and break up visible clumps.
[0206] Characterization of tau aggregates by thioflavin T fluorescence. Aggregation of purified recombinant tau 244-372LM monomers was monitored by measuring the fluorescence of the amyloid-specific dye thioflavin T (ThT) at 485 nm (excitation 443 nm). Samples of tau 244-372LM monomer (50 μM, 25 μM, and 10 μM) were prepared from a 73 μM stock by dilution in buffer (50 mM HEPES, pH 7.4, 30 mM NaCl). Each concentration of tau was transferred in triplicate to a black 96-well microplate with a two-fold molar excess of freshly prepared ThT over tau 244-372LM. Heparin was added to triplicate wells at a heparin to tau molar ratio of 1:4 for each concentration (12.5 μM, 6.25 μM, and 2.5 μM heparin). Fluorescence was collected over 120 hours on a BMG ClarioStar plate reader. Plates were maintained at a constant 37° C. with constant dual orbital shaking at 700 rpm. Measurements were recorded every 15 minutes through the bottom of the plate.
[0207] Transmission electron microscopy of recombinant tau 244-372LM fibrils. Tau 244-372LM fibrils were diluted 1:5 in buffer (50 mM HEPES, pH 7.4, 25 mM NaCl). Approximately 8-10 μL of sample was applied to the center of a 300 mesh formvar-coated copper grid and allowed to incubate for 2 min. Afterwards, filter paper was used to blot the remaining liquid while simultaneously applying 10 μL of 1% uranyl acetate staining solution. Filter paper was then used again to blot excess stain. Images were acquired on a JEOL 1200 EX electron microscope at 80 kV.
[0208] Development of stable tau aggregate cell clones as a source of tau seeding material. HEK293T tau-YFP cells were seeded in 6-well dishes at 500,000 cells / well in DMEM medium. The next day, cells were treated with purified tau 244-372LM fibrils. Tau fibrils (1 μg) were placed in LIPOFECTAMINE™ 2000 (Invitrogen, Cat. No. 11668-019) in Opti-MEM medium and incubated at room temperature for 20 minutes before being added to the wells. The next day, cells were passaged in serial dilutions into 96-well plates, such that each row of the plate received a 2-fold dilution compared to the previous row. Plates were expanded and visually inspected to identify wells containing single colonies. Single cell-derived clones were further inspected by fluorescent microscopy to identify clones that contained tau-YFP aggregates, Agg+, in all cells and maintained their aggregates over the course of several passages. Three clones were validated to evaluate their ability to produce tau seeding activity. Briefly, aggregate-containing cells were grown to confluence in T175 flasks, the medium was replaced with fresh DMEM medium, and the medium was then harvested after 4 days of incubation. The conditioned medium was then centrifuged at 800 rpm for 5 minutes to remove debris, aliquoted, and stored at -80°C. To test tau seeding activity, HEK293T tau-CFP / tau-YFP (tau) biosensor cells were cultured in 75% conditioned medium:25% DMEM medium for 3 days and then harvested for analytical flow cytometry using a CytoFLEX LX (Beckman Coulter) to measure FRET signals in the seeded cells. Tau-YFP Agg+ clone 18 was selected for further expansion based on its retention of aggregates in all cells over many passages and the ability of clone 18 conditioned medium to consistently induce ∼0.1% FRET signal in ∼0.1% of tau biosensor cells, which we defined as the minimal tau seeding treatment.
[0209] As another source of tau seeding activity, whole cell lysates were collected from tau-YFP Agg+ clone 18. Cells were grown in six T175 flasks. When confluent, cells were harvested by scraping into cold PBS. Whole cell pellets were resuspended in 40 μL EDTA (ThermoFisher, Cat. No. 1861283), 40 μL HALT protease and phosphatase inhibitor cocktail (ThermoFisher, Cat. No. 78446) and 4 ml fresh PBS and sonicated for 3 minutes at 51 Amp using a Qsonica Q500 sonicator. After the final centrifugation, the supernatant containing the whole cell lysates was collected and the protein concentration was determined before aliquoting and storing at -80°C.
[0210] Selection of Cas9 expressing tau biosensor clones. HEK293T tau-CFP / tau-YFP (tau) biosensor cells were grown in DMEM medium and transduced with the pLentiCas9-Blast vector (GenScript) packaged in lentivirus in 24-well dishes at high MOI (multiplicity of infection) in the presence of 8 μg / mL Polybrene (Millipore, catalog number TR-1003-G). After 24 hours, the medium was replaced with DMEM medium containing 10 μg / mL blasticidin (Invivogen, catalog number ant-bl-1) and the cells were grown under selection. Three days after transduction, the cells were passaged in serial dilutions. Eight expanded single cell clones were evaluated for both their Cas9 expression levels and their cleavage activity. The level of Cas9 mRNA expression was measured using the Quick RNA96 kit (Zymo Research, Cat. No. R1053) followed by TaqMan qRT-PCR using the Quantinova One-Step RT-PCR kit (Qiagen, Cat. No. 208352) with the VG_Cas9U2 TaqMan assay and the reference assay β2M. Samples were run on a QuantStudio real-time PCR system (ThermoFisher). Cas9 cleavage activity was determined as the percentage of indel alleles following transduction of PERK gRNA6 at the PERK locus. This gRNA was cloned into the pLentiGuide-Puro vector (GenScript), packaged into lentivirus, and transduced into Cas9 clones with three replicate wells. After 24 hours, the medium was replaced with DMEM medium containing 1.5 μg / mL puromycin (Invivogen, Cat. No. ant-pr-1). Cells were grown under puromycin selection. Transduced cells were harvested on days 3 and 7 and genomic DNA was extracted for digital PCR analysis (dPCR) using the Blood & Cell Culture DNA Mini Kit (Qiagen, Cat. No. 13323).dPCR was performed using QuantStudio 3D Digital PCR Master Mix V2 (ThermoFisher, Cat. No. A26358) with a VIC-labeled copy number reference assay, human TERT (ThermoFisher, Cat. No. 4403315), and a FAM-labeled assay targeting the PERK_gRNA6 cleavage site. dPCR reactions were loaded onto a QuantStudio 3D Digital PCR 20K Chip v2 (ThermoFisher, Cat. No. A26316) and run using a ProFlex 2X Flat PCR System (ThermoFisher, Cat. No. 4484078). FAM and VIC dye emission was analyzed by QuantStudio 3D Analysis Suite software. PERK gRNA6 cleavage efficiency was determined as a percentage of the FAM / VIC ratio. Clone E was expanded to perform genome-wide CRISPRn screening. See Tables 4-9.
[0211] Selection of dCas9-SAM expressing tau biosensor clones. Tau biosensor cells were transduced with lentivirally packaged pLentidCas9-P64-Blast and pLentiMS2-P65-HSF1-Hyg vectors (GenScript) (as described above). Cells were grown under 5 μg / mL blasticidin and 100 μg / mL hygromycin (Invivogen, Cat. No. ant-hg-1) selection. Three days after transduction, cells were passaged in serial dilutions. Nine single-cell expanded clones were assessed for both their transgene expression levels and gene activation activity. Levels of dCas9, VP64, MS2 and P65 mRNA expression were assessed by TaqMan qRT-PCR using the following assays: Cas9D_VG_SAM, VP64_VG_SAM, MS2_VG_SAM, p65_VG_SAM with reference β2M. Based on the high expression of both components of the dCas9-SAM system, clone DC11 was expanded for further validation using the ΔCt method (see Tables 8 and 9).
[0212] Tau biosensor dCas9-SAM clone DC11 was transduced with gRNAs targeting 11 genes (l1B, LIN28A, UBA52, RANBP1, EEF1A1, ZFP42, PIN1, ATG7, RBM17, DDX42, and STUB1) (Figure 6E). These genes were selected based on their basal transcript levels in tau biosensor cells, as determined by RNAseq transcriptional profiling analysis and as shown in a previous report that SAM-mediated fold activation is inversely correlated with basal transcript levels. See Duval et al. (2015), Nature, 517:583-588, which is incorporated herein by reference in its entirety in this application. gRNAs were cloned into pLenti_sgRNA(MS2)_zeo vector (GenScript) and packaged into lentivirus. gRNAs 1-3 for each gene target were pooled and transduced into DC11 cells, with three replicate wells per target. After 24 hours, the medium was replaced with DMEM medium containing 600 μg / mL Zeocin (Invivogen, catalog no. ant-zn-1). On day 7, transduced cells were harvested and mRNA expression analysis was performed by TaqMan qRT-PCR using TaqMan Gene Expression Assays (ThermoFisher) with the reference assay β2M. Relative expression was calculated based on the ΔΔCt method and normalized to the average of samples transduced with gRNAs targeting other genes for each assay as non-targeting controls. See Tables 4-9.
[0213] Design and cloning of dCas9-KRAB expression vector. Streptococcus pyogenes Cas9 nuclease sequence was obtained from the National Center for Biotechnology Information (NCBI, accession number NP_269215). The nucleic acid sequence was modified to include a Kozak signal, an N-terminus nuclear localization signal (NLS), and a C-terminal NLS linker fused to the KRAB domain of human zinc finger protein 10 (accession number CAA36558). The nucleic acid sequence was codon-optimized using MacVector 18.1.5, and the nuclease cleavage domain was inactivated by incorporating D10A and N863A amino acid substitutions. The A2A peptide was incorporated to support co-expression of dCas9-KRAB and blasticidin-S deaminase from the EF1α promoter. The complete sequence was synthesized by GenScript and cloned into a lentiviral backbone for packaging.
[0214] Selection of dCas9-KRAB expressing tau biosensor clones. Tau biosensor cells were transduced with lentivirally packaged pLentidCas9-KRAB-Blast. Cells were grown with 5 μg / mL blasticidin selection. Two days after transduction, cells were passaged in serial dilutions. Ten single-cell expanded clones were assessed for transgene expression. The level of dCas9-KRAB mRNA expression was assessed by TaqMan qRT-PCR using the VG_Cas9D and 2629_KRAB.P assays and the reference assay β2M. Transcriptional repression activity was determined in three clones showing the highest levels of dCas9-KRAB expression. Activity was determined by measuring the mRNA levels of four target genes (EGFR, HGF, HSPA8, and NEDD4) after transduction of gRNAs targeting specific sequences located within 200 bp of the transcription start sites of these genes. gRNAs were cloned into pLentiGuide-Puro vector (GenScript), packaged into lentivirus, and transduced into dCas9-KRAB clones. Cells were grown under 1.5 μg / mL puromycin selection and harvested 7 days post-transduction for target mRNA expression analysis by TaqMan qRT-PCR using TaqMan Gene Expression Assays (ThermoFisher) and the reference assay β2M. Clone TK-B4 was determined to have the highest level of dCas9-KRAB expression inducing the strongest transcriptional repression and was selected for subsequent validation experiments. See Tables 4-9.
[0215] Genome-wide CRISPRn screening using hGeCKO library combined with minimal tau seeding. The combined hGeCKO-A and B half library contains 111,985 unique single gRNAs (6 gRNAs per gene) targeting 19,050 genes in the human genome, and 1,000 non-targeting gRNAs as negative controls. We performed library transduction at a low multiplicity of infection (MOI of 0.3) to ensure that most cells received at most one gRNA construct, with a coverage of 300 cells per gRNA, and selected for viral vector integration events in transduced cells by growth in the presence of puromycin. We induced tau aggregates by sampling the transduced cell cultures 3 and 6 days after transduction of the GeCKO library and then transferring the cells to new medium consisting of a 3:1 mixture of Agg+conditioned medium:fresh growth medium. After an additional 4 days of growth, cultures were harvested and FRET+ cells were purified by FACS (Figure 1B). Cas9-expressing clonal E tau biosensor cells were expanded under blasticidin selection and plated in four T175 flasks at 15 × 10 6 Cells were seeded at a density of 1000 cells / flask in DMEM medium. On day 0, cells were transduced with hGeCKO-A or hGeCKO-B lentiviral packaging gRNA libraries at an MOI of 0.3 in DMEM medium in the presence of 8 μg / m2 polybrene, with a coverage of 300 cells per unique gRNA in the library. After 24 hours, the medium was replaced with DMEM medium containing 1.5 μg / mL puromycin and 10 μg / mL blasticidin, and cells were grown under both blasticidin and puromycin selection. On day 3 post-transduction, flasks were washed with PBS and cells were detached using 0.05% trypsin-EDTA (GIBCO, Cat. No. 25300-054) neutralized with DMEM medium. Cell suspensions from four T175 flasks were combined and transferred to three T175 flasks at a 1:4 dilution factor in DMEM medium. Count the remaining cells, approximately 20x10, for genomic DNA isolation and NGS analysis. 6The cells were pelleted. Six days after transduction, the cells were transferred to two T175 flasks at a 1:4 dilution factor (no selection). In each T175 flask, 30 mL of Tau-YFP Agg+ conditioned medium was added to 10 mL of cell suspension. Approximately 20×10 6 Cells were also collected for genomic DNA isolation and NGS analysis. Ten days after transduction, cells were collected for flow cytometry using a MoFlo Astios Cell Sorter (Beckman Coulter). Cells were pelleted and fractionated at 10 × 10 6 The cells were resuspended via cell-strainer cap tube (Falcon, Cat. No. 352235) in Hanks' Balanced Salt Solution (HBSS, GIBCO, Cat. No. 14175-079) containing 2% FBS at a concentration of 10 cells / mL. Collection tubes were coated with 80% FBS and 20% DMEM medium. FRET-positive cells, FRET+, were pelleted for genomic DNA (gDNA) isolation and NGS analysis. CRISPRn screening was repeated five times with both hGeCKO sublibraries, for a total of 10 genome wide CRISPRn screens.
[0216] Next-generation sequencing. gRNA libraries were multiplexed and sequenced on a NextSeq 500 (Illumina) to generate 1 × 80 base pair (bp) single-end reads. After demultiplexing using bcl2fastq (Illumina), reads were screened for 16 bp of rival vector sequence leading to the gRNA, and downstream 20 bp gRNA reads were extracted for gRNA counting. DESeq2 analysis was performed on OmicSoft Studio software version 10.0.1.118 (Qiagen).
[0217] Gene-centric enrichment analysis. The fold change for each gene was obtained by calculating the arithmetic mean of the log2-transformed FRET+10 vs. 3 or 6 ratios generated for the corresponding gRNA by DESEq2. See Love et al. (2014), Genome Biol., 15:550, which is incorporated by reference in its entirety in this application. The enrichment p-value for each gene was calculated as follows: First, in each FRET+10 sample, a gRNA was considered to be present if its DESeq2 normalized read count was 30 or greater, and we considered read counts less than 30 as background noise. The enrichment of the presence of gRNAs corresponding to genes in FRET+10 samples was calculated using the hypergeometric distribution-based function phyper(x, m, n, k, lower.tail=FALSE) in R (https: / / www.R-project.org / ). The number of gRNAs present that correspond to genes minus 1 is x, the number of all gRNAs that correspond to genes in the library is m, the total number of gRNAs in the library minus m is n, and the total number of gRNAs present in the FRET+ sample is k. The p-values were then log10 transformed and averaged across all 10 FRET+ day 10 samples.
[0218] Genome-wide CRISPrA screening using hSAM libraries combined with maximal tau seeding. dCas9-SAM clone DC11 tau biosensor cells were grown under blasticidin and hygromycin selection, with 23 × 10 cells per flask. 6Cells were seeded at a density of 100 cells per 1000 cells into four T175 flasks. On day 0, cells were transduced with the hSAM lentiviral packaging gRNA library at an MOI of 0.3 in DMEM medium in the presence of 8 μg / mL polybrene at a coverage of 300 cells per unique gRNA in the library. After 24 hours, the medium was replaced with DMEM medium containing 600 μg / mL Zeocin and cells were grown under triple Zeocin, blasticidin and hygromycin selection. On days 3 and 7 post-transduction, cells were detached and cell suspensions from the four T175 flasks were combined and transferred to three T175 flasks at a dilution factor of 1:4 in DMEM medium. On day 10, cells were detached and transferred to two T175 flasks at a dilution factor of 1:4 in DMEM medium (without selection). A maximum seeding treatment consisting of a mixture of LIPOFECTAMINE™ 2000 (4 μL / mL of medium) combined with Tau-YFP Agg+ whole cell lysate (5 μg / mL of medium) was added directly to the cells. Cell samples were also collected on days 7 and 10 for genomic DNA isolation and NGS analysis. On day 13, cells were collected for flow cytometry using a MoFlo Astios Cell Sorter to isolate FRET+ and FRET- cells, which were pelleted for DNA isolation and NGS analysis. Genome-wide CRISPrA screening was repeated five times.
[0219] Next generation sequencing was performed on a NextSeq (Illumina) with 80 cycles of multiplexed single read runs. The generated data was demultiplexed using unique index reads. gRNA counts were determined based on perfectly matched sequencing reads for both leader and gRNA sequences.
[0220] Differential gRNA read count analysis. For comparison of gRNA read counts between two groups of samples, we used the DESeq2 Generalized Linear Model (GLM) and tested for abundance differences using a Wald test based on negative binomial distribution in ArrayStudio (OmicSoft). The terms "experiment" and "FRET status" were used to build a model of FRET+ vs. FRET- comparison between samples at the 13th day time point across five experiments. gRNAs with significant read count differences between comparison groups were identified using the following criteria: i) fold change ≧1.5 in either direction, and ii) p-value <0.05. The gRNAs enriched in the FRET samples were further defined using these three criteria: i) FRET- was significantly increased compared to FRET+ in the day 13 samples, ii) FRET- was significantly increased in the day 13 samples compared to the day 10 samples, and iii) FRET+ was not significantly increased in the day 13 samples compared to the day 10 samples (either no significant difference or a significant decrease). We paid particular attention to gene targets with multiple gRNAs enriched in the FRET samples.
[0221] Preparation of cell samples transduced with -hGeCKO or -hSAM libraries for NGS. Genomic DNA from cell pellets was extracted using the Blood&Cell Culture DNA Midi&Cell Culture DNA Midi kit (Qiagen, Cat. No. 13343) or QIAamp DNA Mini Kit (Qiagen, Cat. No. 51304). For the hGeCKO library, genomes from day 3 and day 6 samples were prepared using a two-step nested PCR strategy. In the first PCR, 130 μg of genomic DNA per sample was amplified to achieve 300-fold coverage of the total unique gRNAs of the library. For each sample, 13 100 μL PCR reactions were performed and mixed, with 10 μg of genomic DNA in each reaction, using NEB Next High-Fidelity PCR Master Mix (New England BioLabs, Cat. No. M0541S). For the second nested PCR, 10 PCR reactions were performed on the barcoded samples to attach Illumina adapters and for multiplexing the NGS run. FRET+ samples on day 10 (approximately 50,000 cells per sample) were amplified from the total cell population based on 10 μg of amplified DNA per 100 μL first PCR reaction. 5 μL of the first PCR reaction and equimolar amounts of 9 different forward primers and reverse primer combinations with unique barcodes were used for the second PCR (Table 3). All primers were used at a final concentration of 0.5 μM. PCR cycles started with an initial denaturation at 98° C. for 30 s; followed by 18 cycles for PCR1 and 15 cycles for PCR2 of denaturation at 98° C. for 10 s, annealing at 60° C. for 30 s, and extension at 72° C. for 30 s, and a final extension at 72° C. for 5 min. PCR products were combined, concentrated using a DNA Clean&Concentrator kit (Zymo Research, Cat. No. D4034), purified with a Pippin Prep apparatus (DNA size selection system, Sage Science), and then subjected to NGS.For the hSAM library, 140 μg of genomic DNA from day 7 and day 10 cell samples were amplified for 300-fold coverage of the SAM gRNA library. Both day 13 FRET+ and FRET- samples were amplified from the whole cell population. Only one-step PCR was performed using 2.5 μg of DNA per 100 μL reaction, 10 different forward primers, and a reverse primer with a unique barcode. The PCR cycle started with an initial denaturation at 98° C. for 30 seconds; followed by 26 cycles of denaturation at 98° C. for 10 seconds, annealing at 60° C. for 30 seconds, and extension at 72° C. for 30 seconds; and a final extension at 72° C. for 5 minutes. The combined PCR products were purified and then subjected to NGS. See Table 3.
[0222] Validation of individual tau modifier targets with minimal tau seeding treatment. Based on the analysis of the CRISPRn screen with the hGeCKO library, 30 gRNAs targeting 14 different candidate genes as well as a control gRNA were purchased (GenScript) and packaged into lentivirus. Individual gRNAs were transduced into Cas9 Clone E tau biosensor cells and grown under puromycin selection for 6 days. For each gRNA, three replicate wells were transduced. On day 7, conditioned medium from tau-YFP Agg+ cells or control fresh DMEM medium was added to the transduced cells at 75% conditioned medium vs. 25% DMEM medium. On day 10, cells were collected for analytical flow cytometry using a CytoFLEX LX to assess the percentage of cells positive for FRET signal. Briefly, cells were washed with PBS, trypsinized to form a single cell suspension, centrifuged at 800 rpm for 5 min, and resuspended in 200 μL of HBSS + 2% FBS. Cells were filtered through cell strainer tubes, transferred to a 96-well round-bottom plate, and stained with 0.5 μL of 7-aminoactinomycin D (7-AAD, ThermoFisher, Cat. No. A1310) to assess cell viability. Percent FRET+ cells were assessed as the percentage of live single CFP+ / YFP+ cells that were FRET+. Integrated FRET Density (IFD) was calculated as the product of the percentage of FRET+ cells multiplied by the Median Fluorescence Intensity (MFI) of FRET+ cells. See Tables 4-9.
[0223] Determination of gene editing at gRNA cleavage sites of BANF1, ANKLE2 and PPP2CA. Cas9 Clone E Tau biosensor cells were transduced with BANF1 gRNA1, PPP2CA gRNA5 and control gRNA and grown under puromycin selection. Three days after transduction, cells were passaged and expanded by serial dilution. Nine single cell derived clones (seven for BANF1 and two for PPP2CA) were assessed for FRET signal in response to plating with conditioned media from Tau-YFP Agg+ and Tau-YFP Agg- cells, and for the level of gene editing at the BANF1 and PPP2CA gRNA cleavage sites. This was assessed by amplifying the region surrounding the cleavage site and performing NGS to characterize the sequence and prevalence of indel alleles. The NGS reads from each clone featuring indels as a percentage of total reads were determined to be the percent gene editing.
[0224] NGS Amplicon Library Preparation. Target-specific oligos were designed (21-27 base pairs, bp) to generate a maximum amplicon size of 350 bp with a primer melting temperature (Tm) of 60-65°C. Barcode adapter sequences were added to the target-specific oligos (Tables 8 and 9) and all sequences were ordered from Integrated DNA Technologies (IDT). PCR was completed for each DNA sample. Briefly, in each reaction, 4 ng of DNA was mixed with IDT oligos, Q5 polymerase (New England Biolabs, Catalog No. M0491), 10 μM dNTPs, buffer, and water according to the manufacturer's specifications. The amplified products were then diluted 1:100 and used in a PCR barcoding reaction to generate the final sequencing library. Each barcoding reaction contained a single amplified target with forward and reverse primers containing a unique barcode and index. Each plate of PCR was pooled in equal volumes and then purified in a single tube using AMPure XP reagent (Beckmann-Coulter, Cat. No. A63881) according to the manufacturer's instructions. The final library concentration was measured using a Qubit fluorometer (Invitrogen, Cat. No. Q32866). Four nanomoles of the prepared library was loaded onto an Illumina MiSeq utilizing a 2x300 reads kit (Illumina, Cat. No. MS-102-3003) according to the manufacturer's instructions.
[0225] Sequence mapping and characterization. Barcoded samples were demultiplexed into individual reads (FASTQ format). Then, forward and reverse reads of each FASTQ file were merged using PEAR (ncbi.nlm.nih.gov / pmc / articles / PMC3933873 / ). Merged reads were mapped to the Mus musculus genome version 9 (mm9) using Bowtie2 (ncbi.nlm.nih.gov / pmc / articles / PMC3322381 / ). Each sample was sequenced with a minimum of 20,000 merged reads across the expected induced cleavage location. Finally, characterization of barcoded samples was performed using custom perl scripts. Briefly, all insertions, deletions, or base changes (INDELs) within a 20-base window upstream and downstream of the expected cleavage site were considered to be CRISPR / Cas9-induced modifications. The number of reads containing INDELs was compared to the number of reads with wild-type sequence to determine percent editing per animal and tissue.
[0226] STRING Database Search. BANF1 was used as input in the String database search (https: / / string-db.org). Settings were: minimum required interaction score 0.4 and maximum number of interactions in the first shell <=10.
[0227] Gene expression analysis by qRT-PCR. For all other gene expression analyses in tau organisms, RNA was extracted with Zymo Quick RNA Cell 96 Kit and samples were diluted to 10ng / μL. Gene expression analysis was performed using QuantiNova Pathogen+IC Kit (Qiagen, Cat. No. 208654) and run on a QuantStudio thermocycler (ThermoFisher) in 384-well PCR plates. TaqMan gene expression assays (ThermoFisher or custom designed) were labeled with FAM and the reference assay GAPDH was labeled with VIC to serve as an internal control in each well. See Tables 8 and 9.
[0228] Modifier cDNA cloning into lentiviral backbone. Based on the analysis of CRISPrA screening with hSAM library, cDNA sequences encoding full-length LEMD2, short isoform LEMD2 (LEMDi2), LEMD3, CHMP7, or luciferase (Luc) were cloned into expression vectors as control cDNAs and packaged into lentiviral LV-cDNA. cDNA and protein sequences were obtained from Ensembl and confirmed with Uniprot. Expression plasmids for expression of cDNA sequences were generated by synthesis (GenScript) and subcloning into pLVX-pEF1α-IRES-Hyg expression vector for human and control luciferase cDNAs and into pLVX-phSynapsin1-IRES-Hyg expression vector for mouse and control luciferase cDNAs (expression vectors developed at Regeneron). cDNA fragments were inserted downstream of the EF1α promoter by using Spe-I and Not-I restriction sites (GenScript). Nucleic acid sequences were obtained by reverse translation of protein sequences (Reverse translator tool, MacVector 18.1.5) and codon-optimized for expression in human and mouse cells. Human protein catalog numbers: BANF1 (O75531), LEMD2 (Q8NC56), LEMD2-isoform 2 (Q8NC56-2), LEMD3 (Q9Y2U8), CHMP7 (Q8WUX9). Mouse protein catalog numbers: Lemd2 (Q6DVA0), Lemd3 (Q9WU40), Chmp7 (Q8R1T1). As a control cDNA, the coding sequence of the reporter gene luciferase was cloned into the same expression vector. For live cell imaging studies, NLS:mCherry cDNA was cloned into the same expression vector upstream EF1α promoter. Plasmids were sequence-verified by Sanger Sequencing before lentiviral packaging.
[0229] Expression of tau modifier genes by transduced cDNA. To test the effect of LEMD2, LEMDi2, LEMD3, CHMP7, or luciferase cDNA overexpression on tau aggregates, packaged lentiviruses were transduced into tau biosensor cells. The sequences of the lentiviral constructs are set forth in SEQ ID NO: 32, SEQ ID NO: 34 to SEQ ID NO: 40. After 24 hours, the medium was replaced with DMEM medium containing 50 μg / mL hygromycin, and the cells were grown under hygromycin selection. On day 3 after transduction, the transduced cells were seeded with maximum tau seeding treatment as LIPOFECTAMINE™ 2000 (4 μL / mL) and tau-YFP Agg+ cell lysate (5 μg / mL). On day 4, cells were collected for analytical flow cytometry using a CytoFLEX LX to measure FRET signals in the seeded cells. Transduced cells were also collected for cDNA expression analysis by TaqMan qRT-PCR using codon-optimized cDNA and a TaqMan assay designed to specifically amplify the MAPT-4RD transgene (see Figure 6F, Figure 6G, Table 8, and Table 9).
[0230] To test the effect of overexpression of these modifier targets on biosensor cells with increased propensity for tau aggregation, cDNAs encoding LEMD2, LEMDi2, LEMD3, CHMP7, or luciferase were transduced into tau biosensor cells with decreased expression of BANF1 or ANKLE2. Briefly, dCas9-KRAB clone TK-B4 tau biosensor cells were seeded in 6-well dishes and transduced with gRNA targeting BANF1 (kBANF1_gRNA6), ANKLE2 (kANKLE2_gRNA2) or control gRNA, non-targeting 303, control gNT303, cloned into pLentiGuide-Puro expression vector and packaged into lentivirus (GenScript). Cells were grown under both puromycin and blasticidin selection and passaged into 12-well plates 3 days after transduction, with each sample replicated in two wells. On day 4, cells were transduced with LEMD2, LEMDi2, LEMD3, CHMP7, or luciferase LV-cDNA as described above. After 24 hours, the medium was changed to DMEM medium + 1.5 μg / mL puromycin + 50 μg / mL hygromycin. On day 7, cells were passaged into three sets of 24-well plates and one set of 6 wells for protein cell fractionation (Luc and LEMD2 cDNA expressing cells). On day 9, DMEM medium was changed and minimal tau seeding was added to wells as follows: the first set of plates received 1 μg / mL spinal cord lysate from 9-month-old P301S Het transgenic mice in each well, and the second set of plates received 1 μg / mL tau-YFP Agg+ whole cell lysate in each well. Confluent cells in a 6-well format were treated with 10 μg / mL cell lysate from Tau-YFP Agg+ or Tau-YFP Agg- cells.On day 11, cells from the first two sets of plates were collected for analytical flow cytometry using a CytoFLEX LX to measure FRET signal in plated cells, and cells from the third set of plates were collected for RNA extraction to assess expression of transduced cDNA constructs and knockdown of KRAB gRNA target genes by TaqMan qRT-PCR. Cells in the 6-well format were collected for protein cell fractionation.
[0231] Intracellular protein fractionation combined with Western blot analysis. Total cell lysates were prepared from confluent cells on 6-well plates scraped into 1 mL ice-cold PBS and centrifuged at 3000 g for 5 min. The pellet was resuspended in 150 μL Novex Tris-Glycine SDS sample buffer (ThermoFisher, Cat. No. LC2676) and 150 μL PBS, homogenized with a 23G needle, and heated at 95° C. for 5 min. Proteins were quantified with RC DC Protein Assay Kit II (Bio-Rad, Cat. No. 5000122). Protein fractionation was performed from confluent cells in 6 wells using the Intracellular Cell Fractionation Kit for Cultured Cells (ThermoFisher, Cat. No. 78840), which contains four extraction buffers. According to the manufacturer's protocol, the first buffer added to the cell pellet caused selective membrane permeabilization and released soluble cytoplasmic proteins. The second buffer lysed plasma, mitochondrial, and ER-Golgi membranes, but did not solubilize nuclear membranes. After recovering intact nuclei by centrifugation, the third buffer extracted soluble nuclear proteins. Further nuclear extraction with micrococcal nuclease was performed to release chromatin-bound nuclear proteins. The recovered insoluble pellet was resuspended in the final buffer. Fractions were quantified using Qubit Protein Assay kit (ThermoFisher, Cat. No. Q33212). For Western blot analysis, Novex Tris-Glycine SDS sample buffer (2X) was added to each fraction and heated at 95°C for 5 minutes. 10 μL of protein extract was run on a 4-20% Novex Tris-glycine wedge-well protein gel and dry transferred onto nitrocellulose membrane using the Invitrogen iBlot2 system (ThermoFisher). Membranes were blocked with 5% emulsion in Tris Buffer Saline with Tween® 20 (TBST) for 1 h at room temperature. Primary antibodies were incubated overnight at 4°C on a rocker.Primary antibodies used were: tau (Dako, A0024, 1:250,000), phosphorylated tau-serin 356 (Abcam, ab92682 or ab75603, 1:10,000), BANF1 (Abcam, ab129184, 1:1000), PPP2CA (Proteintech, 13482-1-AP, 1:1000). HRP-conjugated rabbit secondary antibodies were added and imaged using SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher, Cat. No. 34580) and recorded with a FluorChem M imaging system (ProteinSimple).
[0232] Antisense oligonucleotides. 25 ASOs targeting mouse Banf1 and 96 ASOs targeting mouse Ankle2 mRNA transcripts (Banf1 transcript ID NM_011793.3, Ankle2 transcript ID NM_001253814.1) were designed in silico by scanning the entire mature mRNA transcript. All ASOs were designed using a 5-10-5 "gapmer" format, with 5 nt "wings" carrying 2'Methoxy Ethyl (MOE) modifications and a 10 nt core carrying DNA bases to facilitate RNaseH-mediated knockdown. Additionally, the ASOs had phosphorothioate (PS) linkages throughout. To assay for mRNA knockdown, ASOs were individually transfected at 100 nM in NSC34 cells using LIPOFECTAMINE RNAiMaX according to the manufacturer's recommendations. mRNA knockdown was measured after 72 hours using transcript-specific TAQMAN qRT-PCR assays.
[0233] Six potent ASO targets mouse Banf1 and Ankle2 identified from these screens were secondarily screened in primary mouse cortical neurons to determine the best hits. Gymnotic delivery was obtained by diluting a 1 mM ASO stock solution (synthesized by IDT) with Neurobasal culture medium to a final ASO concentration of 2.5 μM.
[0234] For NLS:mCherry experiments, neurons were treated with individual ASOs 3 days after seeding in a 96-well format (gymnotic delivery). Half of the Neurobasal medium volume was replaced 4 days later and replenished with ASOs. Eight days after the first ASO treatment, neurons were transduced with the "EF1α-NLS:mCherry" LV-cDNA construct. Neurons were maintained in culture for an additional 2 days before sample collection for live cell imaging recording and expression analysis by TaqMan qRT-PCR.
[0235] For cDNA rescue experiments, neurons were treated with individual ASOs (gymnotic delivery) at a final concentration of 2.5 μM 3 days after seeding. After 4 days, neurons were transduced with LVhSyn 1-cDNA constructs encoding Lemd2, Lemd3, Chmp7, or luciferase as a control cDNA. After 6 hours, Neurobasal medium was replaced and replenished with ASOs. Half of the Neurobasal medium volume was replaced on day 4. On day 10, neurons were fixed for immunofluorescence studies. Samples were also collected for expression analysis by TaqMan qRT-PCR.
[0236] Culture of mouse cortical neurons. Primary mouse cortical neurons were purchased from ThermoFisher (GIBCO, Catalog No. A15586) and cells were seeded at a density of approximately 20,000 neurons in a volume of 100 μL per well in poly-D-lysine treated 96-well plates (Greiner Bio-One, Catalog No. 655946) in Neurobasal Plus Medium (GIBCO, Catalog No. A35829-01) + 1% B-27 Plus Supplement (GIBCO, Catalog No. A35828-01) + 1X GlutaMAX Supplement (GIBCO, Catalog No. 35050-061) according to the manufacturer's user guide. Three days after seeding, neurons were transduced with (Cas9+gRNA) constructs as mouse targeting gRNAs Banf1_gRNA3, Ankle2_gRNA3, Ppp2ca_gRNA2, or control non-targeting gRNA NT303, cloned into pLentiCRISPR-v2 Cas9 expression vector and packaged into lentivirus (GenScript). After 6 h, half of the Neurobasal medium volume was replaced and replenished every 3-4 days. Neurons were maintained in culture for 2 weeks before fixation for analysis by immunofluorescence.
[0237] Immunofluorescence staining. Primary mouse cortical neurons seeded in 96-well plates were pre-fixed with 2% paraformaldehyde (PFA) (Electron Microscopy Sciences, Cat. No. 15714) in PBS solution on ice for 5 min. After gentle aspiration, fixation solution was added as 100 μL of cold 4% PFA in PBS for 15 min on ice. The fixation solution was washed three times with 150 μL of cold PBS. Finally, 100 μL of cell permeabilization and blocking solution was added as 10% Donkey Normal Serum (DNS) (Sigma-Aldrich, Cat. No. S30-100ML) in TBS-Triton®-0.2% solution (TBST, Millipore, Cat. No. 807423) for 1 h at room temperature. Immunostaining was performed in blocking solution overnight at 4°C with the following antibodies: rabbit anti-phosphorylated tau Ser356 1:1,000 (Abcam, catalog no. ab92682), rabbit anti-tau 1:10,000 (Dako, A0024), and chicken anti-MAP 2 1:20,000 (Abcam, catalog no. ab5392). The next day, each well was washed three times with 150 μL of TBST and incubated with 100 μL of the following secondary antibody solution in TBST at room temperature for 1 h: Alexa Fluor568 donkey anti-rabbit IgG 1:1000 (Invitrogen, catalog no. A10042), Alexa Fluor647 goat anti-chicken IgG 1:1,000 (Invitrogen, Cat. No. A21449), and DAPI (ThermoFisher, Cat. No. 62248). Finally, they were washed three times with 150 μL of TBST, and 100 μL of PBS was finally added per well. Plates were kept at 4° C. until imaging.
[0238] Image analysis. Unbiased image analysis and calculations were performed using the analysis software Harmony 4.9 (PerkinElmer). Immunofluorescence imaging was performed using the Opera Phenix High-Content Screening System (PerkinElmer) equipped with a 40x water objective to capture approximately 40 fields per 96-well. Harmony was used to quantify the percentage of SRRM2 in the nuclei of cells. DAPI staining was used to label the nuclei and YFP immunostaining was used to label the cytoplasm. For HEK293T cells, 30 μm 2 Nuclei were identified using method C with a region of 100. Cytoplasm was defined based on the nucleus (Harmony method A). The percentage of total SRRM2 intensity (Abcam, Cat. No. ab11826) within the nucleus was calculated by dividing the nuclear SRRM2 intensity by the sum of the nuclear and cytosolic intensities per image. Significance was determined using an unpaired two-tailed t-test.
[0239] To quantify phosphorylated tau Ser356 in cultured mouse cortical neurons, DAPI staining was used to label nuclei and MAP2 immunostaining was used to label cell bodies. Nuclear detection method C was chosen due to its robustness regarding nuclear size and contrast variation of fluorescent signal. Cytoplasm was defined based on the nucleus (Harmony method A). Perinuclear and cell body areas were determined using DAPI staining. + A ring of nuclei was defined as a ring surrounding the nucleus. For quantification, a minimum of 1,000 cells were analyzed for each condition.
[0240] For live cell imaging recording, we used a Zeiss Axio Observer 7 microscope equipped with culture components, a colibir 7 LED light source, and an Axiocam 703 Mono sCMOS camera. mCherry fluorescence intensity measurements were performed in Zen Blue (Zeiss) by calculating the average intensity of three subject regions with the same area within the cell body in each individual cell.
[0241] Statistical analysis of NGS data from CRISPR screening. Gene-centric enrichment analysis. Similar to DESeq2, our alternative algorithm has two components: enrichment factor (referred to as fold change in DESeq2) and enrichment p-value. The enrichment factor is similar to that used in DESeq2, except that it is summarized at the gene level by averaging the enrichments of all gRNAs targeting the same gene. Unlike existing CRISPR data analysis methods, our method used a hypergeometric distribution-based p-value calculation that is applied only to the enrichment of different gRNAs targeting a gene in each of the FRET+day 10 samples. The final enrichment p-value of a gene is the average of the p-values obtained from each of the 10 FRET+day 10 samples. The fold change for each gene was obtained by calculating the arithmetic mean of the log2-transformed FRET+day 10 vs. day 3 or day 6 ratios generated for the corresponding gRNA by DESEq2 (Love et al., 2014). The enrichment p-value of each gene was calculated as follows: First, in each FRET+10 day sample, a gRNA was considered to be present if its DESeq2 normalized read count was 30 or more, and we considered read counts below 30 as background noise. The enrichment of the presence of gRNAs corresponding to genes in the FRET+10 day samples was calculated using the hypergeometric distribution-based function phyper(x, m, n, k, lower.tail=FALSE) in R (R-project.org / ). The number of gRNAs present corresponding to genes minus 1 is x, the number of all gRNAs corresponding to genes in the library is m, the total number of gRNAs in the library minus m is n, and the total number of gRNAs present in the FRET+ sample is k. The p-values were then log10 transformed and averaged across all 10 FRET+10 day samples.
[0242] Differential gRNA read count analysis. For comparison of gRNA read counts between two groups of samples, we used the DESeq2 Generalized Linear Model (GLM) and tested for abundance differences using a Wald test based on negative binomial distribution in ArrayStudio (OmicSoft). The terms "experiment" and "FRET status" were used to build a model of FRET+ vs. FRET- comparison between samples at the 13th day time point across five experiments. gRNAs with significant read count differences between comparison groups were identified using the following criteria: i) fold change ≧1.5 in either direction, and ii) p-value <0.05. The gRNAs enriched in the FRET samples were further defined using these three criteria: i) FRET- was significantly increased compared to FRET+ in the day 13 samples, ii) FRET- was significantly increased in the day 13 samples compared to the day 10 samples, and iii) FRET+ was not significantly increased in the day 13 samples compared to the day 10 samples (either no significant difference or a significant decrease). We paid particular attention to gene targets with multiple gRNAs enriched in the FRET samples.
[0243] Statistical analysis of immunofluorescence. Statistical analysis was performed in GraphPad Prism8. Specifically, the Mann-Whitney U (two-tailed) was used to determine significance for immunofluorescence staining of primary mouse cortical neurons and NLS:mCherry fluorescence intensity. Quantitation is reported as mean ± SEM (error bars).
[0244] [Table 3]
[0245] [Table 4-1] [Table 4-2]
[0246] [Table 5]
[0247] [Table 6]
[0248] [Table 7]
[0249] [Table 8]
[0250] [Table 9]
[0251] Example 2. Overexpression of LEMD2, LEMD3, or CHMP7 as a therapeutic modality for tauopathy diseases The inventors identified LEMD2, LEMD3 and CHMP7 as modifiers of tau aggregates (see Example 1). The inventors further validated these modifiers using cDNAs designed to allow overexpression in tau biosensor cells. These targets are further validated ex vivo in mouse cortical neurons and in vivo using mouse models of tauopathy.
[0252] Mouse cortical neurons Experiments are performed to assess whether overexpression of mouse LEMD2, LEMD3, or CHMP7 can reduce tau hyperphosphorylation at Ser356, as detected by immunofluorescence in the nuclear and perinuclear regions of mouse cortical neurons treated with either ASO-targeting Banf1 or Ankle2, which induce greater hyperphosphorylation of tau, or a non-targeting scrambled ASO control.
[0253] Mouse cortical neurons are treated with ASO targeting Banf1 or Ankle2 or non-targeting scrambled ASO control and transduced with AAV (5000VG / neuron) or lentivirus (LV) (10000VG / neuron) encoding codon-optimized mouse LEMD2, LEMD3, or CHMP7. The sequences of the AAV constructs are set forth in SEQ ID NO: 41-43. The sequences of the LV constructs are set forth in SEQ ID NO: 35, SEQ ID NO: 38, and SEQ ID NO: 40. Expression of mouse LEMD2, LEMD3, or CHMP7 is confirmed by codon-optimized TAQMAN assay specific for the codon-optimized cDNA compared to the endogenous gene. Phosphorylated tau is analyzed by immunofluorescence and Western blot combined with cell fractionation. Neuronal cells are assessed for evidence of misfolded tau by combining neuronal cell lysates with LIPOFECTAMINE™ 2000 and adding treated tau biosensor cells (as seeds) for qualitative FRET analysis.
[0254] Mouse models of tauopathy AAV encoding mouse LEMD2 or CHMP7 or mCherry control will be injected into P301S transgenic mouse neonates (P19 mouse model of tauopathy) by intracerebroventricular (ICV) injection to determine whether overexpression of LEMD2 or CHMP7 can prevent tauopathy-associated phenotypes. The sequences of the AAV constructs are set forth in SEQ ID NO: 41 to SEQ ID NO: 43.
[0255] Multiple AAV titers are tested (5E10, 2.5E10, and 1.25E10). cDNA expression is followed by qRT-PCR. Once the optimal AAV titer is determined, it is injected into P301S heterozygous neonates and long-term studies are performed over a period of 6-9 months.
[0256] AAV encoding mouse LEMD2 or CHMP7 or mCherry control are also injected into 3-month-old P301S animals at different AAV titers (1E11 or 5E10 VG / animal). cDNA expression is assessed by qRT-PCR. Once AAV titers are optimized, they are injected into P301S heterozygous 3-month-old mice and long-term studies are performed over a period of 6-9 months.
[0257] PS19 mouse model. PS19(TauP301S (strain PS19); PS19Tg; B6; C3-Tg (Prnp-MAPT *The PS19Vle / J) mouse line is a tauopathy model. The genetic background of this line is C57BL / 6xC3H. PS19 transgenic mice express mutant human microtubule-associated protein tau MAPT driven by the mouse prion protein (Prnp) promoter. The transgene encodes the disease-associated P301S mutation and contains four microtubule-binding domains and one N-terminal insert (4R / 1N). The transgene was inserted at Chr3:140354280-140603283 (build GRCm38 / mm10), resulting in a 249Kb deletion that does not affect known genes. See Goodwin et al. (2019), Genome Res., 29(3):494-505, which is incorporated herein by reference in its entirety. Expression of mutant human tau is 5-fold higher than that of the endogenous mouse protein. See Yoshiyama et al., (2007), Neuron, 53(3):337-351, which is incorporated herein by reference in its entirety in this application. PS19 mice develop neuronal loss and brain atrophy by 8 months of age. They also develop extensive tau aggregates, known as neurofibrillary tangle-like inclusions, in the neocortex, amygdala, hippocampus, brainstem, and spinal cord. See Yoshiyama et al., (2007). It has been shown that the brains of these mice exhibit tau seeding activity prior to the appearance of overt tau pathology by histological methods. That is, tau aggregates present in brain homogenates may induce further tau aggregates, possibly via a prion-like mechanism. See Holmes et al. (2014) Proc. Natl. Acad. Sci. USA 111(41):E4376-E4385, which is incorporated by reference in its entirety in this application.
[0258] Cloning of cDNA into lentiviral expression plasmids. cDNA and protein sequences were obtained from Ensembl (ensembl.org) and confirmed with UniProt. Expression plasmids for overexpression of cDNA sequences were generated by synthesizing nucleic acid fragments and subcloning them into pLVX-Ef1a IRES-Hyg expression plasmid vector. The cDNA fragments were inserted downstream of the Ef1a promoter by using Spe-I and Not-I restriction sites. The nucleic acid sequences were obtained by reverse translation of protein sequences and codons optimized for expression in humans (Homo sapiens) and Mus musculus, respectively. Protein sequences were obtained from UniProt under the following accession numbers: BANF1 (O75531), ANKLE2 (Q86XL3), Lemd2 (Q8NC56), Lemd2-isoform2 (Q8NC56-2), LEMD3 (Q9Y2U8), and CHMP7 (Q8WUX9) for humans; Lemd2 (Q6DVA0), LEMD3 (Q9WU40), and CHMP7-isoform1 (Q8R1T1) for Mus musculus. As a control cDNA, the coding sequence of the reporter gene luciferase was also cloned into the expression vector. The plasmids were sequence-verified by Sanger sequencing before lentiviral packaging.
[0259] Cloning of cDNA into AAV expression plasmids. cDNA and protein sequences were obtained from Ensembl and verified with UniProt. Nucleic acid sequences were codon optimized and synthesized into a lentiviral backbone. PCR was then used to amplify mouse Lemd2 and mouse Chmp7 cDNA and add restriction sites for subcloning into our AAV backbone using the human synapsin 1 promoter. Specifically, 44 mL of Invitrogen AccuPrime Pfx DNA polymerase (cat. no. 12344024) was combined with 0.2 mL each of the appropriate forward and reverse oligos at 100 mM concentration and 1 mL of template. PCR reactions were run for 29 cycles in an Eppendorf MasterCycler ProS thermal cycler with the following parameters: 96° 2 min; (96° 20 sec + 50° 30 sec + 72° 45 sec) 29 times; 4°C.
[0260] The PCR products were purified using QIAquick PCR Purification Kit (Cat. No. 28106) and then digested with New England BioLabs enzymes EcoRI-HF (Cat. No. R3101L) and NotI-HF (Cat. No. R3189L) in CutSmart buffer (Cat. No. B7204S) according to the manufacturer's protocol. The digestion products were visualized on an Invitrogen 1.2% e-gel (Cat. No. 5018-01) and then purified using QIAquick Spin Columns (Cat. No. 28115). The ssAAV backbone was digested as above and then extracted after incubation on a 1.2% agarose gel (Cat. No. 2120-100GM) for 4 hours. DNA fragments were extracted from the agar medium using QIAquick Spin Columns (Cat. No. 28115). Each cDNA fragment was ligated into the backbone using New England Biolabs T4 DNA ligase (Cat. No. M0202L 400U / mL) according to the manufacturer's protocol. Ligations were transformed into MAX Efficiency Stbl2 competent cells (Cat. No. 10268019) and then recovered in Invitrogen SOC recovery medium (Cat. No. 15544-34) for 1 hour at 30°C according to the manufacturer's protocol. One third of the harvest was plated on Teknova LB Agar Plates with Carbenicillin-100 (Cat. No. L1010) and grown overnight at 30°C. The resulting colonies were plated into 5 mL of Sigma-Aldrich Terrific Broth (Cat. No. T5574-500mL) and grown overnight at 30°C. Plasmid DNA was harvested using a QiaPrep Spin Miniprep Kit (cat. no. 27106). Extracted DNA was sequence verified by Sanger sequencing prior to AAV packaging using pHP.eB capsids to cross the blood-brain barrier.
[0261] Example 3. Overexpression of LEMD2, LEMD3, or CHMP7 in PS19 mice To further investigate Lemd2, Lemd3, and Chmp7 as genetic modifiers of tau aggregation, and in particular as therapeutic modalities for tauopathy disease, we designed experiments to test whether overexpression of these mouse genes by introduction of cDNA could delay the onset of tauopathy-associated disease phenotypes in mouse models of tauopathy.
[0262] We utilized the AAV capsid pHP.eB, which allows delivery of cargo, such as modifier cDNA, across the blood-brain barrier to the CNS. We used transgenic mouse models of tauopathy (PS19 as described above (tauP301S (strain PS19); PS19Tg; B6; C3-Tg (Prnp-MAPT * Two different AAV injection routes were tested in the (P301S) (PS19Vle / J) mouse strain: intraperitoneal (IP) and intracerebroventricular (ICV).
[0263] cDNA and protein sequences were obtained from Ensembl and confirmed with UniProt. Plasmids for expression of cDNA sequences were generated by synthesizing nucleic acids and subcloning into expression vectors for mouse and control cDNAs. Nucleic acid sequences were obtained by reverse translation of protein sequences (Reverse translator tool, MacVector 18.1.5) and codon optimized for expression in mouse cells (Mouse Protein Catalog Numbers: Lemd2 (Q6DVA0), Lemd3 (Q9WU40), and Chmp7 (Q8R1T1)). Coding sequences for reporter genes mCherry or GFP were cloned into the same expression vector to serve as non-specific control cDNAs. Plasmid sequences were confirmed by Sanger sequencing prior to AAV packaging using a plasmid encoding the CNS-specific AAV_pHP.eB capsid. The sequences for the AAV-mLemd2, AAV-mLemd3, and AAV-mChmp7 vectors are set forth in SEQ ID NO: 249 to SEQ ID NO: 251, respectively.
[0264] We first optimized the titer required for robust cDNA expression. We injected newborn mice (p0 or p1) with different doses of AAV_cDNA (1.25E10 VG / mouse, 2.5E10 VG / mouse, 5E10 VG / mouse) by ICV and sacrificed the animals after 4 months. We injected 2-month-old mice with different doses of AAV_cDNA (5E10 VG / mouse, 7.5E10 VG / mouse, 1E11 VG / mouse) by IP and sacrificed the animals after 4 months. We collected tissues from liver, spinal cord and brain, from which RNA was isolated and qRT-PCR expression analysis was performed. We showed that cDNA-driven expression was robust and reproducible between animals after ICV injection. The human synapsin-1 promoter allowed more CNS specificity in cDNA expression.
[0265] Three different therapeutic modalities are evaluated to prevent, delay and / or cure tauopathy disease: Lemd2, Lemd3 and Chmp7 cDNA are introduced at birth, before disease onset at 3 months of age, or after disease onset at 6 months of age.
[0266] In a second experiment, PS19 neonates are injected ICV with 2.5E10 VG / mouse for all cDNAs. PS19 heterozygous animals are also injected IP with 1.5E11 VG / mouse.
[0267] A longitudinal study will be performed on serum neurofilament light chain (sNfL), a biomarker of neuronal damage that is a strong indicator of neurodegenerative processes. To assess sNfL, animals will be bled (by the submandibular method) at 4 and 6 months, which will be considered as baseline in this mouse model, and then every 5 weeks to observe the levels of sNfL over time.
Claims
1. 1. A method for inhibiting tau aggregates in a cell, comprising administering to the cell LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding the LEMD2, CHMP7, or LEMD3.
2. A method for inhibiting or reducing tau phosphorylation in a cell, comprising administering to the cell LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding the LEMD2, CHMP7, or LEMD3.
3. 3. The method of claim 2, wherein phosphorylation of tau on serine 356 is inhibited or reduced.
4. 4. The method of claim 2 or 3, wherein tau phosphorylation is reduced in the cell body, perinuclear region, and / or nucleoplasm of the cell.
5. A method for inhibiting or reducing accumulation of insoluble tau in a cell, comprising administering to the cell LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding the LEMD2, CHMP7, or LEMD3.
6. The method of any one of claims 1 to 5, comprising administering to the cell the LEMD2 or the nucleic acid encoding the LEMD2.
7. 7. The method of claim 6, wherein the LEMD2 is human LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO:1 or SEQ ID NO:5, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:
7.
8. 7. The method of claim 6, wherein the LEMD2 is mouse LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO: 10, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO:
255.
9. The method of any one of claims 1 to 8, comprising administering the CHMP7 or the nucleic acid encoding the CHMP7 to the cell.
10. The method of claim 9, wherein the CHMP7 is human CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 15, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 16 or SEQ ID NO:
17.
11. The method of claim 9, wherein the CHMP7 is mouse CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 19, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 20 or SEQ ID NO:
21.
12. The method of any one of claims 1 to 11, comprising administering to the cell the LEMD3 or the nucleic acid encoding the LEMD3.
13. 13. The method of claim 12, wherein the LEMD3 is human LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:23, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:24 or SEQ ID NO:
25.
14. 13. The method of claim 12, wherein the LEMD3 is mouse LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:27 or SEQ ID NO:29, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:29 or SEQ ID NO:
30.
15. 15. The method of any one of claims 1 to 14, wherein the nucleic acid encoding the LEMD2, CHMP7, or LEMD3 is administered to the cell, and optionally the nucleic acid is codon-optimized for expression in a human or mouse cell.
16. The method of claim 15, wherein the nucleic acid comprises a complementary DNA encoding the LEMD2, the CHMP7, or the LEMD3.
17. The method of claim 15, wherein the nucleic acid comprises messenger RNA encoding the LEMD2, the CHMP7, or the LEMD3.
18. 17. The method of claim 15 or 16, comprising administering an expression construct comprising the nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 operably linked to a promoter.
19. The method of claim 18 , wherein the promoter is a heterologous promoter.
20. 20. The method of claim 18 or 19, wherein the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter.
21. The method of claim 20 , wherein the promoter is a neuron-specific promoter.
22. The method of claim 21, wherein the promoter is the synapsin-1 promoter.
23. 23. The method of claim 22, wherein the promoter is the human synapsin-1 promoter.
24. The method of any one of claims 15 to 23, wherein the nucleic acid is present in a vector.
25. 25. The method of claim 24, wherein the vector is a viral vector.
26. 26. The method of claim 25, wherein the viral vector is a lentiviral vector or an Adeno-Associated Virus (AAV) vector.
27. 27. The method of claim 26, wherein the vector is an AAV vector, optionally wherein the AAV vector is an AAV-PHP.eB vector.
28. The method of any one of claims 1 to 27, wherein the cell is a mammalian cell.
29. 29. The method of claim 28, wherein the mammalian cell is a human cell, a rodent cell, a mouse cell, or a rat cell.
30. 30. The method of claim 29, wherein the cell is a human cell.
31. The method of any one of claims 1 to 30, wherein the cell is a neuronal cell.
32. The method of any one of claims 1 to 31, wherein the cell is present in vivo in a subject.
33. 33. The method of claim 32, wherein the cell is a neuronal cell in the brain of the subject.
34. The method of claim 32 or 33, wherein the LEMD2, CHMP7, or LEMD3, or the nucleic acid encoding the LEMD2, CHMP7, or LEMD3, is administered to the subject by intraventricular, intracranial, or intrathecal injection.
35. 35. The method of any one of claims 1 to 34, further comprising assessing one or more signs or symptoms of tauopathy or tau aggregation in the cell.
36. 36. The method of claim 35, further comprising assessing phosphorylated tau levels in the cells.
37. The method of any one of claims 1 to 36, wherein the amount of new tau aggregate formation in the cell is reduced.
38. The method of any one of claims 1 to 37, wherein the amount of existing tau aggregate formation in the cell is reduced.
39. A method for treating a tauopathy in a subject, comprising administering to the subject LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding the LEMD2, CHMP7, or LEMD3, wherein the LEMD2, CHMP7, or LEMD3 inhibits tau aggregates in cells of the subject.
40. A method for preventing tauopathy in a subject, comprising administering to the subject LEM domain-containing protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), or a nucleic acid encoding the LEMD2, CHMP7, or LEMD3, wherein the LEMD2, CHMP7, or LEMD3 inhibits tau aggregates in cells of the subject.
41. 41. The method of claim 39 or 40, comprising administering to the subject the LEMD2 or the nucleic acid encoding the LEMD2.
42. 42. The method of claim 41 , wherein the LEMD2 is human LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO:1 or SEQ ID NO:5, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:
7.
43. 42. The method of claim 41 , wherein the LEMD2 is mouse LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO: 10, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO:
255.
44. The method of any one of claims 39 to 43, comprising administering to the subject the CHMP7 or the nucleic acid encoding the CHMP7.
45. The method of claim 44, wherein the CHMP7 is human CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 15, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 16 or SEQ ID NO:
17.
46. The method of claim 44, wherein the CHMP7 is mouse CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 19, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 20 or SEQ ID NO:
21.
47. 47. The method of any one of claims 39 to 46, comprising administering to the subject the LEMD3 or the nucleic acid encoding the LEMD3.
48. 48. The method of claim 47, wherein the LEMD3 is human LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:23, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:24 or SEQ ID NO:
25.
49. 48. The method of claim 47, wherein the LEMD3 is mouse LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:27 or SEQ ID NO:29, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:29 or SEQ ID NO:
30.
50. 50. The method of any one of claims 39-49, wherein the nucleic acid encoding the LEMD2, CHMP7, or LEMD3 is administered to the subject, and optionally the nucleic acid is codon-optimized for expression in a human or mouse cell.
51. 51. The method of claim 50, wherein the nucleic acid comprises a complementary DNA encoding the LEMD2, the CHMP7, or the LEMD3.
52. 51. The method of claim 50, wherein the nucleic acid comprises messenger RNA encoding the LEMD2, the CHMP7, or the LEMD3.
53. 52. The method of claim 50 or 51, comprising administering an expression construct comprising the nucleic acid encoding the LEMD2, the CHMP7, or the LEMD3 operably linked to a promoter.
54. 54. The method of claim 53, wherein the promoter is a heterologous promoter.
55. 55. The method of claim 53 or 54, wherein the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter.
56. 56. The method of claim 55, wherein the promoter is a neuron-specific promoter.
57. 57. The method of claim 56, wherein the promoter is the synapsin-1 promoter.
58. 58. The method of claim 57, wherein the promoter is the human synapsin-1 promoter.
59. The method of any one of claims 50 to 58, wherein the nucleic acid is present in a vector.
60. 60. The method of claim 59, wherein the vector is a viral vector.
61. 61. The method of claim 60, wherein the viral vector is a lentiviral vector or an adeno-associated viral (AAV) vector.
62. 62. The method of claim 61, wherein the vector is an AAV vector, optionally wherein the AAV vector is an AAV-PHP.eB vector.
63. The method of any one of claims 39 to 62, wherein the subject is a mammal.
64. 64. The method of claim 63, wherein the subject is a human, a rodent, a mouse, or a rat.
65. 65. The method of claim 64, wherein the subject is a human.
66. The method of any one of claims 39 to 65, wherein the cell is a neuronal cell.
67. 67. The method of claim 66, wherein the neuronal cell is present in the brain of the subject.
68. 68. The method of any one of claims 39 to 67, wherein the LEMD2, CHMP7, or LEMD3, or the nucleic acid encoding the LEMD2, CHMP7, or LEMD3, is administered to the subject by intraventricular, intracranial, or intrathecal injection.
69. 69. The method of any one of claims 39 to 68, further comprising assessing one or more signs or symptoms of tauopathy or tau aggregation in the cell or subject.
70. 70. The method of claim 69, further comprising assessing phosphorylated tau levels in the cell or subject.
71. 71. The method of claim 69 or 70, further comprising assessing serum neurofilament light chain (sNfL) levels in the subject.
72. 72. The method of any one of claims 39 to 71, which reduces the amount of new tau aggregate formation in the cell or subject.
73. 73. The method of any one of claims 39 to 72, which reduces the amount of existing tau aggregate formation in the cell or subject.
74. An expression construct comprising a nucleic acid encoding LEM domain-containing body protein 2 (LEMD2), charged multivesicular body protein 7 (CHMP7), or inner nuclear membrane protein Man1 (LEMD3), operably linked to a heterologous promoter.
75. 75. The expression construct of claim 74, comprising the nucleic acid encoding the LEMD2.
76. 76. The expression construct of claim 75, wherein the LEMD2 is human LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO:1 or SEQ ID NO:5, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:
7.
77. 76. The expression construct of claim 75, wherein the LEMD2 is mouse LEMD2, optionally wherein the LEMD2 comprises SEQ ID NO: 10, and optionally wherein the nucleic acid encoding the LEMD2 comprises SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO:
255.
78. 75. The expression construct of claim 74, comprising the nucleic acid encoding the CHMP7.
79. The expression construct of claim 78, wherein the CHMP7 is human CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 15, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 16 or SEQ ID NO:
17.
80. The expression construct of claim 78, wherein the CHMP7 is mouse CHMP7, optionally wherein the CHMP7 comprises SEQ ID NO: 19, and optionally wherein the nucleic acid encoding the CHMP7 comprises SEQ ID NO: 20 or SEQ ID NO:
21.
81. 75. The expression construct of claim 74, comprising the nucleic acid encoding the LEMD3.
82. 82. The expression construct of claim 81, wherein the LEMD3 is human LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:23, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:24 or SEQ ID NO:
25.
83. 82. The expression construct of claim 81, wherein the LEMD3 is mouse LEMD3, optionally wherein the LEMD3 comprises SEQ ID NO:27 or SEQ ID NO:29, and optionally wherein the nucleic acid encoding the LEMD3 comprises SEQ ID NO:29 or SEQ ID NO:
30.
84. 84. The expression construct of any one of claims 74 to 83, wherein the nucleic acid encoding the LEMD2, CHMP7, or LEMD3 is codon-optimized for expression in a human or mouse cell.
85. 85. The expression construct of any one of claims 74 to 84, wherein the nucleic acid comprises a complementary DNA encoding the LEMD2, the CHMP7, or the LEMD3.
86. 86. The expression construct of any one of claims 74 to 85, wherein the promoter is a constitutive promoter, a tissue-specific promoter, or an inducible promoter.
87. 87. The expression construct of claim 86, wherein the promoter is a neuronal cell-specific promoter.
88. 88. The expression construct of claim 87, wherein the promoter is the synapsin-1 promoter.
89. 89. The expression construct of claim 88, wherein the promoter is the human synapsin-1 promoter.
90. 90. The expression construct of any one of claims 74 to 89, wherein the nucleic acid is in a vector.
91. 91. The expression construct of claim 90, wherein the vector is a viral vector.
92. 92. The expression construct of claim 91, wherein the viral vector is a lentiviral vector or an adeno-associated viral (AAV) vector.
93. 93. The expression construct of claim 92, wherein the vector is an AAV vector, optionally wherein the AAV vector is an AAV-PHP.eB vector.
